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ABSTRACT 
 
The Pharmocratics of Misoprostol: 
Race, Drugs, and Reproductive Neoliberalism 
 
By Cecelia Brun Lie-Spahn 
 
 
This dissertation is about underground markets for misoprostol (“miso” or 
Cytotec), a drug originally created in the 1980s to treat stomach ulcers caused by 
nonsteroidal anti-inflammatory drugs (NSAIDs), but which is frequently used off-
label to treat postpartum hemorrhage, induce labor, and induce abortion. In the 
cross-hairs of some of the most polarizing debates in mainstream U.S. political 
discourse—immigration, abortion, and the War on Drugs—depictions of off-label 
miso-use vacillate from hyper-racialized images of flea markets and drug cartels to 
hope for a future of unconstrained reproductive health options, a vision in which 
miso symbolizes the cornerstone of medical, technological, and social progress. 
However, Pfizer—the mega pharmaceutical company that owns, manufactures, and 
distributes miso under the brand name “Cytotec”—is overtly absent from these 
discourses. To bring the pharmaceutical machinery that has so successfully eluded 
these discourses back into the picture, I resituate discourses about underground 
misoprostol within the neoliberal structures from which it emerged in the post-World 
War II period, bringing together two key conceptual frameworks: (1) the 
reproductive justice movement’s long-held emphasis on women of color organizing 
and intersectional, radically inclusive, community-based, and comprehensive vision 
of reproductive freedom; and (2) Kaushik Sunder Rajan’s concept of 
 viii 
“pharmocracy,” wherein pharmaceutical philanthropy acts as a modern form of 
extractive capitalism. I argue that the pharmocratic scripts of modernity and cultural 
backwardness reproduced in discourses about underground misoprostol reflect the 
dangerous proliferation of an updated version of bootstraps individualism I refer to 
as “reproductive neoliberalism”: the idea that, in lieu of state-provided equitable and 
holistic reproductive care, women can still achieve reproductive autonomy through 
entrepreneurial, legal, and pharmaceutical prowess. The individualist language of 
reproductive neoliberalism in Pfizer’s annual financial reports, mainstream liberal 
journalism, and family planning research about underground miso invisibly 
authorizes the uneven transfer of legal and medical liability away from 
pharmaceutical corporations, such that individuals are made to bear legal, medical, 
affective, and cultural liabilities—forms of conscripted labor inherent in the act of 
transgressing federal licensing and malpractice laws, as well as in the fear of 
accidental injury (bodily, emotional) to oneself or someone else in the process. 
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Figure 1: Photo from a flea market in El Salvador, taken by John Poole, published by 
National Public Radio (NPR). The sign in the image—“SE LEEN LAS CARTAS SE 
HACEN TRABAJOS Y LIMPIAS”—advertises odd jobs like reading letters and 
cleaning. NPR’s caption below it reads: “In the markets of San Salvador, El 
Salvador, you can have your palm read, you can buy plumbing tools… and you can 
purchase abortion pills.” 
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INTRODUCTION 
 
Tracking Misoprostol: 
A Material Approach to Reproductive Neoliberalism 
 
 
“In the central market in San Salvador, you can buy just about anything 
you want: tomatoes by the wheelbarrow full. Fresh goat’s milk straight 
from the goat. Underwear. Plumbing supplies. Fruit. Hollywood’s latest 
blockbusters burned straight onto a DVD. 
 
And in the back of the market, in a small stall lined with jars of dried 
herbs, roots and mushrooms, you can buy an abortion.”1 
 
Jason Beaubien 
Investigative Journalist for National Public Radio (NPR) 
All Things Considered, 2014 
 
In September 2014, NPR ran a series looking at the health implications of 
clandestine abortion in developing countries, one of which begins in the San 
Salvador street market described above. According to Beaubien’s account, the 
anonymized female herbalist sells these pills mostly to distraught teenagers with 
“tragic…tales of rape, abuse, betrayal or misguided love” at $200 per 3-pill course.2 
Pictured through the assortment of farmed, pirated, and pharmaceutical items for 
sale in her tent, the drug trafficking figure caricatured in the epigraph above 
mediates a kind of pharma-cultural border within her own street tent: one where 
bagged roots, dangling jerky, and single-use packets of Tide conceal clandestine 
abortion methods. 
 
1 Jason Beaubien, “Even When Abortion Is Illegal, the Market May Sell Pills for 
Abortion,” National Public Radio, September 23, 2014. 
2 Beaubien. 
 3 
 The abortion available for purchase is a reference to misoprostol, a drug 
initially approved in the United States in 1988 for the treatment and prevention of 
gastrointestinal ulcers. In the early 1980s, long before Beaubien’s story was 
published, misoprostol (“miso”) garnered attention from U.S.-based news outlets and 
family planning experts because of its growing use as an off-label abortifacient, as 
the pregnancy contraindication on its warning label—symbolized by a crossed-out 
illustration of a pregnant woman, similar to a no-smoking sign—prompted low-
income women in areas with restrictive abortion laws in Latin America to buy the 
drug over the counter or at flea markets and abort pregnancies at home.3 One can 
 
3 Deborah L. Billings, “Misoprostol Alone for Early Medical Abortion in a Latin 
American Clinic Setting,” Reproductive Health Matters, Supplement: Abortion Law, 
Policy and Practice in Transition, 12, no. 24 (November 2004): 57–64; Deborah L. 
Billings et al., “Pharmacy Worker Practices Related to Use of Misoprostol for 
Abortion in One Mexican State,” Contraception 79, no. 6 (February 23, 2009): 445–
51; Jessica Cohen et al., “Reaching Women with Instructions on Misoprostol Use in a 
Latin American Country,” Reproductive Health Matters 13, no. 26 (2005): 84–92; 
Maria M. Fernandez et al., “Assessing the Global Availability of Misoprostol,” 
International Journal of Gynecology & Obstetrics 105, no. 2 (5/2009): 180–86; C. C. 
Harper et al., “Reducing Maternal Mortality due to Elective Abortion: Potential 
Impact of Misoprostol in Low-Resource Settings,” International Journal of 
Gynecology & Obstetrics 98, no. 1 (7/2007): 66–69; Andrzej Kulczycki, “Abortion in 
Latin America: Changes in Practice, Growing Conflict, and Recent Policy 
Developments,” Studies in Family Planning 42, no. 3 (September 2011): 199–220; 
Diana Lara et al., “How Often and Under Which Circumstances Do Mexican 
Pharmacy Vendors Recommend Misoprostol To Induce an Abortion?,” International 
Perspectives on Sexual and Reproductive Health 37, no. 02 (06/2011): 075–083; 
Maureen Paul et al., eds., “Medical Abortion in Early Pregnancy,” in Management of 
Unintended and Abnormal Pregnancy: Comprehensive Abortion Care (Chichester, 
Hoboken: Wiley-Blackwell, 2009), 111–34; J. Sherris et al., “Misoprostol Use in 
Developing Countries: Results from a Multicountry Study,” International Journal of 
Gynecology & Obstetrics 88, no. 1 (November 14, 2004): 76–81. 
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understand how, for someone seeking clandestine abortion with limited options, the 
warning label could read almost like an instructional pamphlet for self-abortion: 
CYTOTEC (MISOPROSTOL) ADMINISTRATION TO WOMEN WHO 
ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, OR 
PREMATURE BIRTH. UTERINE RUPTURE HAS BEEN REPORTED 
WHEN CYTOTEC WAS ADMINISTERED IN PREGNANT WOMEN TO 
INDUCE LABOR OR TO INDUCE ABORTION BEYOND THE EIGHTH 
WEEK OF PREGNANCY (see also PRECAUTIONS and LABOR AND 
DELIVERY). CYTOTEC SHOULD NOT BE TAKEN BY PREGNANT 
WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see 
CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). 
 
PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT 
PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS.4 
 
The language here is careful: while it is informative about the possible physiological 
effects of miso on pregnant women, it does not specifically direct readers not to use 
the drug for obstetric purposes, stating that pregnant women should not take miso if 
they are doing so to treat NSAID-induced ulcers. The ending instruction “not to give 
the drug to others” suggests that the warning’s primary concern is not pregnant 
women’s physical safety—in fact, the label implies that miso could be taken prior to 
the eighth week of pregnancy without significant risk of uterine rupture—but rather 
the threat of underground distribution. 
While it is unclear who or what the underground distribution of miso 
threatens, the language here produces an illusion of informed pharmaceutical choice 
made by an imagined user-subject, one who rationalizes miso-use according to 
individually calculated risk. In fact, some family planning experts argue that the risk 
 
4 “Label: Cytotec, Misoprostol Tablets,” 2012, 1. 
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of unsupervised, at-home abortions is minimal compared to the potential gains in 
cheaper, safer, and significantly less invasive extra-legal options; as one family 
planning study boldly asserts, “[t]he more widespread misoprostol abortion is, the 
greater the gains.”5 Citing this literature, health activists from a variety of 
professions—public health practitioners, physicians, midwives, peer health 
advocates—have launched projects explicitly calling for the mass distribution of 
instructional pamphlets and websites detailing how to self-abort using misoprostol.6 
Some have even trained women to strategically request the drug from pharmacists 
without revealing their desire to abort. 
 
7 
At the same time, the recurring myth in popular news media and family 
planning literature that off-label miso use is a phenomenon of the so-called Third 
World puts the discourse into the crosshairs of some of the most violent and 
 
5 Harper et al., “Reducing Maternal Mortality due to Elective Abortion,” 68.  
6 Billings, “Misoprostol Alone for Early Medical Abortion in a Latin American Clinic 
Setting”; Cohen et al., “Reaching Women with Instructions on Misoprostol Use in a 
Latin American Country”; Fernandez et al., “Assessing the Global Availability of 
Misoprostol”; Harper et al., “Reducing Maternal Mortality due to Elective Abortion”; 
Diana Whitten, Vessel, DVD, 2014. 
7 “Cytotec (G.D. Searle LLC): FDA Package Insert.” MedLibrary.org, March 1, 2011. 
https://medlibrary.org/lib/rx/meds/cytotec-2/page/4/. 
Figure 2: Cytotec packaging.  
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politically divisive debates in the United States: the War on Drugs, immigration, 
border security, and, of course, abortion. Depictions of off-label miso use thus wildly 
vacillate from an episode of Breaking Bad to hope for a future of unconstrained 
reproductive health options, a vision in which the abortion pill symbolizes the 
cornerstone of medical, technological, and social progress. Remarkably, Pfizer—the 
mega pharmaceutical company that owns, manufactures, and distributes miso under 
the brand name “Cytotec”—is overtly absent from these discourses, despite 
extensive critical journalism and scholarship on Pfizer and Big Pharma more 
broadly. Rather, investigative journalists and family planning experts alike have 
focused almost exclusively on the entrepreneurial ethics of flea market vendors in 
the Global South, erasing Pfizer’s role in contributing to the precarious economic 
conditions, extractive environmental practices, and corporate hegemony from, 
through, and against which these underground markets emerge. What conditions this 
refusal to see Pfizer and underground miso in the same conceptual image? How do 
these partial visibilities shape the pharmaceutical epistemologies expressed and 
constructed through popular journalism and family planning literature? What do 
these hierarchies of pharmaceutical knowledge erase? 
These questions prompt me to understand misoprostol not only as a 
pharmaceutical product contingently available for market consumption and thus in 
need of improved or otherwise reconfigured access, but also as an object through 
which ideas about race, gender, capital, nation, modernity, and reproduction get 
(re)constituted. They also make visible the ways in which the “pharmaceutical 
 7 
imagination”8 not only shapes everyday notions of the self and the body, but also 
contributes to the expansion of what Kaushik Sunder Rajan terms “pharmocracy,” or 
the profit-driven systems by which multinational pharmaceutical corporations 
become powerful biopolitical forces, transforming techno-scientific knowledge into 
capital at the expense of the most underserved populations.9 This dissertation project 
thus pulls misoprostol under the feminist-postcolonial microscope: it traces the 
material-discursive circulation of miso as it transgresses and repurposes a variety of 
state, bodily, disciplinary, and temporal borders. 
Joining feminist science and technology studies (STS) scholarship on 
transnational reproduction and “living drugs”—drugs that “[make] ordinary lives, 
social relationships and political institutions”10—I argue that the pharmocratic 
scripts of modernity and cultural backwardness reproduced in discourses about 
underground misoprostol reflect the proliferation of an updated version of bootstraps 
individualism I will refer to as “reproductive neoliberalism”: the idea that, in lieu of 
state-provided equitable and holistic reproductive care, women can still achieve 
reproductive autonomy through entrepreneurial, legal, and pharmaceutical 
prowess.11 Reproductive neoliberalism engenders a particular form of racialized 
 
8 Barbara L. Marshall, “Sexual Medicine, Sexual Bodies and the ‘Pharmaceutical 
Imagination,’” Science as Culture 18, no. 2 (June 1, 2009): 133–49. 
9 Kaushik Sunder Rajan, Pharmocracy: Value, Politics, and Knowledge in Global 
Biomedicine (Durham: Duke University Press, 2017). 
10 Dr Suzanne Fraser, Kylie Valentine, and Celia Roberts, “Living Drugs,” Science as 
Culture 18, no. 2 (June 1, 2009): 124. 
11 In a radically different context, a similar term, “reproductive libertarianism,” has 
also been used to support the unobstructed use of assisted reproductive technologies 
(ARTs), particularly for folks whose sexual orientation and/or sexual anatomy 
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capital, one that invisibly authorizes the uneven transfer of legal and medical 
liability away from pharmaceutical corporations. As a consequence, the state 
becomes complicit in producing a context wherein individuals are made to bear the 
“hot potato” burdens of legal, medical, and affective/cultural liability—forms of 
conscripted labor inherent in the act of transgressing federal licensing and 
malpractice laws, as well as in the very real, embodied fear of accidental injury 
(bodily, emotional, existential) to oneself or someone else in the process. 
Reproductive Health and Justice in a Neoliberal Context 
Although working from distinct missions and approaches, health activists 
have long taken on this labor of liability in an effort to support bodily and 
reproductive autonomy, whether this has taken the form of community health clinics, 
reproductive health workshops, published collections of women’s reproductive 
experiences, zines and pamphlets for self-induced or do-it-yourself (“DIY”) 
abortions.12 In the United States, many of these projects were in part motivated not 
 
necessitates methods of conception other than cisgender heterosexual intercourse. 
See: Andrew Solomon, “Meet My Real Modern Family,” Newsweek, January 30, 
2011. 
12 The Barnard College Zine Library has an incredible collection of zines about DIY 
reproductive health, rights, and justice. For scholarship on DIY activism in the 
reproductive rights and justice movements, see: Jill E. Adams, Melissa Mikesell, and 
The SIA Legal Team, “Primer on Self-Induced Abortion” (Berkeley: Center on 
Reproductive Rights and Justice, 2017); Charles L. Briggs and Daniel C. Hallin, 
Making Health Public: How News Coverage Is Remaking Media, Medicine, and 
Contemporary Life (Routledge, 2016); Daniel Grossman et al., “Self-Induction of 
Abortion among Women in the United States,” Reproductive Health Matters 18, no. 
36 (November 2010): 136–46; Laura Kaplan, The Story of Jane: The Legendary 
Underground Feminist Abortion Service (Chicago: University of Chicago Press, 
1997); Kelly Suzanne O’Donnell, “Reproducing Jane: Abortion Stories and Women’s 
 9 
simply by the liberatory possibilities of taking one’s health into one’s own hands in 
the face of systemic injustice, but also by the urgent need to more fully realize the 
transformative power of grassroots community organizing. For instance, in response 
to medical malpractice and obstetric violence in municipal hospitals, the Black 
Panther Party set up its own clinics, known as the People’s Free Health Clinics 
(PFHCs). Part of the PFHCs’ mission was to combat violent medical practices 
against Black people—what they described as institutional genocide—in favor of a 
“self-health” praxis, which understood patients as experts on their own health.13 In 
this sense, self-health aimed to disrupt the hierarchical relationship between medical 
professional and patient, enabling patients to be more agential participants in their 
own treatment. Drawing on the medical expertise of their communities, PFHCs 
offered comprehensive health services out of trailers and old store fronts, not only 
including preventative health care for men and women, but also birth control access, 
gynecological exams, mental health services, and drug addiction support. 
Importantly, this self-health praxis did not mean caring for one’s health in isolation, 
but rather, leveraging community members’ medical expertise and DIY solutions 
through a community-driven, holistic health praxis. 
 
Political Histories,” Signs: Journal of Women in Culture and Society 43, no. 1 (2017): 
77–96; Jael Miriam Silliman et al., Undivided Rights: Women of Color Organize for 
Reproductive Justice (Cambridge: South End Press, 2004); Patricia Zavella, 
“Contesting Structural Vulnerability through Reproductive Justice Activism with 
Latina Immigrants in California,” North American Dialogue 19, no. 1 (April 25, 
2016): 36–45. 
13 Alondra Nelson, Body and Soul: The Black Panther Party and the Fight Against 
Medical Discrimination (Minneapolis: University of Minnesota Press, 2011), 89. 
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In particular, reproductive justice activism in the United States has been 
especially crucial for situating community-led, patient-centered healthcare as one 
among many approaches to achieving reproductive freedom. Centering the 
experiences and leadership of women of color and indigenous women, the advocacy 
group Asian Communities for Reproductive Justice (ACRJ) defines reproductive 
justice as 
the complete physical, mental, spiritual, political, economic, and social well-
being of women and girls, and will be achieved when women and girls have 
the economic, social and political power and resources to make healthy 
decisions about our bodies, sexuality and reproduction for ourselves, our 
families and our communities in all areas of our lives.14 
 
Developed as a corrective to the individualist, choice-based approach of the 
mainstream (mostly white, middle and upper-class) reproductive rights movement, 
reproductive justice is intersectional, radically inclusive, and comprehensive. It is as 
much an activist roadmap as it is an epistemological framework.15 As Loretta Ross, 
one of the first to coin the term, puts it: 
 
14 Asian Communities for Reproductive Justice (ACRJ), “A New Vision for 
Advancing Our Movement for Reproductive Health, Reproductive Rights and 
Reproductive Justice” (Asian Communities for Reproductive Justice, 2005), I. 
15 See: Rebecca J. Cook and Bernard M. Dickens, “From Reproductive Choice to 
Reproductive Justice,” International Journal of Gynecology & Obstetrics 106, no. 2 
(8/2009): 106–9; Barbara Anne Gurr, Reproductive Justice: The Politics of Health 
Care for Native American Women (New Brunswick, New Jersey: Rutgers University 
Press, 2015); Zakiya Luna, “From Rights to Justice: Women of Color Changing the 
Face of US Reproductive Rights Organizing,” Societies Without Borders 4, no. 3 
(October 1, 2009): 343–65; Zakiya Luna and Kristin Luker, “Reproductive Justice,” 
Annual Review of Law and Social Science 9, no. 1 (November 3, 2013): 327–52; 
Kimala Price, “What Is Reproductive Justice?: How Women of Color Activists Are 
Redefining the Pro-Choice Paradigm,” Meridians 10, no. 2 (April 1, 2010): 42–65; 
Silliman et al., Undivided Rights; Andrea Smith, “Beyond Pro-Choice versus Pro-
Life: Women of Color and Reproductive Justice,” NWSA Journal: A Publication of 
 11 
Reproductive justice is a theory for thinking about how to connect the dots in 
our lives. It is also a strategy for bringing together social justice movements. 
But also, it is a practice—a way of analyzing our lives through the art of 
telling our stories to realize our visions and bring fresh passion to our work.16 
 
The kind of DIY culture the reproductive justice movement engages is always in 
service of a much more radically transformative mission: to create the foundational 
conditions in which total reproductive freedom can be realized, specifically by 
centering the reproductive experiences of women, trans*, and gender nonconforming 
people whom current political, cultural, economic, and healthcare systems most 
actively reject. 
While mainstream liberal investigative journalists are quick to see 
underground misoprostol as a potentially transformative DIY method, they do so at 
the cost of recentering abortion as the way to achieve reproductive freedom; they 
also tend to attribute off-label use of miso to the innovative accidents of the 
pharmaceutical industry, as opposed to the expertise and community mobilization of 
those using and distributing the drug. In an era in which commodity culture uses the 
term “DIY” to describe a particular middle- and upper-class aesthetic (e.g. home 
decor, beauty treatments, IKEA “hacks,” all claiming to “transform” one’s life), 
stories about misoprostol’s transformative potential merges not only with exclusive 
abortion access, but also with the individualist language of elite commodity culture: 
 
the National Women’s Studies Association 17, no. 1 (2005): 119–40; Robin West, 
“From Choice to Reproductive Justice: De-Constitutionalizing Abortion Rights,” Yale 
LJ 118 (2008): 1394. 
16 Reproductive Justice Briefing Book: A Primer on Reproductive Justice and Social 
Change, n.d., 4. 
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miso gets read as a magic bullet promising a universalist notion of reproductive 
autonomy for women everywhere, despite the substantive cultural and institutional 
transformations such a promise requires. In other words, notions of radically 
transformative reproductive freedom become conflated with the individualist, race- 
and class-blind notions of self-help espoused by mainstream, multiculturalist 
commodity culture, evacuating miso from the broader neoliberal contexts within 
which the drug first arose and continues to circulate. In this way, one of the central 
violences of mainstream discourses about underground miso has been to silence the 
reproductive justice movement’s central mission: by misreading underground miso-
use as evidence of reproductive freedom, rather than as both a symptom of and 
response to systemic dysfunction, consumerist forces endow miso with a 
transformative, cure-all power that, in reality, is far from the kind of systemic change 
toward which the reproductive justice movement has worked for decades. 
Following suit with a reproductive justice framework that understands 
reproduction as both a material reality and epistemological construction powerfully 
shaped by interwoven global and local forces, one of my central goals in this project 
is to correct this violence: to resituate discourses about underground misoprostol 
within the neoliberal structures from which it emerged in the post-World War II 
period, and in particular, bring the pharmaceutical machinery that has so 
successfully eluded these discourses back into the picture. Reproductive 
neoliberalism provides a name for this particular kind of epistemic violence, helping 
to rethink the often counterintuitive relationships between biocapital, state 
 13 
governance, science and technology, and globalization. It also serves as a corrective 
to previous scholarship that has ignored the exploitative possibilities of reproductive 
technologies, not only reductively analyzing the development of the pharmaceutical 
industry itself and erasing the violence of pharmocracy, but also minimizing 
pharmaceutical corporations’ complicity in and perpetuation of systemic inequities. 
Lastly, reproductive neoliberalism roots these blindspots in the material and 
ideological conditions following World War II and the Cold War, particularly in the 
context of what Neda Atanasoski describes as “Euro-America’s [postsocialist] 
humanitarian gaze.”17  
Focusing on misoprostol in particular helps to map how reproductive 
neoliberalism has developed and shifted, particularly in family planning sciences. 
Misoprostol came into public discourse at the peak of what many Americanists 
describe as neoliberal backlash against New Deal-era social infrastructure. In the 
1960s and 70s, this backlash manifested in corporate deregulation, free market 
expansion, increased defense spending, anti-immigrant legislation, and bootstraps 
individualism. Conservative politicians imposed mass restrictions on social 
programs (what they renamed “entitlements”), indexing a move away from post-
World War II notions of national collectivity and solidarity reflected in the New 
Deal.18 In its place was an emphasis on individualistic approaches to health that 
 
17 Neda Atanasoski, Humanitarian Violence: The U.S. Deployment of Diversity 
(Minneapolis: University of Minnesota Press, 2013). 
18 Rebecca J. Hester et al., “Bodies in Translation: Health Promotion in Indigenous 
Mexican Migrant Communities in California,” in Translocalities/Translocalidades: 
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minimized state support while channeling funds into both domestic and international 
population control programs operating under the now controversial name of “family 
planning.”19 At the heart of these discourses and major structural changes was the 
state’s political stake in privileging white heteronormativity modeled by the so-
called nuclear family, perpetuating the false assumption that most welfare recipients 
are poor, single women of color with children. Marked by the provocations of 
population control rhetoric and paranoia about welfare fraud, the neoliberal 
ideologies through which discourses about miso circulate are thus deeply invested 
not only in U.S. notions of the white, heteronormative family unit, but also in the 
privatization of the health industry, which is, for the most part, owned and controlled 
by pharmaceutical companies.20 
One of the hallmarks of reproductive neoliberalism is pharmaceutical 
companies’ entanglement with research and development projects in the Global 
South, a form of humanitarian violence that takes a particular form in family 
planning sciences. Reproductive neoliberalism is both a driver and effect of 
partnerships between family planning and the pharmaceutical industry; in fact, 
 
Feminist Politics of Translation in the Latin/a Americas (Durham & London: Duke 
University Press, 2014), 168–89. 
19 Barbara Herr Harthorn and Laury Oaks, eds., Risk, Culture, and Health Inequality: 
Shifting Perceptions of Danger and Blame (Westport & London: Praeger Publishers, 
2003); Hester et al., “Bodies in Translation: Health Promotion in Indigenous Mexican 
Migrant Communities in California”; Dorothy E. Roberts, Killing the Black Body: 
Race, Reproduction, and the Meaning of Liberty (New York: Vintage Books, 1998); 
Nikolas S. Rose, The Politics of Life Itself: Biomedicine, Power, and Subjectivity in 
the Twenty-First Century, Information Series (Princeton: Princeton University Press, 
2007). 
20 Roberts, Killing the Black Body. 
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pharmaceutical companies have often operated marketing and sales initiatives 
directly through family planning programs. For instance, in U.S.-funded family 
planning initiatives in Puerto Rico in the 1960s, pharmaceutical companies tested 
new forms of birth control on working class Puerto Ricans, subjecting mostly poor 
women of color to dangerous drugs proposing to empower women via fertility 
control.21 Capitalizing on the universalist term “health” to underscore the urgency of 
providing a variety of pharmaceutical resources—drugs, vaccines, education—to the 
so-called developing world, this rhetoric understands Third World peoples as 
lucrative targets for new markets, providing incentives to expand state and 
pharmaceutical interventions globally. It also sutures the language of humanitarian 
aid to liberal elite notions of self-empowerment, recasting population-oriented 
interventions as individualist, choice-based health provisions. As Rebecca Hester 
explains: “In a reversal from previous health models in which socio-economic status 
was a primary determinant of health and therefore one needed to be productive to 
have good health, under neoliberalism, one first needs to have health to be 
productive.”22 In this way, the term “health” solidifies an institutional alliance 
between pharmaceutical companies and family planning organizations that erases the 
ideological alliance between (race-blind) neoliberal multiculturalism and (class-
 
21 Laura Briggs, Reproducing Empire: Race, Sex, Science, and U.S. Imperialism in 
Puerto Rico, American Crossroads 11 (Berkeley: University of California Press, 
2002). 
22 Hester et al., “Bodies in Translation: Health Promotion in Indigenous Mexican 
Migrant Communities in California,” 173. 
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blind) bootstraps individualism, forces that work together to maintain white 
supremacy.23 
It is therefore no coincidence that scandalous reports about underground 
misoprostol emerged right about the same time that family planning practitioners 
began to push back against their field’s name in the late 1980s, ultimately renaming 
it “reproductive health” at the 1994 International Conference on Population and 
Development (ICPD) in Cairo, Egypt. While the “family” signifier had previously 
enabled neo-Malthusian population control organizations to dilute what was, in 
reality, violent, eugenic, coercive medical malpractice, the ICPD institutionalized an 
ethical and political discomfort, in that “family” could no longer be as visibly 
embedded in the liberal-progressive language of health, modernity, and (self-
)empowerment. This institutional eagerness to bury the family planning terminology 
may be a well-meaning response to the prolific scholarship on the persistence of 
eugenic practices exercised via family planning programs; yet, while the shift to 
reproductive health may not explicitly include the family signifier and may more 
accurately represent the more comprehensive kind of preventative and treatment-
focused work they do within the context of their own field, the proliferation of the 
 
23 While one might argue that neoliberal multiculturalism and bootstraps 
individualism are both race- and class-blind, in the sense that both ideologies are 
altogether ignorant to the ways that identity formation shapes material realities (and 
vice-versa), I make the distinction here because neoliberal multiculturalism puts race 
and class into relationship differently than bootstraps individualism does. While 
neoliberal multiculturalism commodifies difference, bootstraps individualism rejects 
difference as a determinant of class (im)mobility. For this reason, when I use the term 
“white supremacy,” I am referring to the whole intersectional machinery of racism, 
classism, patriarchy, and ableism. 
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term “health” also marks the success of mega pharmaceutical companies’ espousal 
of a Western teleology of emancipation via health. Motivated by a secularist, liberal-
progressive politics deeply entangled in the growth of the pharmaceutical industry, 
such language uncritically defines “health” simply as access to pharmaceutical 
resources, what João Biehl calls the “pharmaceuticalization of public health,” in 
which public health is “understood less as prevention and clinical care and more as 
access to medicines.”24 This universalist definition of health—in which health is a 
fixed, personal ability measured by proximity to and proper use of pharmaceutical 
products, rather than a set of conditions for thriving largely determined by 
intersecting systemic forces—reproduces the individualist ideologies that undergird 
neoliberal projects carried out by state and corporate actors. 
The term “pharmocracy” has been an especially helpful tool with which to 
conceptualize the impressively cooperative but often destructive partnerships 
between transnational state and institutional actors. In his work on Novartis’s 2002 
drug donation program (the Gleevec International Patient Assistance Program, or 
GIPAP), which aimed to make Gleevec—a treatment for leukemia—accessible to 
patients in India who could not afford the drug, Kaushik Sunder Rajan writes: 
…corporate philanthropy provides the justification for monopoly even as 
monopoly provides the conditions of possibility for philanthropy. This is a 
case of the multinational pharmaceutical industry projecting itself as an agent 
of humanitarian redemption while emphasizing the necessity of monopoly 
protections in order to do so.25         
 
 
24 João Guilherme Biehl, Will to Live: AIDS Therapies and the Politics of Survival 
(Woodstock: Princeton University Press, c2007), 12. 
25 Sunder Rajan, Pharmocracy, 157. 
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Rajan’s work signals an important shift in manifestations of corporate neoliberalism 
since the rapid growth of the tech and start-up industries. As pharmaceutical 
companies figure the Global South as both the recipients of pharmaceutical 
donations and prime research subjects for clinical trials,26 pharmaceutical products 
have come to be understood as both commodities and lifesaving therapeutic agents 
“increasingly essential in the definition of human rights and projects of humanitarian 
assistance.”27 Capitalizing on the fashionable nexus of entrepreneurship, 
humanitarianism, and scientific and technological innovation, major pharmaceutical 
companies have come to publicly espouse a moral philosophy grounded in 
“corporate citizenship” while routinely committing marketing fraud, bribing medical 
professionals to prescribe their products, raising prices on essential medicines, and 
curating the medical research they submit to the U.S. Food and Drug Administration 
(FDA) for approval. The joined rhetoric of “corporate responsibility” and “social 
entrepreneurship” has thus coincided with the increasing privatization of the health 
industry, suggesting that, under neoliberal multiculturalism, corporations adopt the 
state’s language of official anti-racism as evidence of their ability to self-regulate. 
As a consequence, the state not only fails to regulate corporate activities, but also 
 
26 See: Briggs, Reproducing Empire; Melinda Cooper and Catherine Waldby, Clinical 
Labor: Tissue Donors and Research Subjects in the Global Bioeconomy (Durham: 
Duke University Press, 2014). 
27 Jeremy A. Greene, “Pharmaceutical Geographies: Mapping the Boundaries of the 
Therapeutic Revolution,” in Therapeutic Revolutions: Pharmaceuticals and Social 
Change in the Twentieth Century, ed. Jeremy A. Greene, Flurin Condrau, and 
Elizabeth Siegel Watkins (Chicago, London: University of Chicago Press, 2016), 152. 
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actively concentrates and expands corporate power while maintaining a symbolic 
commitment to official anti-racisms.28 
Today, Global South women continue to be recruited into clinical trials 
funded through partnerships between drug companies and state initiatives. For 
example, Rockefeller University, an offshoot of the Rockefeller Institute that funded 
and collaborated with eugenics societies pre-WWII, offers programs for students to 
work directly with pharmaceutical companies, a so-called public-private partnership 
they advertise on their website: 
Pfizer’s Centers for Therapeutic Innovation, or CTI, is a unique program that 
collaborates with leading academic medical centers, the NIH, and 
foundations to speed the translation of novel targets to the clinic. A 
partnership with CTI may include collaborative use of Pfizer’s technologies, 
publishing rights, and financial awards in the form of milestone and royalty 
payments for successful programs, in addition to providing appropriate funds 
for carrying out the collaborative work.29 
 
Often these public-private partnerships are not exactly partnerships. For instance, 
from 2014-2015, Pfizer funded 100 percent of a USAID project to “improve 
efficiencies in its sales and medical detailing programs.”30 From 2009-2011, Pfizer 
West Africa partnered with USAID Senegal “with the goal of increasing the 
availability of high quality contraceptive products, namely the injectable 
contraceptive Depo-provera, into the private sector market,” again donating 100 
 
28 Jodi Melamed, Represent and Destroy: Rationalizing Violence in the New Racial 
Capitalism (University of Minnesota Press, 2011). 
29 “Pfizer CTI Call for Proposals,” The Rockefeller University: Science for the 
Benefit of Humanity. 
30 USAID, “SIFPO,” USAID Global Partnerships. 
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percent of the funding.31 USAID provided direct access to the target populations, 
explaining: 
Pfizer will be largely available for making the product available at an agreed 
price, while USAID/Senegal will be responsible for the social marketing of 
the product. The overall goal is to increase the availability of high quality 
contraceptive products and services, and meet part of the unmet demand for 
women wanting to space the births of their children, in order to contribute to 
improving the health of Senegalese women and children.32 
 
Media outlets are also invested in these collaborations. From 2001-2004, USAID’s 
Credit Management System (CMS) partnered with Pfizer, Wyeth, Schering-Plough, 
and two anonymized categories of donors labeled “pharmaceutical companies” and 
“host country local media.”33 It was largely a public relations project: 
[The goal of the partnership is] to promote the use of generic low-dose oral 
contraceptives through advertising, public relations and training. The desired 
outcome is to provide information to women about the benefits of oral 
contraceptives, to address the fears of side effects, and to raise awareness on 
the safe use of oral contraceptives.34 
 
Over the course of the three-year project, non-USG (United States Government) 
donors—i.e. the pharmaceutical companies and local media—reportedly made up 
over 65 percent of the total donations to the project, reflecting the significant owning 
power pharmaceutical companies and media together hold in these public-private 
collaborations. These partnerships between pharmaceutical companies, media, and 
Rockefellian family planning sciences are consistently framed as cutting-edge 
research opportunities designed to expedite new drugs into spaces in which they can 
 
31 USAID, “Depo Provera Accessibility,” USAID Global Partnerships. 
32 USAID. 
33 USAID, “CMS Project,” USAID Global Partnerships. 
34 USAID. 
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be bought and consumed. The benefits of such collaborations—publishing rights and 
funding—are defined not only in terms of immediate technological and financial 
resources, but also as patented knowledge that will pay royalties in the future. This 
raises questions not only about how capitalistic and corporate interests influence the 
design and delivery of humanitarian aid in these projects, but also vice-versa: how 
the design and delivery of humanitarian aid supports the growth of the U.S. 
pharmaceutical industry more broadly. 
Scholarly Interventions: The Limits of Economic Analysis 
Until recently, historians of the U.S. pharmaceutical industry have attributed 
its massive growth over the last two centuries to what Charles E. Rosenberg 
famously termed, in 1977, the “therapeutic revolution.”35 In “The Therapeutic 
Revolution: Medicine, Meaning, and Social Change in Nineteenth-Century 
America,” Rosenberg argues that the study of pre-nineteenth century medicine had 
ignored the economic and cultural dimensions of clinical practices, a blindspot he 
describes as the “increasingly aggressive empiricism of the nineteenth century.”36 
According to Rosenberg’s theory, for most of the nineteenth century in the United 
States, pharmacists operated out of family-owned retail stores and apothecaries, 
 
35 Charles E. Rosenberg, “The Therapeutic Revolution: Medicine, Meaning, and 
Social Change in Nineteenth-Century America,” Perspectives in Biology and 
Medicine 20, no. 4 (1977): 485–506. More recent scholarship on the pharmaceutical 
industry problematizes Rosenberg’s use of the term “revolution.” See: Jeremy A. 
Greene, Flurin Condrau, and Elizabeth Siegel Watkins, Therapeutic Revolutions: 
Pharmaceuticals and Social Change in the Twentieth Century (Chicago: University 
of Chicago Press, 2016). 
36 Rosenberg, “The Therapeutic Revolution,” 486. 
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which primarily sold home supplies like soaps, candy, and other odds-and-ends in 
addition to drugs and homeopathic remedies. Pharmacists sourced mostly plant-
based compounds from wholesaler chemical materials companies and then mixed 
and sold prescriptions on site, in small batches, and with very limited or no 
consumer marketing.37 Although both physicians and pharmacists stocked similar 
herbal and chemical materials, in this context, drug synthesis was relatively 
imprecise work, even when mixed by the same person, as compounds were mostly 
mixed and prescribed on an “as-needed,” per person basis. Rosenberg reasons that 
pharmaceutical businesses operated this way in part because of physicians’ 
remarkably holistic approach to the body as an interconnected system of systems: the 
idea of treatments for an isolated malady—for example, the targeted treatment of a 
virus—went against the prevailing pathology that illness was always the outcome of 
a systemic bodily issue. As Rosenberg puts it, “every part of the body was related 
inevitably and inextricably with every other. A distracted mind could curdle the 
stomach, a dyspeptic stomach could agitate the mind. Local lesions might reflect 
imbalances of nutrients in the blood; systemic ills might be caused by fulminating 
local lesions.”38 In other words, the body was a systemic unit that necessitated 
patient-specific treatments; there was no concept of a “miracle drug” that could be 
produced and distributed en masse. 
 
37 Jonathan Liebenau, Medical Science and Medical Industry: The Formation of the 
American Pharmaceutical Industry (Basingstoke, Hampshire: Macmillan Press, 
1987). 
38 Rosenberg, “The Therapeutic Revolution,” 487–88. 
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Rosenberg identifies two major historical events he believed transformed this 
model into the transnational pharmaceutical giants of today. The first, he argues, was 
the Civil War, during which military demand for pharmaceutical products prompted 
pharmacists to create national distribution routes, which in turn required pharmacists 
to specialize in drug production and distribution.39 The second was the development 
of vaccines and antibacterial drugs toward the end of the nineteenth century, which 
inspired major investments in pharmaceutical research and educational institutions, 
producing more consistent, thorough pharmacological training and shared sources of 
knowledge. The assumption among historians of the pharmaceutical industry was 
that this combination of academic prestige, consumer demand, and available funding 
created attractive new business prospects. Newly patented technologies—tableting 
machines, for instance—streamlined drug manufacturing and distribution processes, 
enabling pharmacists to produce drugs with more precision, consistency, and at a 
much faster rate than the “handmade” method.40 
While Rosenberg’s observations help to situate a social analysis of medicine 
within a broader set of political and economic systems, the therapeutic revolution 
theory also uncritically transposes a presumed “revolutionary-ness” onto the 
development of each new drug, reproducing a link between health, modernity, and 
(neo)liberal notions of freedom that the pharmaceutical industry has long 
evangelized (a history I take up in Chapter 1). In a scholarly form of tragic irony, 
 
39 Liebenau, Medical Science and Medical Industry. 
40 For an overview of modern medical manufacturing, see chapter 9 of Liebenau, 
125–134. 
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one of the analytic blindspots the therapeutic revolution theory has thus helped to 
shield is the very paradigm it sought to crystallize: the material-discursive 
relationships between pharmaceutical innovation, capital, and liberal-progressive 
notions of humanitarianism. 
Reflecting on his work nearly four decades after his seminal 1977 article was 
published, Rosenberg admits that “the concept of a twentieth-century therapeutic 
revolution obscures as well as illuminates… the casual invocation of a ‘therapeutic 
revolution’ obscures the ways in which clinical practice is necessarily a component 
in a complex time- and place-specific system of ideas and social practices that 
cannot be understood outside of that larger context.”41 Here, Rosenberg points to an 
epistemological and methodological tension: on the one hand, the therapeutic 
revolution model helps connect pharmaceutical products to their specific economic 
contexts, an epistemic intervention in which scientific and technological innovations 
are always understood as products of the material conditions in which they arise. On 
the other hand, the therapeutic revolution model also inhibits more nuanced analyses 
of what specific material conditions are worthy of investigation and, by the same 
token, what is meant by “therapeutic” and “revolutionary.” He goes on to say: 
There has never been a time or place without modes of curing; we have 
always had therapeutics with us. But it is characteristic of our particular 
system that we assume that modern therapeutic practices are categorically 
different—the result of a cumulative understanding of the natural world and a 
capacity to intervene that somehow removes Western therapeutic practices of 
 
41 Charles Rosenberg, “A Therapeutic Revolution Revisited,” in Therapeutic 
Revolutions: Pharmaceuticals and Social Change in the Twentieth Century, ed. 
Jeremy A. Greene, Flurin Condrau, and Elizabeth Siegel Watkins (Chicago, London: 
University of Chicago Press, 2016), 302–3. 
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the past century from the contingency that is culture… This is a powerful and 
culturally dominant narrative, appealing to our faith in science and the 
inevitability of progress, to hope that sickness will be vanquished through the 
inevitable accumulation of “breakthroughs” and “insights.”42 
 
Rosenberg echoes Michel Foucault’s foundational concerns about the production of 
scientific knowledge as empirical truth, suggesting that his (Rosenberg’s) theory of 
the therapeutic revolution was in part a product of his own internalized “faith in 
science and the inevitability of progress.” As Foucault puts it in The Birth of the 
Clinic, it was not so much that knowledge itself had accrued, but rather that “the 
relation between the visible and invisible—which is necessary to all concrete 
knowledge—changed its structure.”43 
In connection with my project on discourses about underground misoprostol, 
I write so much about Rosenberg’s theory here in order to underscore the point that, 
perhaps more powerful than the technological and educational innovations 
themselves were the ways in which the study of those products—even when put into 
their cultural contexts—has disciplined pharmacology into an elite professional 
science, reinforcing the teleological, epistemic authority espoused in pharmaceutical 
marketing materials. In other words, while I too read material conditions as 
fundamental to understanding how certain pharmaceutical products became and 
become marketable, I resist notions of pharmaceutical revolution that imply a radical 
unleashing of health and medical potential, as opposed to the intensification of 
 
42 305. 
43 Michel Foucault, The Birth of the Clinic: An Archaeology of Medical Perception 
(London: Routledge, (1973) 2003), xii. 
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existing liberal-democratic and capitalist forces. Rather than misunderstanding 
pharmaceutical products as relics of cumulative, progressive knowledge, as the 
therapeutic revolution theory suggested, we need to think of the intellectual 
significance assigned to these objects as being in constant states of revision and 
meaning-making, rippling across time and place, disciplines, and markets. 
Methodologies: Object Phenomenology 
When I have explained this project to friends and colleagues in the past, 
some people have asked me whether I will go to El Salvador or the U.S.-Mexico 
border and ask flea market vendors how they procure misoprostol. Who supplies 
miso to them? How do the suppliers get it? 
While I can understand why people would be curious about this, the subtext 
of these questions (i.e. are the flea market vendors criminals? If not, who is?) 
reproduces a juridical gaze, one that seeks to criminalize individuals rather than state 
and corporate actors who largely control the circumstances under which 
underground miso circulates. To begin with such questions would be to design my 
analysis according to colonial logics of ownership and carcerality. Other people are 
already pursuing these questions—the U.S. Drug Enforcement Administration, for 
one—and it is not a project in which I wish to participate. 
At the same time, this recurrent question has prompted me to think about the 
most basic methodological, logistical aspects of my project. What does it look like to 
track an object without reproducing the limitations and violences of surveillant 
discourses already at work? If I am refusing to seek seemingly basic information—
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where flea market vendors get miso from—what am I really asking in this project? 
What can I ask? In other words: what are the analytical possibilities and limits of 
tracking an object I am not actually looking for, at least not in the most literal sense? 
This kind of analysis—one that traces an object I do not intend to find—
requires a theory of misoprostol as a particular kind of pharmaceutical object, one 
that immediately sets in motion a set of critical deceptions. Ironically, one of the 
reasons misoprostol is said to be such an ideal off-label abortifacient is because of 
the ways it masquerades as natural physiological processes, refusing its own 
objectness and therefore its own trackability: unlike a recreational drug like 
marijuana or cocaine, once swallowed, it dissolves so quickly that it is forensically 
untraceable within thirty minutes. Depending on the context in which it is consumed, 
miso is also metamorphic: it returns menstruation when menses goes “missing”; it is 
a cleansing “wash”; sometimes compared to turmeric, it brings down 
inflammation.44 In other words, miso does not only treat; it finds, it cleans, it 
“brings.” 
Recent work in object phenomenology brings some helpful tools with which 
to conceptualize misoprostol’s objectness, engaging critical race theory, queer 
theory, and disability theory to understand different kinds of nonhuman matter as 
animate forces. In the relatively recent wave of “new materialism,” as it has been 
 
44 Mizanur Rahman, Julie DaVanzo, and Abdur Razzaque, “Pregnancy Termination 
in Matlab, Bangladesh: Maternal Mortality Risks Associated with Menstrual 
Regulation and Abortion,” International Perspectives on Sexual and Reproductive 
Health 40, no. 3 (2014): 108–18. 
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termed, scholars have experimented with making an object do something, 
temporarily imbuing various kinds of matter (metals, cells, words) with what they 
apprehensively describe as life, animacy, agency, willfulness, energy, even 
vibrance.45 As Christopher Pinney succinctly puts it, “Clearly things make people, 
and people who are made by those things go on to make other things. The central 
question, however, is not whether this does or doesn’t happen, but in what kind of 
way it happens.”46 By defamiliarizing the divisions between the human and 
nonhuman—a “living” thing and another’s “thing-ness”—this scholarship 
persuasively confirms that matter accumulates and produces meaning in relational 
processes of cultural, economic, phenomenological intra-action.47 
Yet as Felicity Amaya Schaeffer points out in her recent work, “Spirit-
Matters: Gloria Anzaldúa’s Cosmic Becoming across Human/Nonhuman 
Borderlands,” the new materialist turn in humanities scholarship silences indigenous 
epistemologies that do not think according to Western secular dualisms, such as 
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human/nonhuman. In other words, indigenous peoples have always understood 
nonhuman matter to be animate, a part of what Schaeffer describes as Anzaldúa’s 
“cosmic spirit-mattering.” Schaeffer urges readers to put Chicanx/Latinx decolonial 
“theory in the flesh” and “feminist debates on experiential epistemologies and 
ontologies” in conversation with one another, explaining: 
The importance of questioning the Western split between subject/object in 
early scholarship—such as Donna Haraway’s refusal of the nature/culture 
divide through her theorization of the cyborg, or the intermingling of 
human/machine—was a powerful move, yet it had the effect of blurring the 
lines between elected co-becomings between humans and machines versus 
the uneven and compulsory ways certain groups were forced into tangled 
relationality with techno-objects (and animality).48 
 
I believe a lot of reproductive politics scholarship has done some of this work in 
important ways, analyzing how family planning projects and assisted reproductive 
technologies become powerful biopolitical forces deeply invested in extractive 
capitalism.49 In this way, my project follows suit with the state and institutional 
critiques that this scholarship has already brought forward, demonstrating how 
Pfizer’s research and development practices are, too, part of a modern colonial 
project that renders certain kinds of bodies and land available for capitalistic 
 
48 “Spirit Matters: Gloria Anzaldúa’s Cosmic Becoming across Human/Nonhuman 
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ability of state and institutional systems to discipline bodies into particular states of 
docility, deviance, and redemption that work to maintain hegemonic systems of 
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exploitation and the production of biocapital.50 Working from the premise that 
pharmaceutical matter is made to materialize in order to construct certain kinds of 
bodies and forms of (de)humanization, my project engages in a form of what 
Schaeffer describes as “listening to and becoming utterly otherwise.”51 The 
conceptual frameworks I employ in this project are thus as much about transgressing 
and decolonizing pharmaceutical, experiential, bodily knowledge as they are about 
remaking our orientations to pharmaceutical objects. 
Misoprostol is deeply imbedded in the binaristic language of techno-
scientific modernity and racialized primitivism; it is also somewhat unique in that it 
needs no help challenging its own object-ness. It already does this across disciplines 
and epistemologies; quite literally, misoprostol triggers a cascade of physiological 
processes and disappears from the body at the same time. From this perspective, 
what I really mean when I say that I am “tracking misoprostol” is that I am tracking 
misoprostol’s biopolitical footprint: not how it physically gets from one point to the 
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next, but rather, how miso gets marked, and what its circulation continually leaves 
behind. I am looking for its ripples. When does a drug become a drug? When does it 
exceed the pharmaceutical? 
As a kind of metamorphic pharmaceutical object, one of the gains of 
focusing on misoprostol as opposed to another pharmaceutical object connected to 
reproduction is thus that I can join systemic and global analyses with local and 
bodily ones while simultaneously resisting the distinction between seeing “locally” 
or bodily, and seeing “globally” or transnationally. In other words, allowing 
misoprostol to be my primary (if elusive) object of analysis epitomizes how meaning 
and materiality are mutually constitutive. It embodies how history, culture, and 
politics contingently define objects not by the kind of (secular, molecular) matter of 
which they may be composed, but rather, as a flexible tool through which hegemonic 
forces “unevenly and compulsorily” subject people and the planet to the institutional 
and cultural prisms of techno-scientific rationality and juridical culpability. As a 
thing that pharmaceutical companies, mainstream liberal media, and family planning 
sciences have orientated toward and which orients an “us,” misoprostol becomes 
both the object and the lens through which to bind these material-discursive analytics 
together. 
Chapter Summaries 
In the chapters that follow, I analyze three deeply connected and yet 
discursively severed archives of reproductive neoliberalism enacted via 
misoprostol’s biopolitical footprint: (1) Pfizer’s corporate marketing, research and 
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development strategies post-World War II, with a special focus on their annual 
financial reports; (2) journalistic reports on the underground sale of misoprostol at 
flea markets in the Global South, which, in addition to regions conventionally read 
as “Third World” in U.S. political discourse, also includes disparate parts of the 
United States that are nevertheless linked by discourses about non-white immigrant 
populations, extreme anti-abortion legislation, or both (e.g. the Texas-Mexico 
border, or Washington Heights in New York City); and (3) family planning 
discourses about obstetric uses of misoprostol represented in a variety of scholarly 
and institutional documents, including case studies, op-eds, mission statements, and 
correspondence with major health organizations such as the World Health 
Organization (WHO).52 Bringing these three key points of engagement together 
enables me to unpack some critical blindspots: how might tracking misoprostol’s 
circulation in these discourses help to define and map the emergence of reproductive 
neoliberalism? How might it make visible the ways that pre and postsocialist trends 
in technological research and development in the United States have simultaneously 
corporatized and corporealized reproductive risk and safety? What forms of 
biocapital does reproductive neoliberalism produce? And how might my analysis 
here help to inform contemporary scholarship on empire, reproduction, and 
technoscientific violence in ways that support the reproductive justice mission? 
 
52 “Pfizer’s Annual Review, 2016: Bringing Resources to Bear to Improve Global 
Health,” Pfizer’s Annual Review 2016, accessed October 11, 2017. 
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As I will show in the chapters that follow, U.S.-based discourses about 
underground misoprostol reconstruct and export the ideology of reproductive 
neoliberalism, revealing the ways liberal-democratic ideals of individualism and 
responsibilization permeate pharmaceutical imaginaries and Global South 
subjectivities. In a necessarily paradoxical move, reproductive neoliberalism 
characterizes the Global South as both a barrier to and source of technological, 
medical, and social progress, rendering Global South subjects as populations and 
inhabitants of land that must be managed by technoscientific intervention.53 This is 
an updated iteration of a very old story in which bilateral tropes of primitivism and 
technological edge, spirituality and secularity, globalization and individualism 
mobilize multiculturalist ideologies, which then map onto and emerge from 
(re)productive bodies.54 Persistently read as a phenomenon exclusive to the Global 
South, miso becomes a technology through which to perpetuate reproductive 
neoliberalism—to erase the historical legacies of extraction and colonial violence 
that prop up the technoscience of modern medical discoveries. 
 
53 Ulrich Beck, Risk Society: Towards a New Modernity, Theory, Culture & Society 
(London; Newbury Park, Calif: Sage Publications, 1992); Isabella Bakker and 
Stephen Gill, eds., Power, Production, and Social Reproduction: Human In/security 
in the Global Political Economy (Houndmills, Basingstoke, Hampshire ; New York: 
Palgrave Macmillan, 2003); Harthorn and Oaks, Risk, Culture, and Health Inequality. 
54 Kline, Building a Better Race; Lisa Nakamura, “Indigenous Circuits: Navajo 
Women and the Racialization of Early Electronic Manufacture,” American Quarterly 
66, no. 4 (December 2014): 919–41, 1169; Nancy Stepan, The Hour of Eugenics: 
Race, Gender, and Nation in Latin America (Ithaca: Cornell University Press, 1991); 
Stern, Eugenic Nation; Vora, Life Support. 
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Chapter 1 situates reproductive neoliberalism in the pharmaceutical 
industry’s rapid growth during and following World War II, reading Pfizer’s annual 
financial reports as evidence of the relationship between humanitarian violence and 
the corporate interests of the pharmaceutical industry more broadly. I argue that the 
humanitarian rhetoric espoused by the pharmaceutical industry, and the 
multiculturalist image of U.S. pharmaceutical companies it produces, becomes part 
of the central infrastructure of reproductive neoliberalism, tying the growth of the 
pharmaceutical industry first to U.S. militarism abroad, then to humanitarian aid in 
the Global South, and finally to multiculturalist forms of U.S. official antiracisms. 
This context is critical to understanding how the development of and discourses 
about misoprostol in the late 1980s onward come to embody the transition from the 
United States’ anticommunist patriotism to neoliberal multiculturalism, a timeline 
Jodi Melamed delineates as “a series of successive official or state-recognized U.S. 
antiracisms: racial liberalism (1940s to 1960s), liberal multiculturalism (1980s to 
1990s), and neoliberal multiculturalism (2000s).”55 Observing these shifts through 
literary analysis, Melamed defines neoliberal multiculturalism as “the most recent 
phase of official antiracism, which may have reached its apotheosis in the George 
W. Bush regimes”: 
Neoliberal multiculturalism has responded to the reconfiguration of state 
powers and boundaries under global capitalism by portraying the United 
States as an ostensibly multicultural democracy and the model for the entire 
 
55 Melamed, Represent and Destroy: Rationalizing Violence in the New Racial 
Capitalism. 
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world, but in a way that has posted neoliberal restructuring across the globe 
to be the key to a postracist world of freedom and opportunity.56 
 
For pharmaceutical companies, we can actually see evidence of neoliberal 
multiculturalism as early as the 1960s. I explore how Pfizer’s annual financial 
reports narrate an economic and ideological shift from World War II American 
patriotism to Cold War corporate citizenship, powerfully influencing its research and 
development pursuits. I argue that this production of pharmocratic knowledge is 
what enabled pharmaceutical companies to control family planning initiatives in the 
Global South. In this way, reproductive neoliberalism is a specific (though 
transnational) manifestation of neoliberal multiculturalism that emerged long before 
the George W. Bush administration, one that has taken particular forms in family 
planning circles. 
In Chapter 2, I explore how recent mainstream liberal-progressive 
investigative journalism about underground markets for misoprostol reproduces 
reproductive neoliberalism, wherein misoprostol becomes the vehicle through which 
reproductive neoliberalism gets expressed. In this context, reproductive 
neoliberalism disciplines Global South subjects into a paradoxical subject position in 
which they are valued according to their ability to successfully perform the always-
already racialized markers of techno-scientific and cultural modernity. While the 
well-intentioned, if implicit, support of women and reproductive rights in these 
journalistic pieces seems initially promising, it ultimately misappropriates the 
 
56 Melamed, xxi. 
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language of reproductive freedom in service of reproductive neoliberalism, 
proposing a form of pharmaceutically-enabled reproductive freedom that, in reality, 
silences the systemic, holistic mission of the reproductive justice movement. In this 
context, misoprostol takes on the material-discursive weight of reproductive 
neoliberalism, a recurring pattern in the history of reproductive technologies more 
broadly. As Laura Briggs puts it, Malthusian concerns about overpopulation in 
Puerto Rico in the 1960s—and thus the need for birth control—functioned “as an 
economic theory in drag, which pointed to sex and reproduction to distract from a 
discussion of the role of North American corporations and the federal government,” 
demonstrating “how compacted a symbol birth control really was, at once an 
argument about economics, poverty, nationality, and U.S. political and military 
intervention.”57 Just as birth control became a symbol for neoliberal ideologies, 
misoprostol, too, has become a symbol of and vehicle for reproductive 
neoliberalism. 
Finally, working from reproductive politics scholarship that centers the 
violence of population control executed by family planning programs, Chapter 3 
analyzes how family planning literature on underground misoprostol produces what I 
call an “ethics of rationality,” a data-centric manifestation of reproductive 
neoliberalism. In the process, family planning literature produces another kind of 
Global South subject, one who is morally responsible for the kind of pharmaceutical 
risk-taking underground misoprostol use requires. As a site of knowledge production 
 
57 Briggs, Reproducing Empire, 78, 77. 
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that has historically rendered the relationship between family and nation 
inextricable, family planning research on underground miso acts as a mechanism 
through which reproductive neoliberalism gets reproduced. Yet what also draws me 
to family planning scholarship in this chapter is its complex positionality: straddling 
public and private sectors, much of the family planning programming that exists 
today depends on funding from humanitarian organizations like USAID, which are, 
in turn, frequently funded by pharmaceutical companies. This reality means that the 
aims and structures of family planning programs are inextricable from the marketing 
and distribution efforts of pharmaceutical companies, if not unofficial pharmocratic 
extensions of the technoscientific institutions they serve. At the same time, family 
planning experts have extensive knowledge of the inner workings of the state, 
clinics, pharmaceutical companies, widely disparate structures of care, and—though 
not always reflected in their published work—immense field experience, through 
which many health professionals build intimate, invested relationships rooted in 
reproductive justice advocacy and nuanced theories of collectivity and wellbeing. It 
is this latter set of work that I believe critics of family planning initiatives tend to 
dismiss, partly because partnership between public health professionals and 
academics in the humanities is still relatively unusual, but also because this more 
intimate kind of work in family planning is not usually represented in mainstream 
public health publications. This chapter complicates the ways that such scholarship 
characterizes family planning monolithically, such that the family planning field is 
always-already epistemologically and methodologically violent. While still 
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unpacking the epistemic violence family planning sciences enact, I also “listen 
otherwise” to the counterintuitive ways in which family planning research on 
underground miso both reproduces and disrupts the violence of reproductive 
neoliberalism. 
 I have organized these chapters by genre. Despite my analytical alarm bells 
telling me I ought to resist this way of organizing, I did it anyway in order to mark 
how and when each genre takes up the project of reproductive neoliberalism. 
Melamed’s connecting thread between her chapters is literature; mine is misoprostol 
and its footprints. I also recognize that this structure has inevitably produced its own 
blindspots. In the Epilogue, I expand on the limitations of the work I’ve done so far, 
proposing a vision for ethnographic work that I suspect will deeply enrich this 
project. 
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Figure 3: Full-page ad for Pfizer published in American Chemical Society (August 
10, 1944).  
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CHAPTER 1 
 
Producing Pharmocratic Knowledge: 
The Corporate Citizen as American Patriot 
 
 
 
“You are not a manufacturing company. Manufacturing costs are 
miscellaneous costs. The main costs are the costs of production and 
distribution of knowledge and information.”1 
 
“New knowledge, or new technology, is only potential. Marketing 
converts that potential into fact.”2 
 
Dr. Peter F. Drucker 
Corporate Management Consultant 
Pfizer’s Annual Report, 1981 
 
 
 
In a special feature called “The Transfer of Knowledge” included in Pfizer’s 
1981 Annual Report, Pfizer reimagines the primary work of pharmaceutical 
companies for its shareholders. Featuring an interview with Dr. Peter F. Drucker 
(quoted above), the report frames Pfizer’s increasingly massive investments in 
research and development, marketing, and product distribution processes in terms of 
the infinite economic value and exportability of scientific knowledge. As Drucker 
puts it in another section of the report, the company’s knowledge is “a central 
economic resource” and “a productive force. It is prime energy.”3 From this 
perspective, Pfizer’s most lucrative form of capital is not the pharmaceutical 
 
1 “Annual Report, Special Feature: The Transfer of Knowledge” (Ann Arbor: Pfizer, 
Inc., 1981), 4. 
2 “Annual Report, Special Feature: The Transfer of Knowledge,” 8. 
3 “Annual Report, Special Feature: The Transfer of Knowledge,” 4, 8. 
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products it creates, but rather its power to shape the channels through which 
pharmaceutical knowledge is permitted to take shape—to curate who can be said to 
design, produce, distribute, own, consume, and be knowledgeable about 
pharmaceuticals. In other words, pharmaceutical products constitute just one aspect 
of a much grander purpose to transform pharmaceutical knowledge into capital. 
Marketing is that transformer; as Drucker explains above, it “converts” the 
potentiality of knowledge into “fact,” instilling ways of thinking and knowing that 
encode the pharmaceutical imagination. 
This chapter tracks Pfizer’s role in producing the pharmocratic narratives that 
undergird reproductive neoliberalism. Specifically, I identify the cultural and 
institutional mechanisms through which Pfizer transformed pharmaceutical 
knowledge into capital during the transition from mid-World War II toward the end 
of the Cold War (approximately 1942-1988), demonstrating how the U.S. 
pharmaceutical industry, and Pfizer in particular, sutured humanitarian and 
philanthropic rhetoric to corporate expansion. As Pfizer grew, the intellectualized 
altruism of scientific innovation and universal human benefit masked its corporate 
interests, a key strategy of pharmaceutical neoliberalism more broadly that takes 
particular form in discourses about reproduction (which I develop in Chapters 2 and 
3).  
I especially focus on Pfizer’s annual financial reports for a few connected 
reasons. Although Pfizer and the FDA do not classify annual reports as “marketing,” 
they index the relationship between institution and audience as a producer-to-
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consumer dynamic, in that the reports were specifically designed for audiences 
whom Pfizer’s marketing professionals targeted according to a range of presumed 
characteristics—from consumer behavior, political orientation, and education level 
to shareholding authority and medical, scientific, technological, or legal expertise. 
These materials thus represent a wide variety of forms of consumption and 
distributed capital, as the “consumers” for whom Pfizer designed these reports 
encompass everyday shoppers who purchase Pfizer products in stores and 
pharmacies; health professionals who prescribe Pfizer drugs, implant Pfizer 
technologies into their patients’ bodies, or conduct research using Pfizer products; 
industrial workers who purchase Pfizer products for the purposes of mass production 
(for example, farmers who put Pfizer antibiotics into cattle feed to prevent disease 
and thus maximize milk and meat production); as well as the shareholders on whom 
Pfizer depends and whose wealth is directly tied to Pfizer’s profitability. These 
annual reports thus not only act as unofficial promotional materials (and are thus not 
beholden to FDA regulations on official advertisements) but are also poignant 
illustrations of how products, as objects that signify Pfizer’s institutional brand, act 
as vehicles through which stories of scientific innovation fuse corporate do-gooding 
and economic pragmatism. 
Furthermore, the narrative structure of these reports strikingly models the 
ways in which culture(s) of science, revolution, and economic capital become 
narratively inextricable, constituting the pharmocratic logics that set reproductive 
neoliberalism into motion. Each report contains two parts: a personal letter to 
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stockholders, written and signed by the company’s serving president, followed by 
the accountant’s report, or “raw” financial data. The relationship between these two 
narrative components radically shifted, seemingly overnight, in 1950. Through 1949, 
each report was about 10-12 pages; the letter to stockholders was no more than a few 
paragraphs long, and the rest of each report consisted of tables and numbers (e.g. 
sales in each department, costs of materials, taxes paid), sometimes with short, two-
sentence summaries. In 1950, these legally mandated reports nearly tripled in length. 
Pfizer began incorporating different kinds of media into its reports, including full-
length articles, interviews, photos, illustrations, and biographies of select consumers, 
all of which provide strikingly detailed stories about Pfizer’s history, recent 
milestones, new or revamped products, business philosophy, mission, and bold 
speculations about the future of science and the profitability of that future. Some 
even had their own bylines; in fact, Pfizer actually published its annual reports for 
1956 and 1957 in the New York Times. By this time, the accountant’s statement was 
by far the shortest part of the document, included at the very end (almost like film 
credits few people actually read). Once a straightforward document clearly designed 
to report dollars-and-cents in as few words as possible, the annual report became an 
important form through which to routinely craft Pfizer’s public identity and 
pharmocratic ideals. 
As this chapter will demonstrate, this sudden shift in the form and content of 
Pfizer’s annual reports in 1950 articulates a cultural transition away from the World 
War II language of American patriotism to the universalist language of corporate 
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citizenship, constituting new forms of pharmocratic capital. In this way, the reports 
expose a broader cultural tension between neoliberal logic and the rhetoric of 
scientific innovation: on the one hand, neoliberal logic rested on the belief that inter-
corporate competition would inspire “healthy” innovation, creating conditions in 
which pharmaceutical companies would, in theory, make more effective drugs, 
improve the consumer experience, and force the losing company to take their 
competing product(s) off the market; on the other hand, Pfizer simultaneously 
claimed to be in collaboration with its competitors worldwide in the name of 
scientific revolution and even world peace, quoting in its 1957 annual report 
President Eisenhower’s 1958 State of the Union Address, in which he famously 
called for a “full-scale cooperative program of Science for Peace.”4 This rhetoric 
rendered invisible the contradictions between corporate individualism as it was 
practiced and the idealism of universal scientific progress. As the multilateral 
corporate acquisitions at the turn of the twenty-first century illustrate, large-scale, 
inter-corporate competitions do not result in the global, “cooperative program” 
Eisenhower proselytized; rather, they set the stage for the consolidation of corporate 
power, securing Pfizer’s unrecognized monopoly on the entire production and 
distribution of a huge range of pharmaceutical products worldwide—not only drugs, 
but also medical equipment, industrial chemical materials, consumer goods like 
perfume and laundry detergent, health insurance providers, and advertising 
companies. Under this structure, each subsidiary’s innovative autonomy is always 
 
4 “Pfizer Annual Report, 1957: Inside Pfizer by John Gunther” (Pfizer Inc., 1958), 1. 
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subject to the oversight of the umbrella company it ultimately serves (in this case, 
Pfizer), exposing the contradictory liberal fantasies of “healthy” capitalist 
competition or collaboration that undergird neoliberal ideology. This coupling of 
extreme conservatism and scientific altruism is the hallmark of reproductive 
neoliberalism enacted via the pharmaceutical industry more broadly.  
We can still see this coupling in Pfizer’s more recent marketing initiatives, 
particularly its “corporate citizenship” project, which aims to ensure “that all 
individuals everywhere have access to quality medicines, vaccines and health care, 
and the opportunity to lead healthy lives.”5 Like those of many of its competitors, 
Pfizer’s corporate citizenship project grew out of the neoliberal ideologies 
characteristic of U.S. governance in the latter half of the twentieth century, policies 
that emboldened major corporations to expand overseas investments through various 
development projects in the Global South, ranging from philanthropic interventions 
to the creation of new markets for Pfizer products, new factories and research sites, 
clinical trials, and the extraction of natural resources to synthesize into chemicals 
and drug compounds. As recent feminist and postcolonial scholarship illustrate, 
these corporate philanthropic and humanitarian initiatives are premised on the idea 
of the Global South as “in need” and the Global North as the best administrator of 
those “needed” goods and institutions, reconstituting deeply rooted systems of 
colonial governance in ways that not only homogenize geopolitically disparate 
 
5 “Pfizer’s Annual Review, 2016: Bringing Resources to Bear to Improve Global 
Health.” 
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contexts, but also erase Euro-America’s role in having produced and perpetuated 
such inequities for centuries.6 Ironically, this form of modern colonial violence and 
extractive capitalism necessarily depends on pharmaceutical companies functioning 
as one of, if not the, source of relief for underserved populations. 
Building on this scholarship, I argue that the emergence of the Corporate 
Citizen7 subject leading up to the end of the twenty-first century reflects a shift in 
Cold War-era, neoliberal notions of freedom and health that prompted Pfizer to 
transform their marketing strategies from the wartime rhetoric of American 
exceptionalism to that of urgent international scientific cooperation. Under these 
circumstances, the American patriot figure so prolifically used in just about every 
form of marketing throughout World War II was remodeled into the multicultural, 
scientifically progressive Corporate Citizen subject. Couched in the claim that the 
pharmaceutical knowledge Pfizer was said to generate was not only universally, 
unequivocally beneficial but urgently life-saving, the beneficent Corporate Citizen 
subject repackaged WWII notions of U.S. exceptionalism, drawing on colonial-era 
distortions of identity formation in service of the corporation’s epistemic authority 
and economic power. With this in mind, this chapter marks how parallel stories of 
scientific, economic, and altruistic “revolutions” so consistently sustained across the 
 
6 For example, see: Greene, Condrau, and Watkins, Therapeutic Revolutions; Adriana 
Petryna, Andrew Lakoff, and Arthur Kleinman, eds., Global Pharmaceuticals: 
Ethics, Markets, Practices (Durham: Duke University Press, 2006); Sunder Rajan, 
Pharmocracy. 
7 I capitalize Corporate Citizen here (and not previously) when referring to the 
Corporate Citizen as a specific kind of subject, as opposed to the corporate citizen as 
a “project” or broader concept that enables subjecthood but is not itself a subject. 
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latter half of the twentieth century presented unique challenges to crafting the public 
discourse around misoprostol when Pfizer acquired G.D. Searle and added the drug 
to its pharmaceutical repertoire in 2003—challenges that the machinery of 
reproductive neoliberalism has so successfully masked. 
Pharmaceutical Patriotism, Inc. 
Although Pfizer’s business pursuits have operated differently across 
changing economic and cultural conditions over the last two centuries, its annual 
reports have always articulated a consistently two-pronged approach to their 
mission: 1) to build a lucrative, expansive business; and 2) to make products that 
“contribute to man’s needs.”8 In order to satisfy both their shareholders and 
everyday consumers, these two goals could not be understood as antithetical; rather, 
they had to be understood as necessary to one another. Pfizer’s annual reports thus 
suture economic incentives to a scientifically rigorous, universalist vision of human 
prosperity, defining corporate expansion as the means to a liberated public, free of 
illness and inefficiency. Furthermore, this rhetoric took a particular form during and 
after World War II: by espousing the project of attending to human “need” as an act 
of American patriotism, Pfizer tied their public image to a militant morality of 
sustaining and healing specific kinds of human life—one that cast industry growth 
(particularly in research and development) as a universal good, justifying their own 
 
8 “Annual Report” (Ann Arbor: Pfizer, Inc., 1977), 4. 
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corporate control over other forms of life and resources (animal, plant, mineral) to 
suit this purpose. 
Pfizer’s annual reports achieve this narrative by conflating the language of 
business acumen with that of patriotic altruism, explicitly aligning its research and 
development projects with the war effort. For instance, the 1942 report reads: 
Our Company finds itself, as often before, called upon for production of 
substantial quantities of Chemicals essential to military as well as civilian 
activities. This is an obligation which we have been glad to assume and 
which we believe has been carried out with success. More than 150 of our 
former staff are now enrolled in the Army Forces of our country. The 
remaining personnel have accepted increased duties and responsibilities and 
have trained new employees in the tasks at hand.9 
 
Above, economic and manufacturing matters—production, sales—are framed not as 
business choices, but rather as an “obligation” the company was “called upon” to 
complete. The last sentence reassures stockholders that although a significant 
number of Pfizer staff left to join the military, the company adapted without 
negatively impacting its profits; if anything, the war appears to have provided a new 
market for “military activities.” 1944’s annual report shifts particularly abruptly 
between war and business matters. Immediately after honoring the deaths of six 
former employees killed in the war, the very next paragraph boasts the company’s 
“success of the operations for the year by the improvement in processes, increased 
efficiency and reduced costs.”10 Even the products themselves are oxymoronically 
 
9 “Chas. Pfizer & Co., Inc. Annual Report, 1942” (America’s Corporate Foundation; 
Chas. Pfizer & Co., Inc., March 1, 1943), 3. 
10 “Chas. Pfizer & Co., Inc. Annual Report, 1944” (Chas. Pfizer & Co., Inc., 1945), 2. 
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described as critical life-saving “weapons.”11 Pfizer products are said to be 
“deployed” and to “attack… the armor” of “stubborn,” “malicious” germs, all in the 
effort to “save Allied lives.”12 Vacillating between seemingly concurrent revolutions 
of science, business, and nation, these reports attach a sense of nobility and patriotic 
sacrifice to Pfizer’s financial success. 
As the ad at the beginning of this chapter suggests, Pfizer’s massive 
investment in penicillin research was especially important for linking pharmaceutical 
expansion to American patriotism. In 1942, the U.S. government commissioned 
major pharmaceutical companies to find a way to mass-produce penicillin, an 
antibiotic that could eliminate most bacterial infections but was difficult to produce 
in large quantities.13 Pfizer succeeded one year later, ultimately putting nearly $3 
million toward new facilities to manufacture the drug in the world’s largest 
fermentation tanks.14 The letter to stockholders in the annual report presents this 
enormous investment as evidence of the company’s profound commitment to the 
war effort. As then Pfizer President George A. Anderson put it, “The management 
and employees have thus demonstrated their solid determination to support our 
fighting forces to the utmost in the attainment of ultimate victory,” determination 
 
11 “Pfizer Annual Report, 1956: The Chemist and the Whale” (Pfizer Inc., 1957), 4. 
12 “Pfizer Annual Report, 1956: The Chemist and the Whale,” 4–5. 
13 Edmund T. (Jr.). Pratt, Pfizer: Bringing Science to Life, Newcomen Publication 
Number 1247 (1985 National Meeting of the Newcomen Society of the United States, 
New York: Pfizer, Inc., 1985), 9. 
14 This number is based on Pfizer’s financial reports: “Chas. Pfizer & Co., Inc. 
Annual Report, 1943” (Ann Arbor: Chas. Pfizer & Co., Inc., 1944); “Chas. Pfizer & 
Co., Inc. Annual Report, 1944”; “Chas. Pfizer & Co., Inc. Annual Report, 1945” 
(Ann Arbor: Chas. Pfizer & Co., Inc., 1946). 
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that also apparently yielded “splendid results” for the company in 1943.15 By the end 
of the war, Pfizer was producing half of the world’s supply of penicillin. The 
company had “captured the public’s imagination and had shown the potential of 
pharmaceutical research,” as Edmund T. Pratt, Jr. (Pfizer’s president from 1971-
1971, CEO from 1972-1991, and Chairman from 1972-1992) later put it in his 
honorary speech at the Newcomen Society of the United States in 1985.16 
 
 
Figure 4: Photo included in Pfizer’s in-house science journal, 
Spectrum (1967). 
 
Yet penicillin also exemplifies what happens when Pfizer’s desire for mass 
profit motivates its performance of scientific altruism. Although Pfizer gained a 
 
15 “Chas. Pfizer & Co., Inc. Annual Report, 1943,” 3. 
16 Pratt, Pfizer: Bringing Science to Life, 15. 
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reliable military market during the war and immense cultural capital for its success, 
penicillin was not a patentable drug, and as other companies began producing it, 
Pfizer’s penicillin profits fell. As John McKeen, a member of the board at the time, 
put it, “If you want to go broke in a hurry, go into the penicillin business.”17 
Incentivized to maximize profitability through patents, in 1950, Pfizer patented 
Terramycin, an antibiotic with the same uses as penicillin, but which was derived 
from a different type of soil.18 Pfizer marketed Terramycin in seven different forms: 
as an oral capsule, oral “elixir,” intravenous liquid, ophthalmic (for eyes) solution, 
ophthalmic ointment, topical ointment, and “troches” (lozenges).19 While both 
penicillin and Terramycin radically reduced previously fatal infections that plagued 
military forces during the war, the strategy here was to slightly alter an existing drug, 
patent it as a brand new drug, and expand methods of easy-consumption.20 
During this period, Pfizer’s reports mimic the rhetoric of Cold War American 
foreign policy, only instead of explicitly anti-communist military action, Pfizer 
packages corporate interests (e.g. patenting untapped drug markets and pursuing 
cheaper research, development, and manufacturing centers) as acts of service to the 
 
17 Pratt, 11. 
18 “Chas. Pfizer & Co., Inc. Annual Report, 1950” (Chas. Pfizer & Co., Inc., 1951). 
19 “Chas. Pfizer & Co., Inc. Annual Report, 1950,” 3. 
20 I want to be careful here not to conflate the benefits of the drugs themselves with 
the practices of the corporations. My point here is that the neoliberal ideologies of 
revolution, health, and longevity embedded in these discourses become a form of 
capital that maintains and produces new forms of colonial violence, a self-
perpetuating corporate system that gets hidden or at least distorted by the (very 
possible but unevenly realized) promise of healthy life. 
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country and, by extension, the world. In the 1950 annual report, McKeen (who had 
become President and Chairman of Pfizer’s board by that time), writes: 
As the year 1950 closes it is obvious that the people of the United States are 
entering an era of uncertainty with the threat of yet another world war 
constantly before them. Your Company which can point to a record of 
participation in every emergency since 1849, pledges its resources and its 
skills to the country’s service in this hour of need.21 
 
Above, McKeen sees Pfizer as a longstanding extension of the U.S. military, a 
reserve of skilled laborers who have always been ready to serve the country in the 
face of potentially volatile political instability. The subtle references to an invisible 
and yet omnipotent enemy create a sense of fear and an unpredictable future—an 
enemy that is a “threat” and “emergency” in an “era of uncertainty” and an “hour of 
need”—a problem to which Pfizer “pledge[s]” its resources and skills. 
The 1951 annual report takes this a step further: in addition to its devotion to 
the U.S. military, the report also espouses a moral obligation to extend their work 
beyond the United States, encoding corporate imperialism as an expression of 
patriotic, humanitarian integrity. The cover pictures three objects on a desk: a large, 
smoking vial; a cage with a live chick inside; and a globe. Inside, it explains that the 
cover photo is meant to portray the “scope of Pfizer activities, not only of its 
principal products, but also of the area of its service.”22 The study of 
pharmaceuticals is again depicted as a “stimulating and humbling” privilege, one 
that “aids in the unremitting war against disease and malnutrition” while also 
 
21 “Chas. Pfizer & Co., Inc. Annual Report, 1950,” 7. 
22 “Chas. Pfizer & Co., Inc. Annual Report, 1951” (Chas. Pfizer & Co., Inc., 1952). 
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establishing the “important components for industrial growth.”23 The report even 
piggybacks on one of the most central axioms of canonical American political 
thought, describing Pfizer as uniquely positioned to fully realize the “pursuit of 
health and happiness” (emphasis mine).24 
Perhaps the most explicit expression of this kind of pharmaceutical 
patriotism is in the 1957 report, which begins by quoting President Eisenhower: 
Mankind’s hope for a better life in a safe and prosperous world “requires 
more than words of peace. It requires works of peace.” With those words, 
President Eisenhower urged the nations of the world to unite in a program of 
“Science for Peace.” 
The President called for a co-operative campaign to eradicate malaria, 
heart disease, cancer… “diseases that are the common enemy of all mortals.” 
He envisaged the bounty that could flow from waging total peace: “Hunger 
and disease could increasingly be driven from the earth. The age-old dream 
of a good life for all could, at long last, be translated into reality.” 
This is an account of how one American company, operating for 
profit under a system of free enterprise, is turning its scientific knowledge 
and business resources to the task of creating the raw materials of human 
betterment. It reports some of the meaningful contributions being made by 
private industry to a world in which all can share in the abundance of 
scientific and technological progress.25 
 
Drawing on Eisenhower’s dream of eradicating disease and hunger, the passage 
above suggests that U.S. science has the potential to lead nations out of global 
conflict, asserting that free enterprise is the key to Eisenhower’s presidential vision 
of “peace” and the “good life.” The letter ends with a thank-you to shareholders: “By 
their participation in Pfizer’s corporate enterprise—by creating the raw materials of 
human betterment—employees and shareholders alike are playing an important part 
 
23 “Chas. Pfizer & Co., Inc. Annual Report, 1951,” i. 
24 “Chas. Pfizer & Co., Inc. Annual Report, 1951,” i. 
25 “Pfizer Annual Report, 1957: Inside Pfizer by John Gunther,” 1. 
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in ‘waging total peace.’”26 Pfizer’s reports not only constitute a fundamental 
relationship between their own corporate interests and the wellbeing of “mankind,” 
but also set the stage to secure stockholder support for what the 1951 report 
describes as an “ever-renewing challenge for the future.”  
With romanticized patriotism came performances of transparency and 
altruism, narratives Pfizer’s 1957 report describes as a “new approach to financial 
journalism.”27 Following suit with Pfizer’s previous reports that glorify and 
militarize the labor of scientific research, John Gunther—a popular journalist at the 
time, known for a series called the “Inside” books—wrote “Inside Pfizer,” a 
journalistic article featured in both the annual report and the New York Times. 
Navigating the specters of past and future world wars heightened by the threat of 
nuclear weapons, Gunther dances between depictions of Pfizer as austere, 
mysterious, and deeply scientifically rigorous on the one hand, while curiosity-
driven, well-meaning, even playful on the other. After noting that Pfizer “rhymes 
with Kaiser,” a title given to emperors of the German Empire, Gunther writes: 
Antibiotics relieve untold human suffering and save millions of lives. We all 
know that… they [antibiotics] depend on research, on the work of hundreds 
of virtually anonymous scientists, whose names are unknown to the public, 
who wage unceasing and relentless war on the depredations of disease. 
Nobody who visits Pfizer can doubt the value of research in a free society. 
Research equals science in these troubled days, and science equals survival.28 
 
 
26 “Pfizer Annual Report, 1957: Inside Pfizer by John Gunther,” 3. 
27 “Pfizer Annual Report, 1957: Inside Pfizer by John Gunther,” 2. 
28 “Pfizer Annual Report, 1957: Inside Pfizer by John Gunther,” 4. 
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Gunther imbues the anonymous scientists’ labor with a sense of amazement and god-
like prestige, qualities their apparent anonymity only seems to magnify. Impressed 
by their “businesslike” affect and “aseptic way,” Gunther writes, “These men are 
scouts, patrolling the frontiers of the unknown”; yet he is quick to reassure readers 
that “Pfizer gives a homely atmosphere. This is a friendly company, even if science-
minded,” playfully referring to Pfizer’s microbial antibiotics as “beneficent little 
miracle workers.”29 In the wake of the United States’ use of nuclear weapons and 
escalating tension with the Soviet Union, this piece applauds the power of 
pharmaceutical science used for “human betterment.” Pfizer reprocessed fears about 
dangerous science (e.g. nuclear weapons) into excitement about the so-called “life 
sciences”—pharmaceuticals and technology.  
These documents reflect a clear rhetorical strategy: Pfizer was said to be not 
only an immensely profitable company with the capability to unlock previously 
unimagined scientific and economic potential all over the world, but an honest, well-
meaning company with the United States’ (anti-communist) interests at heart. This 
rhetoric made it impossible to understand economic growth and the healing of 
human life—or, at least, pharmaceuticalizing of it—as contradictory desires, creating 
a culture in which rapid and unhindered corporate expansion was understood not 
only as universally “good,” but also as a national security issue. 
 
29 “Pfizer Annual Report, 1957: Inside Pfizer by John Gunther,” 5. 
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From War to “Concern and Action” 
By the 1960s, Pfizer consistently identified five main sectors of their 
business: health care, agriculture, specialty chemicals, materials science, and 
consumer products. Going “international,” as Pfizer’s reports from this era describe 
it, became a catch-all for the consolidation of lucrative markets and philanthropy 
targeted at “in need” populations—people lacking basic resources, but also liberation 
from political and cultural systems that were said to contest their existential freedom. 
In other words, Pfizer not only asserted that research and development investments 
were a strategic economic opportunity for the company, but, even more 
fundamentally, it inculcated investors with the belief that Pfizer’s financial success 
precipitated a healthier, freer, more democratic world. Pfizer’s annual report from 
1963 proclaims: “Our work in the pharmaceutical field, involving as it does creative 
research, efficient production, progressive marketing and service to those who use 
our products, represents one of the finest manifestations of competitive economic 
effort in and for a free society.” 30 Put simply, the narrative was: when Pfizer profits, 
everyone profits. 
At the same time, while Pfizer’s emphasis on freedom (scientific, political, 
existential) is consistent with the reports during and immediately following World 
War II, the reports never mention any other U.S. war—surprising, given how central 
WWII is in the previous reports. Rather, the reports recruit a much broader rhetoric 
 
30 “Annual Report for the Year 1963” (Ann Arbor, United States: Chas. Pfizer & Co, 
Inc., 1963), 4. 
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of “concern” enacted through various philanthropic projects in the Global South. By 
1976, Pfizer was operating in over one hundred different countries in order to take 
advantage of different “profiles of disease” in developing countries.31 As Dr. 
Laubach puts it in a special interview in the 1976 report: “We are everywhere in the 
world and very frequently we were the first American company in a given country. 
This presence is a significant commercial, medical and social opportunity.”32 
As reproductive politics scholars have long observed, these philanthropic 
projects have historically served as conduits for drug testing, operating under the 
guise of techno-scientific, humanitarian progress espoused by family planning 
initiatives, contraceptive research, and environmentalism.33 In this context, 
philanthropic projects represent modernized versions of state-sanctioned eugenics 
that, while often carried out by institutions thought to be techno-scientifically (and 
therefore socially) progressive, replicate the abuse, incarceration, and 
pathologization of women of color.34 By the same token, a major intervention that 
reproductive politics scholarship has made is to disturb the prevalent assumption that 
the contraceptive technologies often disseminated in these projects are inherently 
liberatory, a fantasy in which more technological and medical advancements 
automatically result in reproductive autonomy for all women. Contrary to discourse 
that claims the dissemination of reproductive technologies and especially 
 
31 “Pfizer Annual Report, 1976” (Pfizer Inc., 1977), 15–16. 
32 “Pfizer Annual Report, 1976,” 14. 
33 Kline, Building a Better Race; Stern, Eugenic Nation. 
34 See: Jade S. Sasser, On Infertile Ground: Population Control and Women’s Rights 
in the Era of Climate Change (NYU Press, 2018). 
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contraception unequivocally allow for reproductive freedom, reproductive politics 
scholars show how, rather than simply offering new opportunities for women to 
control their fertility, these technologies also constitute new biopolitical mechanisms 
through which to surveil and control populations. 
Yet less scholarly attention has been given to the ways in which Pfizer turned 
the concept of corporate philanthropy into a product in and of itself. The 1971 report 
states the public relations benefits of philanthropy outright, repeatedly reiterating 
that an “awareness of the role of Pfizer in the community has been stressed.”35 The 
report even adds a sixth sector to their business under the heading, “Concern and 
Action,”36 claiming that the Concern and Action sector helps to address “three of the 
most critical questions of our times”: “the environment,” “minority and community 
action,” and “social health.” Notably, the formatting of this sixth sector is identical 
to that of the other five, suggesting, at least visually, that “Concern and Action” is 
itself a kind of pharmaceutical product, one that embodies the affective labor of care 
and humanitarianism. But what makes these “critical” concerns different from the 
other five sectors, which also profess the capacity to achieve “human betterment”? 
What determined whether a given project fell under Concern and Action or 
one of the other five sectors was in part the targeted population, but perhaps more 
importantly, the illness being treated. While Pfizer’s previous sections stress specific 
 
35 “Pfizer Annual Report, 1971: Development Technology -- A Complex Link to 
Product Reality” (Pfizer Inc., 1972), 21. 
36 “Pfizer Annual Report, 1971: Development Technology -- A Complex Link to 
Product Reality,” 21–22. 
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product developments to treat cardiovascular disease and diabetes in the Global 
North, the projects under Concern and Action focus almost exclusively on venereal 
diseases and drug abuse in the Global South. The latter projects also tend to take an 
educational approach, as opposed to a product-development approach. For example, 
the report claims that “Operation Great Concern” distributed “more than three 
million pamphlets and 300,000 posters explaining the symptoms and consequences 
of venereal disease.”37 Descriptions of the results or impacts of these projects are 
remarkably vague, stating that Pfizer “participated in a number of local programs to 
alleviate health problems and emergencies,” which consisted of “the contribution of 
Pfizer pharmaceuticals to the National Health Fund in India and responses to the 
earthquake in Peru and the polio epidemic in the Dominican Republic.” But what, 
exactly, was Pfizer’s participation? What was their contribution? What were their 
responses? According to the reports, Pfizer appears to have reserved the longer-term 
and more costly product development “response” for the more lucrative consumer 
market in the Global North, leaving the substantially less costly response—
pamphlets and posters—to the Global South. Furthermore, by focusing efforts on so-
called “education,” Pfizer implicitly vied for behavior changes in the Global South 
rather than on immediate physical relief, as it did for consumers in the Global North. 
 
37 “Pfizer Annual Report, 1971: Development Technology -- A Complex Link to 
Product Reality,” 21. 
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This distinction between education and product development approaches is thus 
socially stratified: education for the poor, products for the rich.38 
There are a few tangible consequences that are important to glean from this. 
The first is the reality that Pfizer is inherently designed to profit from illness, a 
reality that its claims to survival in the Global South and human betterment in the 
Global North tend to conceal, but that the reports make explicit. For instance, in 
summarizing the company’s profits for the year, the 1973 report states: “Most 
encouraging was the continued strong growth of antibiotics sales despite increasing 
competitive pressures, especially in the important European market… Substantial 
increases were reported in Japan, and outstanding results were achieved in Africa.”39 
The next sentence is almost concessory, stating, “The sharp increase of antibiotic 
sales in many countries was influenced by some degree by a high incidence of 
respiratory infections.” Ironically, the passage cleaves Pfizer’s celebration of 
increased sales from the reality that those sales result from more incidence of 
respiratory illness, leaving the reader with the understanding that sales and illness 
are economically connected, but ignorant to the lived consequences of that reality. 
Second, while Pfizer makes claims to universal human betterment, the 
company only seeks product developments inspired by the most profitable 
 
38 There are of course exceptions to this, but in most cases, it’s because the 
purchasing power does not come from the Global South. Even though economically 
disenfranchised patients receive the treatment a given product provides, they do not 
constitute the market because the funding for such products comes from U.S.-funded 
organizations (e.g. USAID) or independently wealthy private donors.  
39 “Pfizer Annual Report, 1973” (Pfizer Inc., 1974), 7–8. 
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illnesses—those experienced most commonly, in places with the highest 
concentrations of wealth. Expanding pharmaceutical resources to the Global South—
what Pfizer calls “worldwide deployment”40—only happens when Pfizer identifies a 
new potential market. From this perspective, Pfizer’s primary goal is not necessarily 
to improve health outcomes, but rather, to define new markets of illness that they can 
then “treat.”  
Yet this is not solely a critique of Pfizer’s predictably inequitable distribution 
of capital invested in the Global North and the Global South; it is also about how 
Pfizer instrumentalized their philanthropic initiatives in order to shape federal 
economic policies. As Pfizer expanded these philanthropic projects throughout the 
1970s, the annual reports reflect a brewing strain between Pfizer and the state, 
expressing increasing frustration with the state’s regulation of their pharmaceutical 
enterprise. The 1975 report ends with a complaint that “society has not fully 
recognized the impact that public policies and attitudes have on the rates of 
therapeutic discovery” and advocates for eliminating “cumbersome and often 
redundant constraints on clinical studies.”41 Pfizer ultimately proposes a new role of 
government: 
The view that the sole function of drug regulation is the protection of the 
public from harm should be replaced by a new and broadened conception of 
the regulators’ mission. The public interest would be best served if the 
Congress broadened the mandate of FDA to include a positive responsibility 
to encourage drug innovation and to expedite the development and 
availability of new drugs.42 
 
40 “Pfizer Annual Report, 1976,” 5. 
41 “Pfizer Annual Report, 1975” (Pfizer, Inc., 1976), 18–19. 
42 “Pfizer Annual Report, 1975,” 19. 
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In other words, the report not only argues that people are better served when Pfizer is 
most profitable—again misleadingly implying that Pfizer’s profitability is evidence 
of improved health outcomes—but also implies that Pfizer is better suited to serve 
the “public interest” than the state. The report goes on to explain Pfizer’s unique 
position: 
Pharmaceutical research is unusual as compared with all other kinds of 
applied chemical research, in that meaningful discovery involves issues of 
increasing political and social sensitivity. In fact, pharmaceutical innovation 
is now not only a scientific process, but also a socio-political one. If this 
delicate process is further complicated, there will certainly be an even greater 
reduction in the flow of beneficial therapeutic innovations, thereby 
perpetuating human suffering and economic losses.43 
 
While the report’s description of pharmaceutical innovation as a “socio-political” 
process is, from one perspective, remarkably insightful, the passage is really about 
chastising the state, asserting that state regulation only over-complicates Pfizer’s 
ability to save lives and improve health. The section ends with the coded posturing 
of a high-stakes business negotiation: “We are confident that this dialogue will have 
an increasing impact on policy. If so, the American pharmaceutical research 
laboratory can continue to fulfill its important role as the main source of new 
medicines for better health for people everywhere.”44 Veiled as a diplomatic 
“dialogue,” Pfizer warns that their potential to relieve human suffering all over the 
planet can only be fully realized in a free market. 
 
43 “Pfizer Annual Report, 1975,” 19. 
44 “Pfizer Annual Report, 1975,” 19. 
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Erasing Pharmocracy, Making Pharmaceutical Subjects 
By the early 1980s, each new product took about a decade of research and 
about $70 million for it to go on the market.45 Pfizer justified this massive cost in 
time and resources to its shareholders by arguing that big investments upfront would 
generate much bigger profits in the long run. Each annual report is very much a 
performance of this argument, in part because, each year, shareholders had to 
recalibrate to an even bigger scale of investment. To reflect the massive range of 
products it came to manufacture and own, Pfizer rebranded itself as a “life sciences” 
corporation, developing so many products that it is more difficult to name a product 
that Pfizer did not contribute to in one way or another. In addition to some of the 
most popular drugs still currently on the market (e.g. Diflucan, Viagra, Zoloft, 
Zithromax, Celebrex, Lipitor), Pfizer also patented a slew of lesser-known but (at 
least as) lucrative products in this period. Some examples include: Pferrox, a 
magnetic oxide whose “unique magnetic properties… and its analog compounds 
made it possible for the major tape-producing companies to develop premier, high 
quality audio recording tapes”; Flocon 4800, an “anthem gum fermentation broth for 
use in enhanced oil recovery (EOR)”; Coxistac, an injection “for use in swine to 
improve weight gains and enhanced feed efficiency”; Pfinodal, which “utilizes 
Pfizer powder metallurgy to produce a unique copper-nickel-tin alloy for use as a 
connector in micro-miniature electronic circuits”; and “Hot Pants,” a fragrance for 
 
45 “Annual Report, Special Feature: The Transfer of Knowledge,” 10. 
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women.46 While the “life sciences” rebranding is remarkably vague, it befit their 
mission to develop products in every corner of consumer life, permeating the 
disciplinary, financial, and geopolitical constraints that previously limited the scope 
of their business. Today, Pfizer Inc. is the parent company of over 500 subsidiaries, 
including Monsanto, Warner Lambert, Wyeth, and Pharmacia—some of the biggest 
pharmaceutical, agricultural, and marketing companies in the world, all of which are 
parent companies of other subsidiaries.47 
As Pfizer constructed the narrative that the very expensive pursuit of elite, 
precise, and curative technologies would, eventually, amass astronomical profits, the 
reports represent the beneficiaries of Pfizer products strikingly differently. While the 
reports go to great lengths to illustrate the health benefits for representatives of the 
Global North through individualized profile stories, representatives of the Global 
South are predictably depicted as “in need” of Pfizer products. Despite Pfizer’s 
promise that its products have unprecedented healing potential, consumers in the 
Global South appear to be not only in a perpetual state of receiving, but also of 
 
46 “Annual Report, Special Feature: The Transfer of Knowledge,” 24, 26; “Annual 
Report 1982, Living with Heart Disease: The Revolution in Cardiovascular 
Medicine” (Ann Arbor: Pfizer, Inc., 1982). 
47 A “subsidiary” is legally defined as a company that gives fifty percent or more 
voting stock to its “parent” or “holding” company. There are also subsidiary “tiers,” 
meaning that a parent company can be a subsidiary of another parent company. Most 
mega pharmaceutical companies today control all production, marketing, and 
distribution processes by acquiring subsidiaries that specialize in each industry, a 
loophole that allows companies to operate as monopolies without violating anti-trust 
laws. See: Jeffrey L. Harrison, “Business Associations, Economics Of,” in 
Encyclopedia of Law & Society: American and Global Perspectives (Thousand Oaks: 
Sage Publications, Inc., 2007); “Subsidiaries of the Company (Pfizer)” (U.S. 
Securities and Exchange Commission, December 31, 2014). 
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becoming pharmaceutically educated and responsibilized. In this way, Pfizer’s 
pharmaceutical products act as vehicles through which neoliberal ideals of freedom 
and individualism masquerade as multiculturalism and corporate benevolence. 
The 1981 report (highlighted at the very beginning of this chapter in the 
quote from Dr. Drucker, one of Pfizer’s business consultants) illustrates this 
multiculturalist narrative especially overtly. Dispersed throughout the text of 
Drucker’s interview are full-page photos of Pfizer employees, each specifying a 
stage in what the report calls the “transfer of knowledge.” American manufacturers 
conduct quality control on a sea of dark, globular hip implants (Figure 5). Pfizer 
researchers discuss lab results while a topless patient lurks uncomfortably in the 
background, a spiraled wire connecting his arm to a machine we cannot see, though 
the caption tells us it tracks heart rate (Figure 6). In an unspecified Latin American 
village, a crowd of young brown children surround a white male Pfizer employee 
clothed in a white lab coat, sitting at a desk distributing an antiparasitic drug called 
Combantrin (Figure 7). In Japan, an ambiguously titled “medical specialist” trains a 
new sales representative on a Pfizer product, their concentrated faces upstaged by the 
complex formulas written on a chalkboard behind them (Figure 8). While the images 
available in the archive are extremely low-quality, the story they tell is clear: those 
on the receiving end of this “transfer” represent a multicultural, multiracial world 
eager to be the recipients of Pfizer’s pharmaceutical knowledge. This is a global, 
humanitarian revolution predicated on corporate success. 
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Figure 5: Design engineers and quality control personnel inspecting hip implants at 
Pfizer’s Howmedica plant in Ireland, c. 1981. Under the heading, “The Transfer of 
Knowledge: Design Engineers and Quality Control,” Pfizer’s report assures: “The 
manufacture of products to quality standards is an important aspect of Pfizer’s 
worldwide operations… [D]esign engineers and quality control personnel consult 
frequently throughout the manufacture of prosthetic devices.” (“Annual Report, 
Special Feature: The Transfer of Knowledge” (Ann Arbor: Pfizer, Inc., 1981), 9.) 
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Figure 6: Titled, “The Transfer of Knowledge: The Physician and Clinician.” The 
description reads: “Extensive clinical studies are needed to evaluate new drugs. Here 
a member of Pfizer’s medical staff discusses clinical findings with a physician who 
conducted studies on Procardia, Pfizer’s new cardiovascular drug. Prior to its 
approval at the end of 1981, Procardia was administered to approximately 18,000 
angina patients throughout the U.S. in clinical trials and on an emergency basis.” 
(“Annual Report, Special Feature: The Transfer of Knowledge,” 7.) 
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Figure 7: Titled, “The Transfer of Knowledge: Physician and Patients.” The 
description reads: “In the developing world, where sanitation and medical facilities 
are limited, drugs offer the most cost-effective form of medical treatment. Here a 
physician administers Combantrin, a Pfizer antiparasitic drug, to villagers in Latin 
America. Medical and community health education programs are conducted by the 
Company in many countries of the Third World.” (“Annual Report, Special Feature: 
The Transfer of Knowledge,” 15.) 
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Figure 8: Titled, “The Transfer of Knowledge: Medical Specialist and Sales 
Representative.” The description reads: “The professional sales representative is a 
crucial factor in the transfer of knowledge about new products. In Japan, where four 
new drugs were launched in 1981, the Company has increased its sales force by 
almost one-third over the past three years. A new representative is seen here 
receiving training from a medical specialist.” (“Annual Report, Special Feature: The 
Transfer of Knowledge,” 11.) 
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Because the reports from the 1980s tend to lump people of color into the 
same multicultural (i.e. “non-white”) pool of knowledge recipients, it is tempting to 
presume that the reports maintain the individuality of its white American consumers. 
To some degree, this is true—the individual profile stories are almost all about white 
men, and they provide comparatively specific information about each of their lives, 
including their names, where they live, their jobs, marital statuses, even their 
personal aspirations. But the biographical form of these stories primarily serves to 
craft a very generalizing consumer subjecthood: that of a mostly white, productive, 
heteronormative person with hobbies they are apparently very eager to get back to. 
For instance, the cover of the 1986 report features Edward Lomanto, a trial lawyer 
from upstate New York, who controls his angina with Procardia (Figure 9). The 
description tells readers that “According to his wife, Nancy, Mr. Lomanto has 
always been a strong, active man,” and that “Golf and gardening are favorite 
pastimes,” activities he was able to return to after taking Procardia for one month.48 
In the same report, Hans Eberhardt, a bank manager, treats his back pain with 
Feldene I.M. so he can ski in the Alps, “a pastime he once again enjoys” (Figure 
10).49 Dennis Ballweg, a dairy farmer in Sun Prairie, Wisconsin, gives his cows 
Rumatel, a deworming treatment that does not interrupt milk production nor require 
him to discard any milk, allowing him to keep his milk sales on target (Figure 11).50 
Lastly, the “warming power” of Ben-Gay Sports-Gel helps the women’s rowing 
 
48 “Pfizer Annual Report, 1986: Bringing Science to Life” (Pfizer, Inc., 1987), 2. 
49 “Pfizer Annual Report, 1986: Bringing Science to Life,” 2, 8. 
50 “Pfizer Annual Report, 1986: Bringing Science to Life,” 16. 
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team at the Massachusetts Institute of Technology (MIT) “concentrate on work 
rather than sore muscles” (Figure 12).51 All of these stories position Pfizer products 
as the keys to realizing a middle- and upper-class American fantasy in which 
performing “good” citizenship leads to luxury, longevity, and personal bests. 
 
 
Figure 9: The cover of Pfizer’s 1986 Annual Report. Unfortunately, this off-
center, poorly cropped image is the only version in the archive. Curiously, 
someone also blacked-out the square-ish patch to the right of the man’s head; I 
don’t know what it conceals. 
 
 
 
51 “Pfizer Annual Report, 1986: Bringing Science to Life,” 21. 
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Figure 10: Hans Eberhardt, 37, gets “back in form” with the help of Feldene I.M., an 
NSAID designed to relieve pain for longer periods of time than other NSAIDs. 
(“Pfizer Annual Report, 1986: Bringing Science to Life” (Pfizer, Inc., 1987), 8.) 
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Figure 11: Featured in Pfizer’s 1986 report, this photo was taken on Dennis 
Ballweg’s cow farm in Sun Prairie, Wisconsin. Presumably, these cows have been 
treated with a deworming drug called Rumatel. (“Pfizer Annual Report, 1986: 
Bringing Science to Life,” 17.) 
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Figure 12: The women’s rowing team at Massachusetts Institute of Technology 
(MIT) celebrating a victory apparently enabled by Ben-Gay Sports Gel. (“Pfizer 
Annual Report, 1986: Bringing Science to Life,” 20.) 
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One of the featured biographies in the 1986 report stands out from the rest. 
While other profiles in the report clearly describe those pictured as satisfied 
consumers of featured Pfizer products, no description was provided for this 
particular image (figure 9). It is unclear what exactly is going on here—who they 
are, how they are connected to Pfizer—but we could do some guesswork based on 
the context. The image separates two pages: 1) a description of Pfizer’s recent 
developments in the study of calcium channel blockades (CCBs) for the treatment of 
various cardiovascular issues, and 2) a journalistic piece about the Infusaid 
Implantable Pump that “helped save Mr. Kreismann’s right foot” (Mr. Kreismann is 
a construction supervisor for the St. Charles County Highway Department in 
Missouri but is a different person in another photo).52 What is striking about the 
photo is the foregrounding of the two figures. With a downed tree between them, 
each man poses with a tool: in front, the white man holds a clipboard and a Number 
2 pencil, half grinning; a few paces back, a black/brown man rests a chainsaw on the 
tree, a serious, sobering expression on his face. The literal and symbolic separation 
between the two figures is uncomfortable in part because, without much information, 
we are primed to understand that the man in front represents a beneficiary of a Pfizer 
product; the man in back is an onlooker, a witness, and yet an implicit participant in 
the overarching narrative. 
 
 
 
 
52 “Pfizer Annual Report, 1986: Bringing Science to Life,” 11–13. 
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Figure 13: Full-page photo (resized for this page) in Pfizer’s 1986 Annual Report. 
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This image points to an important rhetorical ambivalence between 
pharmocratic, multiculturalist philanthropy and (white) American patriotism, an 
ambivalence that shields from view the pharmocratic machinery upholding the 
Corporate Citizen subject. The Corporate Citizen subject is inherently oxymoronic: 
it is itself a (hypervisible) individual capable of care and duty, and an (invisible) 
corporate body exempt from the punitive aspects of citizenship. Straddling signs of 
the collective and signs of the individual, the Corporate Citizen enacts a kind of 
strategic essentialism, producing its own contradictory subjecthood. It is an 
anthropomorphized, singular figure that is simultaneously pluralized—a visible sign 
with an invisible body. Where is the body of the Corporate Citizen? What are its 
contours, its corpse? 
In some ways, this chapter has attempted to answer these questions—to make 
the cultural machinery of the pharmaceutical industry visible. Today, Pfizer still 
casts corporate expansion as both a humanitarian necessity and an act of American 
patriotism. Echoing the rhetoric of bootstraps individualism, Pfizer frames the shift 
from local apothecary to transnational, multibillion-dollar industry as a rags-to-
(world)-riches story, in which the self-starting owners of a small, family-owned shop 
seize a business opportunity and—with the right combination of hard work and 
innovative, entrepreneurial spirit—come to revolutionize the field of biomedicine 
across time and space for the next century and a half. The “Our Journey” section of 
Pfizer’s website is emblematic of this teleology, inviting users to “[j]ourney through 
Pfizer’s history from the first storefront to the beaches at Normandy to the New 
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York Stock Exchange” via an interactive digital timeline.53 The first event (1849) 
reads: 
With $2,500 borrowed from Charles Pfizer’s father, cousins Charles Pfizer 
and Charles Erhart, young entrepreneurs from Germany, open Charles Pfizer 
& Company as a fine-chemicals business. A modest red-brick building in the 
Williamsburg section of Brooklyn, New York, serves as office, laboratory, 
factory, and warehouse. 
 
Their first product is a palatable form of santonin—an antiparasitic used to 
treat intestinal worms, a common affliction in mid-19th century America. 
Combining their skills, Pfizer, a chemist, and Erhart, a confectioner, blend 
santonin with almond-toffee flavoring and shape it into a candy cone. The 
“new” santonin is an immediate success and the company is launched. 
 
The literal and metaphorical sugar-coating here is quite striking: although now 
widely known among medical professionals as a drug with potentially fatal side 
effects in malnourished children,54 here, the “new” santonin not only purged 
consumers of their intestinal worms—it was also a tasty dessert. Pairing the familial 
relationship between Pfizer and Erhart with the $2500 loan (comparable to about 
$80,000 today) that pays for the “modest” yet remarkably multi-purpose building, 
the first paragraph evokes entrepreneurship, familial nostalgia; it is an assimilation 
success story in which German immigrants nobly perform their American 
citizenship, an apparent prerequisite to their fulfilment of the American dream. The 
rest of the timeline goes on to attribute quite a variety of impressively patriotic deeds 
to Pfizer’s production of tartaric acid and cream of tartar in 1862. According to 
 
53 Inc Pfizer, “Our Timeline, 1849 - Present,” Our Journey, accessed February 4, 
2018, https://www.pfizer.com/people/history. 
54 Santonin has long been replaced by safer drugs, but concern about santonin 
poisoning has circulated among pharmacologists and physicians since the early 
1900s. See: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1658882/?page=1 
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Pfizer, these compounds not only “help[ed] meet the needs of the Union Army,” but 
also made it possible for Mathew B. Brady, elsewhere described as the “father of 
photojournalism” as well as an “innovator, entrepreneur, and tireless self-promoter,” 
to photograph the Civil War.55 The timeline marks another milestone at the year 
1880, when Pfizer began selling citric acid to Coca-Cola, Dr. Pepper, and Pepsi-
Cola, three iconically American soda companies.56 Each description cites the soaring 
economic growth of the company, tying each product innovation not only to fiscal 
success, but also emblems of American patriotism, whether the product saves lives 
on the frontlines or brings American families to the dinner table. 
 Pfizer’s recent marketing projects also double down on this public image. In 
a recent television ad, Pfizer abandons naming specific drugs altogether, instead 
tracing the process by which an unnamed drug is made. While maintaining the 
drug’s anonymity absolves Pfizer of any accountability to laws that restrict them to 
promoting drugs only for FDA-approved purposes, this approach also allows for a 
renewed focus on their most reliable selling strategy: philanthropic science. Called 
 
55 To emphasize just how bold Pfizer’s assertion here is: after Brady became famous 
for his series of thirty-five photos of Lincoln, apparently Lincoln said, “Brady and the 
Cooper Union speech made me President.” See: Mitchel P. Roth, “Brady, Mathew B. 
(1823-1896),” in The Encyclopedia of War Journalism, 1807-2015 (Grey House 
Publishing, 2015). 
56 For more on the strong cultural association between Coca-Cola and U.S. empire, as 
well as a rich history of boycotting American soda companies, see: Bartow J. Elmore, 
Citizen Coke: The Making of Coca-Cola Capitalism (New York: W. W. Norton & 
Company, 2015); Maurice Jr M. Labelle, “De-Coca-Colonizing Egypt: Globalization, 
Decolonization, and the Egyptian Boycott of Coca-Cola, 1966-68,” Journal of Global 
History 9, no. 1 (March 2014): 122–42; Liang Yao, “Nationalism on Their Own 
Terms: The National Products Movement and the Coca-Cola Protest in Shanghai, 
1945–1949,” Modern Asian Studies 51, no. 5 (September 2017): 1439–68. 
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“Before It Became a Medicine,” the sixty-second commercial begins with a fit, white 
man, presumably in his mid-thirties, brushing his teeth at the bathroom sink in a 
white undershirt and plaid pajama pants.57 As he reaches into the medicine cabinet 
and pops the lid off of an unlabeled prescription container, the narrator—a 
disembodied, didactic male voice with a youthful, conventionally likeable vocal 
fry—begins: 
Before it became a medicine, it was an idea, an inspiration—a wild, “What 
if?” So scientists went to work. They examined eighty-seven different protein 
structures; had twelve years of setbacks and breakthroughs; four thousand, 
four hundred and twenty-three sleepless nights; and countless trips back to 
the drawing board. At first they were told, “No.” “Well, maybe.” And finally: 
“Yes.” Then it was thirty-six clinical trials, eighty-five hundred patient 
volunteers, [pause] and the hope of millions. 
 
A series of representative clips accompanies each sentence in the process described 
above. First, lab workers and researchers, each working in isolation at a lamplit desk 
littered with papers and bubbling vials, look up from their desks, one at a time, all 
apparently experiencing consecutive “Aha!” moments while the tick-tock, tick-tock 
of an omnipresent clock echoes in the background. Once the scientists “go to work” 
in the second sentence, the music picks up, and the action propels into fast-forward 
motion as scientists in Pfizer lab coats skitter from workspace to workspace in 
fluorescent-lit labs. They order a late-night pizza; they work in bed next to their 
sleeping spouses; they present charts to corporate representatives in a windowed 
boardroom. The “thirty-six clinical trials” and “eighty-five hundred patient 
 
57 Before It Became a Medicine (Pfizer Inc.), accessed December 9, 2017, 
https://www.pfizer.com/news/featured_stories/featured_stories_detail/before_it_beca
me_a_medicine-0. 
 81 
volunteers” are represented by three individuals of different races, genders, and ages, 
each of whom utters a playful “Ouch!” as a nurse injects a needle into each of their 
arms. Just before the narrator says, “the hope of millions,” the music fades, and the 
camera shifts to something new: hundreds of multicolored balloons floating up into a 
vast, bright blue sky, a symbolic expression of freedom, release, conquered limits. 
After lingering for a moment on the balloons, just long enough to see them begin to 
scatter in different directions, we return back to the first scene with the man in the 
bathroom, who has finished brushing his teeth. The narrator recites the final line of 
the commercial: “And so after it became a medicine, someone who couldn’t be 
cured, could be: [pause] me.” As the now embodied narrator utters the last word—
“me,” with a slight upward inflection, as if surprised that all the work he described 
was done just for him—a blonde-haired toddler joyfully runs toward the man, who 
we are now led to assume is the boy’s father. Laughing, he picks up his son and the 
two embrace. The camera zooms in on their entwined faces, their eyes closed and 
lips smiling. A white glow emanating from a nearby window enshrines them, and the 
commercial ends. This is about crafting a multiculturalist image of the corporate 
citizen; it is corporate altruism commodified. 
Conclusion: Misoprostol and Abortion 
When G.D. Searle first put Cytotec on the U.S. market in 1989, miso initially 
modeled this pharmocratic fusion of economic, intellectual, and philanthropic 
progress in newly profitable ways. First used to treat stomach ulcers caused by non-
steroidal anti-inflammatory drugs (NSAIDs) in arthritic patients, it was, essentially, 
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a drug that treated the side effects of another drug, creating a kind of economic 
symbiosis between NSAIDs and Cytotec. According to a Chicago Tribune article in 
1989, Searle was “sitting on a medical breakthrough and a potential gold mine.”58 
Searle published ads in popular medical journals and launched a six-part television 
mini-series on Lifetime describing how Cytotec treats NSAID-induced stomach 
ulcers, funneling millions of dollars into what they billed as an “education effort.”59 
Although a new set of problems emerged when clinicians realized that Cytotec could 
also prompt the same physiological mechanisms of a medication abortion, presenting 
a major legal and marketing liability, Searle representatives were confident they 
would “offset this disadvantage” and “crack this [ulcer] market.”60 
Unexpectedly, Cytotec came to represent the possibility of revolution for two 
entangled but fraught sets of interests: those of profit-seeking pharmaceutical 
companies, for whom Cytotec was expected to bring substantial business; and those 
of reproductive rights activists, for whom Cytotec could bring radically safer 
clandestine abortion options. For the latter group in particular, the subversive 
possibilities seemed almost too good to be true: here was an abortifacient that had 
 
58 Steven Morris, “Winner for Searle, Arthritis Sufferers,” Chicago Tribune (1963-
Current File); Chicago, Ill., April 9, 1989, 8. 
59 Morris, 8. According to an article in the Detroit Free Press in 1989, the FDA 
repeatedly threatened to take the “docu-drama” off the air because, not only was it 
clearly promoting Cytotec—a form of direct-to-consumer (DTC) advertising that 
would have required FDA-approval under the Federal Food, Drug, and Cosmetic Act 
(FDCA)—but it was also promoting off-label uses of Cytotec, which is never legal in 
DTC advertising. (This is probably why I have been unable to procure a copy of the 
series.) Apparently all six episodes aired anyway. 
60 Morris, 8. 
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the resources and institutional bandwidth of Big Pharma, which was eager to make 
the drug as easily accessible (i.e. buy-able) as possible. Reproductive rights activism 
appears to buy into Pfizer’s pharmocratic rhetoric, once again marrying capital to 
freedom while erasing the conflicts of interest therein. 
This is where the logics of pharmocratic cultural production—a nexus of 
technological edge, social progress, and business acumen—meet reproduction. The 
next chapter analyzes how recent journalistic discourses about underground 
misoprostol take up these mid-century pharmocratic threads, casting miso as a 
vehicle through which to perpetuate reproductive neoliberalism. 
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Figures 1-3 (above): Photos of ancient sculptures published in Spectrum, Pfizer’s in-
house science journal, in 1965. 
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CHAPTER 2 
Imagining the Global South vis-à-vis Misoprostol 
 
“Whatever the artist’s motive, he had a medical story to 
tell and he told it in clay.”1 
 
 
 The quote above comes from an article in one of the last issues of Spectrum, 
Pfizer’s in-house science journal that ran from 1952-1966. “Like an ancient 
physician lecturing to modern colleagues,” the article begins, “sculpture and pottery 
dug from the graves of Mexico and Central and South America tell us of the 
astonishing medical knowledge of civilizations that vanished long ago.”2 According 
to the article, these clay pieces are “specifically medical in their subject matter.”3 
Inspecting a row of six “bowlegged” and “clearly female” figures resting on 
“primitive hospital beds” (rectangular slabs of clay, about four-by-two inches), the 
writer concludes that these figures “may therefore represent puerperal osteomalacia 
(a likely possibility in primitive society), with associated postpartum psychosis.”4 As 
 
1 Spectrum (Chas. Pfizer & Co., 1965), 27. 
2 Spectrum, 26. 
3 Spectrum, 26. 
4 Spectrum, 27. Osteomalacia [os″te-o-mah-la´shah], also called “rickets” in children, 
refers to “softening of the bones, resulting from impaired mineralization, with excess 
accumulation of osteoid, caused by a vitamin deficiency in adults… The deficiency 
may be due to lack of exposure to ultraviolet rays, inadequate intake of vitamin D in 
the diet, or failure to absorb or utilize vitamin D. There is decalcification of the bones, 
particularly those of the spine, pelvis, and lower extremities.” Puerperal osteomalacia 
is “exhaustion of skeletal stores of calcium and phosphorus by repeated pregnancies 
and lactation.” See: “Puerperal Osteomalacia,” in Miller-Keane Encyclopedia and 
Dictionary of Medicine, Nursing, and Allied Health (Saunders, an imprint of Elsevier, 
Inc., 2003), https://medical-dictionary.thefreedictionary.com/puerperal+osteomalacia. 
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though prodding readers to Look!, to witness the mid-century medical knowledge the 
sculptures are made to certify, the article’s archaeo-medical fascination demands 
readers think of these ancient sculptors as performing a kind of medical-
pharmaceutical modernity. This form of modernity is measured by the ancient 
sculptor’s (or perhaps sculptors’) ability to “capture the visible signs of malnutrition, 
deformity, physical and mental sickness, the stages of pregnancy and childbirth, the 
techniques of amputation, trephining and, it is believed, even cesarean section.”5 
Apparently, ancient sculptors from the 4th century A.D. spoke the language of 1960s 
medical experts. 
The writer’s fascination with these ancient objects obscures critical parts of 
the story—for example, the fact that these five hundred or so sculptures were dug up 
from sacred gravesites; collected (as the article terms it) by Dr. Abner I. Weisman, 
Clinical Professor of Obstetrics and Gynecology of New York Medical College; and 
displayed at the Pfizer Building in New York from June 21-24, 1968. As humanities 
scholars writing about archaeological digs have argued, framing these acts of theft as 
“collecting” normalizes settler colonial violence against indigenous and Latinx 
peoples, descendants of these ancient sculptors who, according to the Spectrum 
article, simply “vanished” like a magic trick.6 Yet once these objects are stolen from 
their ancient tombs, the processes of scientific study to which they become subject 
also produce a paradoxical indigenous subject: one who embodies hegemonic 
 
5 Spectrum, 27. 
6 Spectrum, 26. 
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definitions of modernity and primitivism simultaneously, a contradiction that renders 
indigenous subjects as perpetually trying, working, aspiring to perform modernity, 
but always imperfectly. In other words, Global South knowledge here is defined as 
the imperfect discovery of Global North knowledge; the ancient artifacts act as 
evidence of both the primitivity of indigenous cultures and the timeless, static, 
“factness” of modern science. In this way, as Pfizer’s researchers explain and 
diagnose these clay sculptures and their sculptors, indigenous subjects become 
participants in “modern medicine” in a way that further exoticizes them; the ancient 
“physicians” who molded the sculptures are, by another kind of magic trick, made to 
posthumously participate in their own objectification. To what extent can indigenous 
subjects have epistemic agency here? What are the limits of this epistemic agency? 
What seems to differentiate the Global North’s knowledge (Fact) and the 
Global South’s knowledge (imperfect discovery of Fact) is a surveillant gaze, one 
that wishes to find or recuperate markers of liberal-modern definitions of equality, 
progress, and (secular) scientific empiricism. For instance, one of the full-page 
spreads features quite an array of allegedly maladic sculptures: three figures in 
different stages of pregnancy (Figure 14); a crouched figure with a bubbly, coral-like 
crust covering their abdomen and face (Figure 15); and two joined, crowned figures, 
their arms wrapped around one another’s shoulders, each clasping the other’s hand 
(Figure 16). The captions beneath each set of images shift abruptly between 
scientific and cultural registers. While the encrusted figure on the bottom left is 
described as an “[e]dematous male figure with skin and mucocutaneous lesions 
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identical in pattern” whose “[a]bdominal edema, swollen left arm, and agonized 
expression suggests that lesions may be terminal metastatic carcinomatosis” or the 
“gummatous stage of tertiary syphilis,” the joined figures’ “diagnosis” is socio-
cultural: though they “may not represent Siamese twins,” the caption nevertheless 
explains, “In some tribes twins denoted infidelity; the second child, considered 
evidence of wife’s exposure to another male, would be killed, and the wife severely 
punished.”7 This impulse—to both diagnose and pathologize the sculptors and 
sculpted, even while claiming that the sculptures are specifically, inherently 
“medical”—reflects a desire not to meaningfully attribute a kind of medical-
scientific intellect to ancient peoples, but rather for the writer to perform 
pharmocratic identity: modern, progressive, scientifically and socially advanced. 
The sculptors can never fully embody modernity because the pharmocratic gaze 
requires that they be understood as socially and culturally unsophisticated. In other 
words, the article is not about the sculptors, but about telling a story in medical terms 
about what was, about who was, about translating ancient embodied experiences into 
the language of modern medicine. From this perspective, we might revise the 
writer’s claim—“Whatever the artist’s motive, he had a medical story to tell and he 
told it in clay”—to a far more straightforward observation: Whatever the writer’s 
motive, he had a medical story to tell and he told it in Spectrum. 
This chapter explores how and why this labor of being almost modern—of 
performing a kind of scientific and medical prowess that normalizes pharmocratic 
 
7 Spectrum, 29. 
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logics of social and scientific progressiveness—shows up in much more recent 
journalism about underground markets for misoprostol. I begin this chapter with 
Spectrum because it so strikingly models the processes of cultural production that I 
see at work in this journalistic archive: using the affect of fascination and mystery, 
writers endow Global South subjects with techno-scientific agency, but only to the 
extent that this agency further entrenches Global South subjects into joined rhetorics 
of primitivism and self-responsibilization. This discourse—which starts in the late 
1980s, goes silent for nearly ten years, and then repeatedly reemerges as “news” 
from 2000 to the present—reveals the journalists’ liberal-progressive desire to 
endow Global South subjects with a specific kind of techno-scientific and 
entrepreneurial agency, one that reflects and upholds the ideology of reproductive 
neoliberalism. 
As I describe in the Introduction, reproductive politics scholars have focused 
intensively on right-wing rhetoric (marked broadly by xenophobic anti-immigration 
sentiments, paranoia about tax fraud, and devotion to bootstraps economics) for 
perpetuating the fiction of overpopulation that has historically enabled systemic 
obstetric violence. While we might expect the same right-wing thinkers to engage in 
the discourse about underground misoprostol, perhaps with even more xenophobic 
gusto, what makes the journalistic discourse about underground miso so unique from 
other abortion discourses is that it appears almost solely in mainstream liberal 
journalism, where issues of race, gender, rights, poverty, and women’s health are 
read through the lens of liberal-progressive humanism. In this way, miso’s 
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journalistic archive illustrates the sometimes counterintuitive ways that pharmocratic 
logics take root in liberal-progressive discourses. I ask: How does mainstream 
liberal-progressive journalism employ the rhetoric of archaeo-medical fascination 
and modernity/primitivism? What role do these narratives play in the expression and 
production of reproductive neoliberalism? What cultural imaginaries and 
pharmaceutical subjects does this kind of journalism encode, and to what ends? 
As I will show, strikingly similar to the Spectrum piece described at the 
beginning of this chapter, journalists read miso-users and underground sellers 
through the lens of reproductive neoliberalism, recruiting representatives of the 
Global South to perform a kind of approximate modernity—performances that are, 
by design, failed performances. I argue that these journalistic pieces reflect a liberal 
desire to endow figures of the Global South with a kind of pharmaceutical savvy that 
comes to define women’s agency; yet, ironically, this agency can only be legible 
through a distorted ethnocultural spectacle, a kind of journalistic violence that gets 
read and validated as “progressive.” In this way, the Global South subjects who are 
both impacted and produced by the discourses of reproductive neoliberalism occupy 
an impossible subject position: one in which their agency is contradictorily read as 
performing, threatening, and being victim to pharmocratic forms of modernity. By 
reading women’s (reproductive) agency specifically as an ability to use 
pharmaceutical products, journalists implicitly endorse the pharmocratic structures 
that prop up reproductive neoliberalism. 
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Imagining Brazilian Women: Vigilantes in “Wholesale Defiance” 
The first few journalistic pieces written about miso-induced abortions 
jumpstart a number of statistical inaccuracies that journalists have repeated to this 
day—statistics that help to produce an image of Latinx women seeking self-induced 
abortion as engaged in a kind of mysterious pharmocratic subversion. To some 
degree, mainstream liberal journalism situates underground miso in the same 
population-centered, Malthusian logics reproductive politics scholars mostly 
attribute to right-wing conservatism. Referencing two studies about underground 
miso published in the Lancet, a well-known medical journal, James Brooke writes in 
the New York Times that the studies “shed new light on the shadowy world of 
abortion in Brazil, Latin America’s most populous nation.”8 Throughout, the United 
States serves as the point of comparison for understanding Brazil’s population 
statistics, distorting the realities of clandestine abortion in both countries. 
Calculating that, although the number of abortions per year in Brazil is the same in 
the United States, the latter’s population is “about a hundred million more than that 
of Brazil,” Brooke’s arithmetic insinuates that Brazilian women (successfully) opt 
for abortions at a much higher rate than women in the United States do. In another 
instance, Brooke compares the annual number of women in Brazil treated via 
curettage (a very unpleasant medical procedure in which tissue vulnerable to 
 
8 James Brooke, “Ulcer Drug Tied to Numerous Abortions in Brazil: At $6 a Dose, 
Wholesale Defiance of an Abortion Ban,” New York Times, May 19, 1993. 
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infection is preventatively “scraped” out of the womb) to the annual number of 
women in the United States who are hospitalized for abortion complications: 
Curettage was the fourth most frequent medical procedure conducted in 
Brazilian public hospitals in 1991, where the operation was performed on 
342,000 women. About 10,000 American women are hospitalized yearly for 
abortion complications. The drug, which is available in the United States 
only by prescription, is not thought to be used there to induce abortion. 
 
While the numbers themselves are striking—342,000 women in Brazil compared to 
10,000 women in the United States—they are troublingly misleading, as they are not 
actually measuring the same phenomenon: curettage can be a treatment for abortion 
complications, but it is also a treatment for miscarriage and retained placenta, as well 
as to remove abnormal endometrial cells from the vaginal wall, very common 
conditions (particularly because women are at a significantly higher risk of retained 
placenta if they have a cesarean section) that have nothing to do with abortion.9 In 
the last sentence of the above passage, Brooke not only incorrectly reports that 
women in the United States do not use miso for abortion, but also implicitly 
attributes this deceptive statistical comparison to the United States’ tighter regulation 
of miso, reasoning that “with the world’s largest Roman Catholic population, few 
 
9 “Retained placenta” refers to placenta tissue that stays attached to the womb, even 
after the body expels the placenta following birth. The American College of 
Obstetricians and Gynecologists (ACOG) notes that incidence of retained placenta 
has significantly increased in the United States, ranging from a rate of 1 in 2,510-
4,017 in the 1970s and 80s to a rate of 1 in 272 in 2016. See: “Placenta Accreta 
Spectrum,” American College of Obstetricians and Gynecologists, accessed October 
9, 2019. 
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politicians [in Brazil] want to confront the problem posed by 1.5 million clandestine 
abortions performed each year.”10  
 This language constructs an image of Brazilian women as frugal and 
resourceful on one hand, while culturally and pathologically inclined to seek 
clandestine abortions on the other hand, an image that perpetually reemerges in later 
journalism about underground miso in and beyond Latin America. According to 
Brooke, Brazilian women go to “[great] lengths” to procure abortions, lengths that 
the bolded byline—“At $6 a dose, wholesale defiance of an abortion ban”—puts into 
economic terms, as though suggesting that miso enables Brazilian women to buy-in-
bulk their own rebellion, despite the reality that poor women are most likely to seek 
self-induced abortion of any kind. It is quite frankly irresponsible to suggest that 
seeking the most inexpensive abortion methods is evidence of women’s defiance 
against tight abortion restrictions or bans; rather, it is more likely reflective of the 
fact that flea markets are often one of the few viable sources of a host of basic 
essentials—not just medicine, but also healthy food and clothing.11 Instead, Brooke 
predicts that underground miso acts as a medium through which Brazilian women 
can engage in criminal (reproductive, pharmaceutical, entrepreneurial) behavior and 
deception, warning about the legal loopholes miso-induced abortion presents: “a 
Brazilian woman could claim she had a miscarriage and could legally check into a 
hospital for emergency curettage, or scraping of the womb, which completes the 
 
10 Brooke, “Ulcer Drug Tied to Numerous Abortions in Brazil: At $6 a Dose, 
Wholesale Defiance of an Abortion Ban.” 
11 Patricia Zavella to Cecelia Lie-Spahn, September 3, 2019. 
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abortion” (emphasis mine). Although sympathetic to the legal restrictions on 
abortion in Brazil, Brooke ignores the correlation between poverty and incidence of 
self-induced abortion, instead reproducing a juridico-surveillant gaze that reads 
women’s agency and the flea market itself as always-already criminal. 
The kind of strategic cunning Brooke associates with miso-induced abortion 
is at odds with his later report that Brazilian women do not know how to use birth 
control pills: 
Although the Brazilian birthrate has dropped sharply over the last 25 years 
[with the average dropping from six to three children per family], birth 
control is still erratic… [O]ne-quarter of Brazilian women who do not want 
to become pregnant use no birth control. Ninety percent of those who use one 
method, birth control pills, buy them over the counter at pharmacies, with 
little or no instruction as to their use. 
 
The message here is that Brazilian women are smart, strategic, self-motivated, even 
entrepreneurially inspired when it comes to using miso as an off-label abortifacient, 
but not so when it comes to birth control pills. While it makes sense that women 
would be knowledgeable about birth control in a different way than about 
misoprostol, the distinction Brooke makes between knowledge about birth control 
pills and that of off-label miso here is less about analyzing how pharmaceutical 
knowledge circulates differently from drug to drug (especially since, if anything, one 
would expect women to know more about how to use birth control pills than about 
how to use misoprostol off-label for abortion), and more about constructing an 
image of Brazilian women as exceptionally adept at using “illegal” underground 
drugs for clandestine abortion and lawless when it comes to the “legal” 
pharmaceuticals that help prevent pregnancy. Furthermore, by depicting Brazil as a 
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simultaneously pharmaceutically unregulated, hyper-religious area ripe for criminal 
behavior, the Global North becomes the implicit benchmark not only for how to 
effectively teach women about their contraceptive options, but also for progressive, 
secular policymaking and responsible pharmaceutical regulation. 
Although nearly a decade passed before any journalists wrote about 
underground miso again, many of these same patterns of Global South subject 
production reemerged when the story was taken up again in 2000. Journalists 
repeatedly cite the same legal, cultural, and health barriers to progress in the Global 
South: restrictive abortion laws; a corrupt government ruled by political greed; 
religious conservatism; and the World Health Organization’s (WHO) statistics on 
unsafe abortion and maternal mortality and morbidity. The phrase “Up to 70,000 
women die a year from complications of abortions” appears in nearly every article, 
despite a publication span of over fifteen years and the reality that this number only 
reflects the year 2001.12 In this way, mainstream liberal journalism depicts the 
 
12 For specific examples, see: Amy Allina, “Women Taking Abortion Pills on Their 
Own,” The Women’s Health Activist 39, no. 4 (July 2014): 4–4,7; “Backtalk,” Mother 
Jones 26, no. 2 (March 2001): 12; Emily Bazelon, “‘I Retrieved the Medicine from 
the Post in Nairobi Yesterday. I Kissed the Pills When They Fell Into My Hand.’,” 
New York Times (1923-Current File), 2014; Erik Eckholm, “A Pill Available in 
Mexico Is a Texas Option for Abortion,” The New York Times, July 13, 2013; Ann 
Friedman, “Mail-Order Abortions,” Mother Jones; San Francisco, Nov/Dec 2006; 
David Goodman, “Forced Labor,” Mother Jones, 2001; Nicholas D. Kristof, 
“Another Pill That Could Cause a Revolution,” New York Times, August 1, 2010; 
Jennifer S. Lee and Cara Buckley, “For Privacy’s Sake, Risking Do-It-Yourself 
Abortion,” New York Times (1923-Current File), 2009; John Leland, “Abortion 
Might Outgrow Its Need for Roe v. Wade,” New York Times, 2005; Sharon Lerner 
and Christina Cauterucci, “The DIY Abortion,” Slate, January 18, 2011; Nina Liss-
Schultz, “The New Abortion Underground,” Mother Jones 43, no. 2 (March 2018): 
46–51,58; Aaron Nelsen, “Taking Calls On Abortion, And Risks, In Chile,” New 
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Global South as having failed to embrace modern juridical and statistical grammars 
of Progress such as women’s rights, fertility decline, and secular governmentality.13 
At the same time, the journalism continues to cast Global South women as 
extraordinarily, techno-scientifically savvy, but only when it comes to the extra-legal 
buying and selling of underground misoprostol. This contradiction epitomizes the 
fused humanitarian and capitalistic rhetorics that undergird reproductive 
neoliberalism: racialized primitivism on one hand, economic and techno-scientific 
individualism on the other. 
 
York Times (1923-Current File), 2013; Louise Rimmer, “Hard to Swallow: These 
Pills Were Designed to Treat Ulcers. But to Millions of Latin American Women 
Denied Legal Abortion, They Have Become a Controversial Symbol of Hope,” The 
Independent; London (UK), September 2, 2003; Thanh Tan, “Looking to Mexico for 
Alternative to Abortion Clinics,” The Monitor; McAllen, Tex., August 13, 2012; 
Phoebe Zerwick, “The Rise of the DIY Abortion,” Glamour, accessed March 14, 
2017. 
13 This is besides the point, but this depiction is especially unfounded given that 
fertility has been radically declining in Latin America since the 1950s. Family 
planning studies frequently describe their work in Latin America as a booming 
success, citing statistics of declined unmet need for contraception. At the same time, 
these studies do not account for forced or coercive family planning practices, despite 
prolific scholarship on coercive sterilizations in the region. See: Martha M. Campbell, 
Ndola Prata, and Malcolm Potts, “The Impact of Freedom on Fertility Decline,” The 
Journal of Family Planning and Reproductive Health Care / Faculty of Family 
Planning & Reproductive Health Care, Royal College of Obstetricians & 
Gynaecologists 39, no. 1 (January 1, 2013): 44–50; John Cleland et al., “Family 
Planning: The Unfinished Agenda,” World Health Organization, Sexual and 
Reproductive Health, 3 (n.d.); John Cleland, Sarah Harbison, and Iqbal H. Shah, 
“Unmet Need for Contraception: Issues and Challenges,” Studies in Family Planning 
45, no. 2 (2014): 105–22. 
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Centering the Self in Investigative Journalism 
What makes the second batch of journalism (starting in 2000) distinct from 
the few pieces published in the early 90s is that, perhaps in the spirit of investigative 
journalism, almost all of the journalistic pieces from 2000 and on begin with the 
writer’s own “encounter” with the flea market, spectacularizing the prospect of an 
underground pharmaceutical abortifacient originating in the Global South and 
making its way into the United States. Remarkably similar to the archaeo-medical 
fascination produced in the Spectrum article at the beginning of this chapter, 
journalists take on a kind of prophetic mysticism, marveling at the drug’s 
revolutionary potential while cautioning against the dangers of underground 
pharmaceutical markets. This rhetoric exoticizes difference, centering the writer’s 
experiences of said difference while claiming to unearth previously unseen truths. 
This is precisely the form of cultural production at work in the Spectrum article at 
the beginning of this chapter, in the sense that the techno-scientific innovations of 
Latinx women represented in these stories, however celebratory, only work to 
further marginalize and exoticize Latinx women via the rubrics of reproductive 
neoliberalism. 
For example, in a 2014 piece for The Atlantic, Erica Hellerstein describes her 
encounter as a personal quest: 
Under canopies in the converted parking lot, vendors in dark sunglasses stand 
behind tables heaped with piles of clothing, barking in Spanish and hawking 
their wares. The air is hot and muggy, thick with the scent of grilled corn and 
chili… I’m here to look for a small, white, hexagonal pill called 
misoprostol… As policies restricting access to abortion roll out in Texas and 
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elsewhere, the use of miso is quickly becoming a part of this country’s 
story.14 
 
The racial tropes here are reminiscent of colonial-era travel writing. Men “bark” and 
“hawk” like animals, their dark sunglasses masking their identities, while two 
stereotypically Tex-Mex dishes—grilled corn and chili—cook nearby. This flea 
market is described as temporary, transient, “converted” from its supposedly 
intended use (a parking lot) to another (apparently, to grill corn and sell miso), 
despite the fact that many of these flea markets are permanent. The “small, white, 
hexagonal pill” Hellerstein is looking for stands out against the image of piles of 
clothing and food. The final sentence raises alarm about border security: the “use” of 
miso is transgressive, a seemingly contagious phenomenon infiltrating the “story” of 
the United States—and fast. 
This caricature of abortion-seeking women—women who “[know] exactly 
what to ask for at the small, family-run pharmacy”15—and persistently “shadowy” 
flea markets in the Global South must be understood in the context of a broader 
discourse about the supposed “backwardness” of Latinx culture and the gendered 
carceral logics of the United States’ war on drugs. Right-wing political and 
journalistic rhetoric on the war on drugs has historically cast Latinx people as the 
primary producers, traffickers, and consumers of so-called “illicit drugs” such as 
 
14 Erica Hellerstein, “The Rise of the DIY Abortion in Texas,” The Atlantic, June 27, 
2014, http://www.theatlantic.com/health/archive/2014/06/the-rise-of-the-diy-
abortion-in-texas/373240/. 
15 Jennifer 8. Lee and Cara Buckley, “For Privacy’s Sake, Taking Risks to End 
Pregnancy,” The New York Times, January 4, 2009, 
https://www.nytimes.com/2009/01/05/nyregion/05abortion.html. 
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heroin, marijuana, and cocaine.16 Mothers have played a particular role in this 
narrative: while the prevailing rhetoric of the New Right beginning under the Reagan 
administration accused poor mothers—especially single, Black mothers—of cashing 
in welfare checks to pay for their supposed drug addictions, Latinx women were, 
too, painted as excessively reproductive, having so-called “anchor babies” they 
could not financially support in order to secure their residency and their families’ 
future citizenship. For Latinx mothers in particular, the New Right’s outrage hinged 
not only on the question of tax fraud, but also on a belief about Latin American 
“culture,” one that “highly values the woman’s ability to procreate a family” with 
“almost a religious significance.”17 These infantilizing and xenophobic narratives not 
only worked to legitimize tax-payer resentment, contributing to the fiction that 
Latinx communities were “stealing” the jobs of hardworking Americans and sapping 
social programs funded by American taxpayers, but also made borderland 
communities a nearly exclusive target of the war on drugs. As a result, Latinx 
women have been disproportionately incarcerated for drug-related crimes in the 
United States, especially as the United States has continued to privilege funding for 
Immigration and Customs Enforcement (ICE) and the Drug Enforcement 
 
16 Juanita Diaz-Cotto, “Latinas and the War on Drugs in the United States, Latin 
America, and Europe,” in Global Lockdown : Race, Gender, and the Prison-
Industrial Complex, ed. Julia Sudbury (New York: Routledge, 2005), 137. 
17 Elena R. Gutiérrez, Fertile Matters: The Politics of Mexican-Origin Women’s 
Reproduction, 1st ed, Chicana Matters Series (Austin: University of Texas Press, 
2008), 46; Roberts, Killing the Black Body. 
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Administration (DEA).18 This context profoundly shapes the U.S. discourse about 
underground miso specifically and reproductive imaginaries of the Global South 
more broadly. 
It is thus tempting to read these stories about underground miso as re-
enacting the fantasy of colonial encounters with the racialized Other “in need” of 
civilizing. Gayatri Spivak might call these racial tropes acts of “subjective 
essentialism,” in which a Western gaze re-presents a supposedly authentic or 
otherwise made to be “real” non-Western subject.19 As bell hooks puts it, “Within 
commodity culture, ethnicity becomes spice, seasoning that can liven up the dull 
dish that is mainstream white culture… In many ways it is a contemporary revival of 
interest in the ‘primitive,’ with a distinctly postmodern slant.”20 Masked by the fact-
ness or constructed authenticity of detailed physical and spatial descriptions, these 
investigative journalism pieces only reaffirm this savior-complex reading. 
Yet while the New Right reads underground markets as evidence of a kind of 
innate exploitative greed and dereliction in Latin American people—so-called 
“breeders” of disease, criminality, primitivism, and economic and environmental 
destruction21—reproductive neoliberalism indexes these underground markets as 
 
18 Diaz-Cotto, “Latinas and the War on Drugs in the United States, Latin America, 
and Europe,” 138. 
19 Gayatri Chakravorty Spivak, A Critique of Postcolonial Reason: Toward a History 
of the Vanishing Present (Cambridge: Harvard University Press, 1999), 264. 
20 bell hooks, Black Looks: Race and Representation (Boston: South End Press, 
1992), 21. 
21 Briggs, Reproducing Empire; Gurr, Reproductive Justice; Gutiérrez, Fertile 
Matters; Roberts, Killing the Black Body; Silliman et al., Undivided Rights; Stern, 
Eugenic Nation. 
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evidence of Global South women’s desire for liberal-modern markers of progress in 
the Global South—i.e. free markets and rights—rather than as desires for bodily 
autonomy. This narrative works to justify the dangers these journalists inflict on 
clandestine abortion providers and seekers, even when they explicitly wrestle with 
the reality that they could be “ratting out” the revolution: 
I talked to dozens of clandestine providers, and our conversations offer a rare 
glimpse into a world that is shrouded in secrecy and fear. Some urged me not 
to write about their work. But their efforts reveal a new aspect of how the 
war on reproductive rights has played out, and how a new generation of 
activists has come to believe that it’s reasonable to handle this aspect of 
women’s health care outside a medical setting. And they are determined to 
give more women that opportunity, no matter the legal risk.22 
 
After dismissing the fears expressed by her informants, the journalist justifies her 
decision to report on underground miso anyway by citing its epistemic value, even if 
only offering a “glimpse.” The “efforts” women have taken to survive become 
models not only of reproductive rights activism, but wartime ideals of determination, 
reasonability, and risk-taking. 
Yet what is most remarkable in this passage is that, rather than depicting 
subjects of the Global South as overly reproductive bodies to be culturally and 
physically remedied, mainstream liberal journalists refigure subjects of the Global 
South as reproductive vigilantes whose individual actions need to be existentially 
redeemed. In other words, instead of following suit with conservative anti-
immigration rhetoric that renders non-white (over)reproductivity dangerously 
irresponsible, the mainstream liberal journalism in which these discourses primarily 
 
22 Liss-Schultz, “The New Abortion Underground,” 48. 
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appear turn individual reproductive risk into a kind of social responsibility—a form 
of civil disobedience necessary to embrace neoliberal definitions of reproductive 
freedom. In this context, we might understand these journalistic texts as a 
manifestation of a liberal-progressive fantasy in which the street vendor’s skilled 
subversion of the state’s social conservatism and undisciplined market forces 
actually enable progressive activism in the Global South. This redemption narrative 
is consistently premised on a racialized fantasy of necessary criminality; those 
described as buying and selling miso “underground” can only be read as redeemable 
against the backdrop of a kind of socially responsible, forgivable form of criminality. 
In this way, Global South subjects are simultaneously subversively agentic and the 
non-agentic effect of a backwards legal/cultural context, carrying forth the torch of 
liberal modernity despite the personal costs. 
To be clear, the public health and legal circumstances these journalists 
perceive here are legitimately concerning. It cannot be overstated that more adequate 
legal protections—legal work premised on the understanding that the need for self-
induced abortion is deeply connected to the political, economic, and cultural 
structures in which it occurs—would not only help prevent people from being 
criminally targeted for self-inducing abortion, but also help protect them if 
prosecuted.23 The problem is that, rather than pointing to the deeply entrenched 
systems of violence (i.e. not exclusively juridical) that hurt poor women of color the 
most, these journalistic discourses (however well-intentioned) contradictorily read 
 
23 Adams, Mikesell, and The SIA Legal Team, “Primer on Self-Induced Abortion.” 
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underground miso as both a conduit through which to speculate about Latinx 
criminality and a catch-all solution to achieving reproductive freedom. As a 
consequence, underground miso gets read as evidence of the efficacy of so-called 
“DIY” or “self-help” strategies said to be newly enabled by liberal and techno-
scientific modernity, propelling reproductive neoliberalism in the form of a deeply 
misguided assumption that major economic and institutional change is unnecessary 
for women to achieve reproductive freedom. In other words, under reproductive 
neoliberalism, pharmaceutical agency is said to be all that is required to achieve 
Euro-America’s liberal humanist vision of reproductive freedom, moving the focus 
away from systemic change and onto individual actions. 
This is the central violence this journalism produces: the deeply racialized 
language in liberal-progressive journalism distorts women’s desire for bodily 
autonomy as evidence of the dangerous and yet liberatory possibilities of 
pharmocracy itself. In other words, the journalism misconstrues women’s desire for 
control over their own bodies—and the powerfully creative and agential ways in 
which women have historically pursued this—into an impossible Global South 
subjectivity: one that is only read as agential when her desire for bodily autonomy is 
characterized as simultaneously a desire for and yet threat to the pharmocratic 
market structures Pfizer espouses in Chapter 1. This is an updated version of what 
Saidiya Hartman describes as “benevolent corrections and declarations” of humanity 
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that, perhaps counterintuitively, act to “teether, bind, and oppress.”24 In this case, 
Latinx women’s humanist “agency” gets re-scripted as either criminal or evidence of 
liberatory techno-science, ignoring the impact of poverty that powerfully shapes the 
ways women seek reproductive healthcare. It is therefore no coincidence that so 
much of the investigative journalism focuses almost exclusively on the 
entrepreneurial ethics of the flea market vendors: under reproductive neoliberalism, 
pharmocratic individualism masquerades as attention to the systemic (law, poverty, 
politics), reading women’s creative agency as permission to maintain the structures 
of neoliberalism more broadly.25 This form of U.S.-based journalistic violence is 
important not simply because it is offensive, but because it fulfills the pharmocratic 
desires described in Chapter 1: it redirects public attention from pharmaceutical 
companies to its users, reproducing the individualist paradigms of reproductive 
neoliberalism. 
Fantastic Markets: Temporalities of Underground Miso 
While quick to point out the juridical and cultural contexts that inhibit 
reproductive freedom for women in the Global South, journalists almost completely 
 
24 Saidiya V. Hartman, Scenes of Subjection: Terror, Slavery, and Self-Making in 
Nineteenth-Century America, Race and American Culture (New York: Oxford 
University Press, 1997), 5. 
25 This is in spite of the reality that women who have abortions are more likely to be 
poor; and since 1976, the Hyde Amendment has barred the use of federal funds to pay 
for abortions except if the pregnancy arises from incest or rape, or when a pregnant 
woman’s life is endangered. See: Sabrina Tavernise, “Why Women Getting 
Abortions Now Are More Likely to Be Poor,” The New York Times, July 9, 2019, 
https://www.nytimes.com/2019/07/09/us/abortion-access-inequality.html. 
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ignore the pharmaceutical industry, erasing the material realities within which 
underground markets for miso emerge, but also basic facts about the drug. For 
example, none of these U.S.-based journalistic texts explain where miso is 
manufactured (Connecticut). Rather, they consistently describe underground miso as 
coming into the United States from the Global South, reflecting liberal anxiety that 
southern states have become so antithetical to the progressive agenda, so alienated 
from the political ideologies of iconically progressive states (e.g. Vermont, 
California, New York), that they have now taken on the “backwards” cultural 
politics associated with a monolithic image of the developing world. An article 
published in Women’s Health Activist, a journal supported by the National Women’s 
Health Coalition, begins with this very concern: 
When a woman in Idaho, who had taken drugs that she ordered over 
the Internet to end her unintended pregnancy, told a friend about what she 
experienced, she ended up under arrest, charged with a felony for having an 
illegal abortion. 
When a woman in Mexico suspects she might be pregnant when she 
doesn’t want to be, she can buy drugs at a pharmacy or an informal market 
that she can take at home to bring on her period.26 
 
The writer’s observations above literalize her own surprise: how could it be that, in a 
backwards place with limited legal abortion opportunities, women can apparently so 
easily procure an abortion? How could it be that they don’t even have to call it 
abortion? 
In this way, discourses about underground miso are deeply entangled with an 
almost existential curiosity about the flea market itself: what constitutes a market, 
 
26 Allina, “Women Taking Abortion Pills on Their Own,” 4. 
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where markets can exist, what can be sold at them, who can sell at them, even what 
these markets look like (though still, no questions about the pharmaceutical 
industry). Detailed descriptions of the flea market position readers at the limits of 
consumer familiarity and desire, marking the flea market as a kind of consumer 
wonderland where everything is available in mass quantities and everything is cheap. 
In a 2014 article about abortion in developing countries (also quoted in the 
Introduction), Jason Beaubien writes: 
In the central market in San Salvador, you can buy just about anything you 
want: tomatoes by the wheelbarrow full. Fresh goat’s milk straight from the 
goat. Underwear. Plumbing supplies. Fruit. Hollywood’s latest blockbusters 
burned straight onto a DVD. 
 
And in the back of the market, in a small stall lined with jars of dried herbs, 
roots and mushrooms, you can buy an abortion. 
 
Although purchasing underwear and milk at the same time is pretty routine for most 
readers, or at least those immersed in superstore culture à la corporate giants like 
Walmart and Target, journalists tend to indulge the eccentricity of this one-stop-shop 
experience. In the process, notions of difference solidify into commoditized objects. 
Racial and cultural fetishisms spill over, extending through and beyond the body: 
polarized notions of modernity and primitivism, here indiscriminate from the 
dichotomy of whiteness and blackness/brownness, map not only onto the animate 
bodies in the scenes, but also onto the inanimate objects. If boxes of Advil represent 
the technological advances developed by the biotech industries of the Global North, 
the black and brown, non-Western bodies that sell these drugs act as the Global 
North’s exoticized corollary, a distorted opposite. The flea market becomes a place 
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of such unprecedented consumptive readiness that abortion itself—a complex, 
subjective experience tied to the body but is not itself neatly discernable as a unified, 
tangible body or thing—becomes commoditized in the form of a “white, hexagonal 
pill” (miso).27 Miso itself becomes a racialized and racializing good one can “buy” in 
the back of a street tent. 
Yet while these dichotomous notions of modernity and primitivism are 
essential for casting misoprostol as one among many unexpected commodities in the 
flea market, miso also represents multiple, contradictory forms of essentialism that 
cannot be neatly classified into unidirectional or bidirectional Subject/Other 
relationships. For instance, the act of classifying objects that do not belong—
culturally, temporally, racially—from those that do ironically produces a kind of 
double-racialization in which misoprostol is both an object of whiteness and its 
exoticized opposite. Recontextualizing the NPR piece below, the breaks between 
paragraphs quite literally compose this double-racialization: 
In the central market in San Salvador, you can buy just about anything you 
want: tomatoes by the wheelbarrow full. Fresh goat’s milk straight from the 
goat. Underwear. Plumbing supplies. Fruit. Hollywood’s latest blockbusters 
burned straight onto a DVD. 
 
And in the back of the market, in a small stall lined with jars of dried herbs, 
roots and mushrooms, you can buy an abortion. 
 
“I have all types of plants to treat all kinds of diseases,” the woman who runs 
the shop says through an interpreter. “For example, problems with your liver, 
your kidneys, stomach problems, nerves, for cancer—for everything.” 
 
She says she also has a bitter tea that can take care of an unwanted 
pregnancy. 
 
27 Hellerstein, “The Rise of the DIY Abortion in Texas.” 
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Abortion is completely banned in El Salvador and punishable with a prison 
term of anywhere from two to 50 years in prison. So this woman asks that we 
not use her name. 
 
Her tea only works, she says, in the first six weeks of pregnancy. If a woman 
is seeking an abortion later than that, the herbalist arranges to get something 
far stronger from a local pharmacy: pills used to treat stomach ulcers that are 
sold generically as misoprostol.28 
 
In the excerpt above, each new paragraph categorizes the objects and practices that 
belong from those that do not. The offset paragraph about “taking care of an 
unwanted pregnancy” subsumes the previous paragraph, which describes ample 
stocks of plant-based medicine used to treat ailments as far-ranging as stomach 
problems and cancer (“I have all types of plants to treat all kinds of diseases”). By 
contrast, abortion apparently requires a “far stronger,” more effective method that 
can only come from a pharmacy. In other words, this placing of pharmaceuticals as a 
contrast to plant-based medicine exacerbates the perceived ineffectiveness of the 
herbalists’ knowledge and relative “strength” of Western pharmaceuticals. It also 
defines abortion as a trial-and-error process that necessitates pharmaceutical 
intervention when “primitive” methods fail. This privileging of miso as the more 
effective option produces a meeting point of racial, economic, and pharmaceutical 
narratives that marginalizes and exoticizes indigenous medical expertise while 
marveling at its resourcefulness. 
 
28 Beaubien, “Even When Abortion Is Illegal, the Market May Sell Pills for 
Abortion.” 
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This contradictory essentializing renders miso itself a metamorphic object, 
one that comes to signify the scientific achievements of the Global North and the 
combined economic resourcefulness and criminality of the Global South at the same 
time. For example, it is only when miso is consumed as an abortifacient that it 
becomes an import from the Global South. This is best reflected in left-leaning 
journalism that depicts the underground sale of miso as a workaround solution to 
anti-abortion legislation in the southern United States, a zone with so much 
organized resistance to abortion that, in 2017, the Lady Parts Justice League 
facetiously awarded state representatives for “Best Original Science” and “Best 
Adaptation of Reality.”29 For instance, in 2013, mainstream liberal journalism on 
clandestine abortion was primarily concerned with Texas Senate Bill 5 (Texas SB 5), 
which would have required all abortion clinics in the state to adhere to the structural 
requirements of an ambulatory surgical center, shutting down over half of the 
abortion clinics since 2013 despite the Supreme Court overturning the bill in 2016. 
Because of this bill, the shape and size of abortion clinics in Texas not only came to 
determine the legality of the procedure, but also prompted journalists to focus on the 
aesthetics of over-medicalized spaces the bill threatened to necessitate. One New 
York Times journalist compares the before-and-after aesthetics of a Whole Women’s 
Health Clinic in McAllen, Texas: 
With plush recliners, a Georgia O’Keeffe flower print on the wall and herbal 
tea, the center’s recovery room resembles a small first-class lounge. 
Ambulatory surgery centers, in contrast, must have large, hospital-style 
 
29 Texas: Best Original Science, Film (Lady Parts Justice League), accessed August 3, 
2017, http://www.ladypartsjustice.com/video/texas/. 
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recovery rooms, with medical equipment on the walls. Patients must rest on 
gurneys, separated by ceiling-mounted curtains. The herbal tea would not be 
allowed.30 
 
The excerpt above reflects nostalgia for a physical space that disrupts the affective 
sterility of hospitals, a place where “patients must rest on gurneys” and where “the 
herbal tea would not be allowed.” While it makes sense that left-leaning journalists 
would highlight the administrative absurdity of the legislation, the description above 
speaks to an anxiety about hitting the right balance of medical expertise and the 
“natural” (flowers, tea), reinforcing the idea that medical aesthetics are intrinsically 
in conflict with the latter. 
In this context, misoprostol signifies the ability to have an abortion without 
sacrificing one’s relationship to other “natural” or “organic” signifiers. Rather than 
emphasizing the strength of pharmaceuticals as a marker of biomedical triumph, 
miso comes to represent the potential to de-professionalize abortion in the United 
States, what has been labeled in several contexts as the latest “DIY” abortion 
method.31 As various forms of DIY healthcare have long been a part of feminist 
activism in the United States—DIY speculums of the 1970s, vacuum aspiration 
abortions, menstrual regulation—the DIY-ness associated with miso abortions 
prompts the repetition of very old one-liners about women’s reproductive rights. For 
instance, a New York Times article quotes Dr. Jerry Edwards, an abortion provider in 
Little Rock, Arkansas, stating: “We won’t go back to the days of coat hangers and 
 
30 Eckholm, “A Pill Available in Mexico Is a Texas Option for Abortion.” 
31 Hellerstein, “The Rise of the DIY Abortion in Texas”; Lerner and Cauterucci, “The 
DIY Abortion”; Zerwick, “The Rise of the DIY Abortion.” 
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knitting needles. Rich women will fly to California; poor women will use Cytotec.”32 
In other words, whether or not medically supervised abortion is available will not 
prevent women from ending unwanted pregnancies. Ironically, Dr. Edwards’ 
insistence that we won’t “go back” to the days of coat hangers and knitting needles 
prompts him to resuscitate the same language of mainstream pro-choice advocacy of 
the very era he doesn’t want to go back to, right down to the sentence construction: 
rich women will get a surgical abortion; poor women will go to back alleys. In 
placing the responsibility for reproductive healthcare into the hands of the patients 
themselves, the liberal mainstream replicates the right’s notion of pulling up one’s 
bootstraps in the face of adversity. 
Perhaps one of the most revealing public debates about using underground 
miso as a DIY abortifacient appears in the online comments to an anonymously 
written Jezebel article titled, “I Help Desperate Women, and I Could Go To Jail for 
It.”33 After describing women who could not afford an abortion or could not travel to 
a clinic several hours away—women whom the author “know[s]…most of them so 
far are immigrants [sic]”—the author discloses that they mail these women a “small, 
unmarked envelope” containing misoprostol. “I am one of America’s unlicensed, 
untrained illegal abortionists,” they confess. One commenter, “notsodumbblonde,” 
writes that they respect the author’s desire to “help people and provide medical care 
 
32 Leland, “Abortion Might Outgrow Its Need for Roe v. Wade.” 
33 Anonymous, “I Help Desperate Women, and I Could Go To Jail for It,” Jezebel, 
accessed October 8, 2017, https://jezebel.com/i-help-desperate-women-and-i-could-
go-to-jail-for-it-1320076409. 
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and opportunity that would otherwise be unobtainable,” but that they are concerned 
about the medical risk, asking: 
But could you elaborate on your medical background a little 
more?...Especially if you’re just (not saying you are) some random regular 
person who did a little internet search on drug side effects and decided to 
play pharmacist. 
 
Notsodumbblonde is careful to support the blogger’s impulse to “help” while 
challenging an ethical gray area in which this form of support presumes that anyone, 
even a self-proclaimed “unlicensed, untrained abortionist,” can take the place of a 
pharmacist or medical professional. The debate that then ensues revolves around 
questions of expertise. What constitutes expertise? What training is really necessary 
to prescribe off-label abortifacients? 
yvanehtnioj > notsodumbblonde (9/17/13 12:19pm) 
If someone in my house says they have a headache and I tell them I have 
aspirin, do I need to justify my medical training to do so? It’s not like she’s 
using some secret family recipe that she swears works wonders, the pills 
she’s sending are made for this express purpose. 
 
notsodumbblonde > yvanehtnioj (9/17/13 12:22pm): 
I understand your point, and you make a good one, but these medications are 
not aspirin. They induce abortion, which to me sounds like they are a strong 
enough drug to be cautious of and not throw around. But that’s just me, and 
I’m paranoid when it comes to “quick-fix” pills.  
  
MilkCat > notsodumbblonde (9/17/13 12:27pm): 
In most instances, they are, essentially, extra strength birth control pills (with 
some exceptions). So yes, there is always risk involved, but not nearly as 
much as some would have you believe. 
 
The commenters here are all working through a few contradictory ideas about 
misoprostol. On one hand, miso is more powerful than aspirin and thus not 
something to “throw around.” On the other hand, miso is understood as a “quick-fix” 
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drug, no more powerful than “extra-strength birth control pills.” Some of these 
assertions are troublingly misguided—for example, miso is no more an extra 
strength birth control pill than saran wrap is an extra strength condom—but the 
conversation is indicative of how underground miso discourses become avenues 
through which to both redefine expertise and reallocate responsibility according to 
the paradigms of reproductive neoliberalism. 
Consequences: Redistributing Pharmaceutical Risk 
One of the repeated assumptions in mainstream liberal media reporting on 
underground miso markets is that the highly corporatized pharmaceutical industry is, 
by contrast, “regulated.” In their fixation on the medical risks of taking miso for off-
label purposes, journalists implicitly suggest not only that federal and state policies 
successfully protect consumers from economic and bodily exploitation, but also that 
underground misoprostol markets somehow evade these protections in more 
dangerous ways. The irony is that Pfizer’s own off-label marketing strategies over 
the last few decades have proven to be one of their biggest liabilities, and journalists 
have not missed the opportunity to broadcast the long list of egregious crimes and 
handsome settlements they have paid as a result. In 2004, Pfizer paid $430 million to 
the federal government for the illegal marketing of Neurontin, a drug the FDA had 
approved to treat epilepsy, but was also being prescribed to treat bipolar disorder, 
Lou Gehrig’s disease, attention deficit disorder, restless leg syndrome, and seizures 
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from drug and alcohol withdrawal, off-label uses that made up ninety percent of their 
overall sales.34 According to the New York Times, the court concluded that Pfizer 
[…] suppressed study results, planted people in medical audiences to ask 
questions intended to put gabapentin [Neurontin] in a good light, lavished 
perks on doctors, used ghostwriters, gave generous “consultation fees” to 
“thought leaders,” and used psychological profiling of doctors in its 
successful bid to move gabapentin to so called blockbuster status (annual 
sales in excess of $1bn).35 
 
Using tactics usually associated with the FBI (e.g. psychological profiling, or “a 
range of techniques [mainly psychology based] for inferring the characteristics of 
offenders from crime scene behaviours in order to assist in the prioritizing of 
suspects and lines of inquiry”36), Pfizer clearly organized a highly elaborate, 
surreptitious campaign in order to reach sales goals. In 2009, Pfizer paid another 
$2.3 billion settlement—the biggest settlement ever reached in U.S. criminal 
history—after the company was convicted of marketing off-label uses of Bextra, a 
painkiller that has since been withdrawn from the market.37 In 2011, Pfizer paid over 
$60 million in fines for violating the Foreign Corrupt Practices Act of 1977 (FCPA), 
which prohibits making payments to foreign government officials in order to win 
 
34 Gardiner Harris, “Pfizer to Pay $430 Million Over Promoting Drug to Doctors,” 
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35 Jeanne Lenzer, “Pfizer Pleads Guilty, but Drug Sales Continue to Soar,” British 
Medical Journal 328, no. 7450 (2004): 1217. 
36 Alison Laurence, “Offender Profiling,” in Dictionary of Policing, ed. Tim Newburn 
and Petere Neyroud (Willan Publishing, 2008). 
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overseas business.38 In 2014, journalists re-reported the Neurontin scandal when 
Pfizer paid a second installment of $325 million toward the case. All told, Pfizer has 
paid at least $4 billion to the federal government and individual whistleblowers for 
illegal marketing practices, most of which stemmed from their promotion of off-
label drug use. According to John Kopchinski, a former Pfizer sales representative 
and one of the whistleblowers in the Bextra case, “The whole culture of Pfizer is 
driven by sales, and if you didn’t sell drugs illegally, you were not seen as a team 
player.”39 
What is misleading about these reports is that, although the settlements do 
reflect intensified federal action against unethical pharmaceutical marketing 
practices, in reality, the fines (however impressive) do not discourage 
pharmaceutical companies from disseminating information about off-label uses of 
their products. While it is illegal for pharmaceutical companies to market drugs for 
off-label uses in the United States, physicians are free to prescribe drugs for off-label 
purposes provided that they are “well-informed about the product, base its use on 
firm scientific rationale and on sound medical evidence, and maintain records of the 
product’s use and effects.”40 On one hand, this exception to federally mandated 
 
38 Christopher Matthews and Joe Palazzolo, “Pfizer Near Settlement on Bribery,” 
Wall Street Journal (Online); New York, N.Y., November 21, 2011. 
39 Harris, “Pfizer Pays $2.3 Billion to Settle Marketing Case.” 
40 Thomas Szivos, “Recent Developments in the Law of Off-Label Promotion of 
Prescription Drugs: Litigation and Federal Guidelines,” American Journal of Law & 
Medicine 35, no. 1 (March 2009): 238; FDA, “‘Off-Label’ and Investigational Use of 
Marketed Drugs, Biologics, and Medical Devices: Info Sheet,” Guidance for 
Institutional Review Boards and Clinical Investigators, accessed December 8, 2017, 
https://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm. 
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marketing ethics policies allows physicians to treat illnesses that do not yet have a 
designated cure, providing treatment options to patients who would be otherwise 
untreatable. On the other hand, physicians’ authority to prescribe drugs for off-label 
purposes presents a conflict between practices understood as “innovative medical 
care” and regulatory safeguards designed, at least in theory, to protect patients.41 But 
perhaps even more troubling is the assumption that information mediated via “non-
advertising” forms is inherently neutral—that the principles and formal qualities of 
an advertisement are distinct from those of scholarly, professional, or journalistic 
texts—despite overwhelming evidence that Pfizer manipulates these forms through 
fraudulent scientific studies, bribery, and even hiring ghostwriters in order to meet 
sales goals. From this perspective, it becomes clear that pharmaceutical companies 
are still incentivized to produce and distribute information about off-label drug use, 
just in alternative forms, ones the law cannot characterize as an advertisement. There 
is thus good reason to assume that, far from eliminating the fraudulent marketing 
practices for which Pfizer has been known for most of the twentieth century, recent 
convictions have only ushered in more covert forms of marketing fraud for which 
Pfizer cannot be held legally accountable. 
Despite Pfizer’s long criminal record of paying journalists to report on their 
drug products as a covert form of marketing, there have been no allegations that 
Pfizer was connected to journalistic texts about underground miso markets, and this 
 
41 Szivos, “Recent Developments in the Law of Off-Label Promotion of Prescription 
Drugs,” 238. 
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chapter has not aimed to make these accusations. Rather, my purpose here has been 
to show how the mainstream liberal media industry reproduces the underlying 
pharmocratic narratives Pfizer has deployed throughout the post-World War II 
period (the subject of Chapter 1). The question of whether or not Pfizer played a 
direct role in circulating these texts becomes less urgent when faced with the 
possibility that unethical practices like bribery and ghostwriting may no longer be 
needed to carry out illicit marketing practices specifically designed to generate 
corporate profit. From this perspective, mainstream liberal media appears to 
compensate for Pfizer’s marketing limitations, not only creating a no-cost, low-risk 
form of illicit off-label advertising (from Pfizer’s perspective), but also producing an 
implicit alliance—what Roderick Ferguson and Grace Hong might call a “strange 
affinity”42—between the pharmaceutical industry and mainstream liberal media. 
 Accordingly, both Chapter 1 and Chapter 2 have been primarily focused on 
the production and circulation of pharmaceutical knowledge vis-a-vis misoprostol. 
Chapter 1 historicizes the joint rhetoric of pharmaceutical patriotism and capitalism, 
while Chapter 2 illustrates how liberal-progressive journalism reproduces this 
pharmocratic project in new forms, rendering liberal-progressive journalism a 
critical site of pharmocratic knowledge production. The next chapter moves to 
another critical site of reproductive neoliberalism: family planning literature about 
underground miso.  
 
42 Grace Kyungwon Hong and Roderick A. Ferguson, “Introduction,” in Strange 
Affinities: The Gender and Sexual Politics of Comparative Racialization, Perverse 
Modernities (Durham [NC]: Duke University Press, 2011), 2–22. 
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CHAPTER 3 
Benevolent Interventions 
 
 
 
“I feel like people must have felt when they discovered the nuclear bomb. 
This technology is world-shaking.”1 
 
Dr. Beverly Winikoff 
President of Gynuity Health Projects 
 
 
 
 In 2009, Gynuity Health Projects and Venture Strategies for Health and 
Development (two reproductive health organizations based in New York City and 
Berkeley, respectively) submitted an application to the World Health Organization 
(WHO) to add misoprostol to the Model List of Essential Medicines (EML) for the 
treatment of postpartum hemorrhage. Of the more than twenty-six letters and studies 
Gynuity and Venture submitted for the application, all from some of the most elite 
public health organizations in the world (the American College of Obstetricians and 
Gynecologists, International Federation of Gynecology and Obstetrics, Marie Stopes 
International, Stanford School of Public Medicine), as well as one letter from Sigma 
Pharmaceuticals, all but one document depicts miso as a miracle drug for Third 
World mothers. According to the application, miso is the perfect drug for this 
population: it is inexpensive, user-friendly, multi-purpose, and able to withstand hot 
climates without refrigeration, a combination said to indicate its potential to nearly 
 
1 Kristof, “Another Pill That Could Cause a Revolution.” 
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eradicate maternal death in the so-called developing world. Repeating the same 
figures and sense of urgency almost verbatim, the many letters and documents read 
like a chorus of pleas to support institutional recognition and community-based 
distribution of this “world-shaking” drug. 
One of the documents, however, is an outlier: 
 
Name: A Concerned Citizen WHO EML 
Email: zaidi-s@ 
country: usa 
sector: health 
suggestion_type: other_general  
 
Message: I am concerned about the attempts made by Venture Strategies 
and it's [sic] partners to include misoprostol in the WHO EML list. They use 
unethical practices to spread this drug at the community level in the 
underdeveloped parts of the world. All of us are aware that misoprostol is 
unsafe for pregnant women. However Venture Strategies is promoting it's 
[sic] use to cause abortions.We [sic] know that abortion must not be 
advocated as a means to control population and is not a method of 
contraception. However if WHO agrees with Venture Strategies and allows 
misoprostol use for PPH [postpartum hemorrhage] etc, there is a very serious 
reason for alarm. 
 
Shabina H. Zaidi, MPH 
Electronic message, November 24, 2008 
 
 
Compared to the other carefully researched and letterhead-ed documents the WHO 
considered, Zaidi’s hastily written message reads a bit like an alarmed conspiracy 
theorist. Yet her message does several important things. She rightfully situates 
family planning initiatives in a long history of covert population control projects, a 
history that family planning professionals have long tried to relegate to a 
phenomenon of the past. But even further, Zaidi’s message reveals the irony that 
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miso pits two of the most well-funded and recognized Safe Motherhood initiatives 
against each other: clandestine abortion and postpartum hemorrhage. In other words, 
the drug said to save women’s lives from postpartum hemorrhage is the same drug 
that enables clandestine abortion, a phenomenon thought to be one of the most 
dangerous and pervasive causes of maternal death. In this way, Zaidi’s message is 
poking a (thought-to-be) sleeping bear—it points to the central ethical tensions 
plaguing family planning debates about community-based distribution of 
misoprostol impacting the WHO’s decision: should we be worried about miso being 
used for the “wrong” reasons? What if community-based distribution of miso just 
further enables clandestine abortion? And what if that is precisely Gynuity’s 
unstated goal here? More fundamentally: for whom is misoprostol really the “ideal” 
drug? 
 Building on the last two chapters, which traced the pharmocratic narratives of 
individualism, responsibilization, racialization, and humanitarianism so central to the 
proliferation of reproductive neoliberalism, this chapter analyzes what I am calling 
an “ethics of rationality” in family planning discourses about obstetric uses of 
misoprostol. By “ethics of rationality,” I am referring to a form of neoliberal 
knowledge production that derives its moral, ethical, and humanitarian authority 
from the data-based methodologies characteristic of family planning sciences. In 
discourses about miso, family planning professionals both rely on and produce data 
that not only comes to define ethical problems, risks, and solutions, but to empiricize 
the ideologies of reproductive neoliberalism. I ask: How does this ethics of 
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rationality shape the moral and statistical paradigms these discourses reflect? Put 
another way, how does family planning data about underground miso materialize—
as in, make material—the ideologies of reproductive neoliberalism? And whom does 
this particular manifestation of reproductive neoliberalism ultimately serve? 
I argue that the ethics of rationality reflected in family planning literature 
about misoprostol both reproduces and ruptures the pharmocratic forces 
undergirding reproductive neoliberalism. Family planning debates about misoprostol 
are fundamentally motivated by a sense of humanitarian benevolence that, as 
Chapters 1 and 2 have discussed, places reproductive risk onto individuals, 
subjecting the so-called developing world to continued surveillance via case studies 
and clinical trials. At the same time, a small but powerful subset of family planning 
scholarship’s performance of the ethics of rationality appears to function as 
rhetorical capital, an attempt not only to disrupt the Malthusian violence of their own 
discipline, but also to contribute to a much more expansive project of feminist 
knowledge production in support of the holistic and inclusive mission of 
reproductive justice. While this work inconsistently wavers between reproducing and 
resisting the forces of reproductive neoliberalism, I want to embrace these moments, 
however fleeting, as opportunities to materialize a form of resistance co-created by 
unlikely partners. 
My goal here is not to suggest that performing an ethics of rationality to 
secure rhetorical capital is evidence of family planning’s subversive relationship to 
its own discipline. Describing the joined languages of ethics and quantitative 
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rationalities as simply rhetorical moves would be reductive and overly speculative; 
frankly, it would let too much family planning scholarship off the hook. However, 
one of the goals of this chapter is to complicate existing reproductive politics 
scholarship that critiques the family planning discipline as a whole. This body of 
scholarship powerfully exposes the violent consequences of Malthusian paranoia 
about overpopulation; family planning initiatives’ use of humanitarian rhetoric to 
justify state-supported pharmaceutical corporations’ presence overseas, as well as 
disastrous government interventions; and more broadly, the distortive pitfalls of 
data-based analysis, which have not only racialized and gendered practices of 
medicine and public health, but also subjected people of color in particular to mass 
surveillance and abuse of the data collected.2 As I will show, these forms of 
epistemic, physical, and identity-based violence are indeed reflected in family 
planning literature on obstetric uses of misoprostol, and I intend to sustain these 
critiques, situating each section of this chapter within a reproductive politics 
framework. At the same time, I also want to challenge the tendency of these critiques 
to overlook evidence of more radical thinking in the family planning field—not 
necessarily to redeem the field itself, but rather to embrace the counterintuitive 
patterns of evidence I see in this particular subset of family planning literature, such 
as an emphasis on centering local knowledges and the narratives of miso-users. In 
this way, I hope not only to contribute more complexity to the already profound 
 
2 See: Briggs, Reproducing Empire; Gutiérrez, Fertile Matters; Kline, Building a 
Better Race; Stern, Eugenic Nation. 
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disciplinary and institutional critiques reproductive politics scholars have made, but 
also to lay the groundwork for visions of disciplinary intervention emerging in 
family planning discourses. 
Producing Obstetric Knowledge: Axioms of Legality, Safety, and Risk 
Family planning experts have been publishing research on the popularization 
of misoprostol as an off-label abortifacient in Latin America for decades.3 Initially 
marketed only as a treatment for gastric ulcers, misoprostol circulated widely 
throughout Latin America until the late 1980s, when the U.S.-based pharmaceutical 
company, G. D. Searle & Company (now merged with Pfizer), submitted the drug 
for FDA approval as an abortifacient to be used in conjunction with mifepristone, 
drawing attention to its off-label uses.4 As abortion was strictly illegal in the vast 
majority of Latin America, government officials began restricting access and 
condemning its use as an abortifacient shortly thereafter.5 
As described in the Introduction to this dissertation, any analysis of family 
planning literature must be understood not only in the context of the United States’ 
history of institutionalized eugenics, of which population-focused family planning 
 
3 Maria del Carmen Elu, “Between Political Debate and Women’s Suffering: 
Abortion in Mexico,” in Abortion in the Developing World (World Health 
Organization, 1999), 245–58; Susan Pick et al., “Pharmacists and Market Herb 
Vendors: Abortifacient Providers in Mexico City,” in Abortion in the Developing 
World (World Health Organization, 1999), 293–310. 
4 Gina Kolata, “U.S. May Allow Anti-Ulcer Drug Tied to Abortion,” The New York 
Times, October 29, 1988, http://www.nytimes.com/1988/10/29/world/us-may-allow-
anti-ulcer-drug-tied-to-abortion.html; Kulczycki, “Abortion in Latin America.” 
5 Kulczycki, “Abortion in Latin America.” 
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methodologies play a major role, but also in the field’s response to this history. Just 
as the term “eugenics” was washed out of the titles and mission statements of 
population-focused organizations following World War II, in the 1980s, the newly 
taboo title of “family planning” neutralized to “reproductive health”; programs 
focused on contraceptive access were said to be motivated not by the desire to 
reduce overpopulation, but rather to empower Third World women; and public 
health and pharmaceutical companies alike embraced what Jodi Melamed calls the 
official language of anti-racism and multiculturalism.6 Yet reproductive politics 
scholarship has prolifically argued that these rhetorical pivots reflect more about 
institutional and state concerns about public image rather than a desire to actually 
transform ideologies and practices, merely producing new language through which 
to continue eugenic projects. In the case of family planning and reproductive health 
fields, the intensive focus on maternal mortality and morbidity that emerged in the 
1980s merely repackaged population control efforts into a very narrow focus on 
fertility regulation, solidifying the gendered assumption that maternal mortality is 
always pregnancy-related. As a result, attributing maternal mortality only to 
pregnancy-related issues evacuated Third World death from what Soheir A. Morsy 
calls a “web of mortality-conducive conditions”—poverty, malnutrition, exposure to 
oil spills, pesticides, and other toxic chemicals, mistreatment or abuse at health 
centers, overwork, unsanitary drinking water—that directly and indirectly impacts 
 
6 Melamed, Represent and Destroy: Rationalizing Violence in the New Racial 
Capitalism. 
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pregnancy and childbirth experiences, but also many other aspects of life that extend 
far beyond motherhood.7 For this reason, Morsy urges family planning researchers to 
understand maternal mortality as a consequence of systemic inequities that do not 
only manifest in and through pregnancy. Such an approach, Morsy argues, would 
prompt public health and family planning professionals to prioritize the root causes 
of death-conducive conditions (e.g. colonization, privatization of primarily agrarian 
economies, labor conditions, enormous wealth disparities, state corruption) rather 
than only treating the symptoms (e.g. antepartum and postpartum hemorrhage, 
complications from incomplete abortion, toxemia of pregnancy, obstructed labor, 
anemia, ruptured uterus, and so on). In other words, Morsy is prompting the family 
planning field to resist the forces of reproductive neoliberalism, forces that maintain 
the persistent focus on surface solutions vis-à-vis the rhetoric of pharmocratic 
humanitarianism.  
Much of the family planning scholarship on obstetric uses of miso in the 
Global South falls right into the epistemological traps that reproductive 
neoliberalism sets up. Nearly every study situates its analysis in alarming statistics 
on maternal mortality, identifying postpartum hemorrhage and incomplete abortion 
as the leading causes of maternal death and illness in the developing world. From 
this perspective, it makes sense that family planning experts would describe 
 
7 Soheir A. Morsy, “Deadly Reproduction among Egyptian Women: Maternal 
Mortality and the Medicalization of Population Control,” in Conceiving the New 
World Order: The Global Politics of Reproduction, ed. Faye D. Ginsburg and Rayna 
Rapp (Berkeley, Los Angeles: University of California Press, 1995), 164. 
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misoprostol as ideally suited for a monolithically described environmental and 
cultural Third World context, emphasizing that miso is a “heat-safe, non-invasive, 
extremely effective, and inexpensive” drug. Physiologically similar to menstruation, 
miso’s ability to prompt uterine contractions makes it multi-purpose: it can help the 
body “expel the products of conception” (as in either abortion or labor induction) or 
enhance vasoconstriction, slowing excessive bleeding (as in postpartum 
hemorrhage).8 Writers are keen to highlight miso’s ease of use, measured by the 
frequency of doses and number of ways to consume it: abortion requires just a few 
doses, taken through just about any orifice—swallowed, dissolved in the cheek, or 
inserted vaginally.9 Scholars are careful to explain that side effects vary among 
women, but can include “unpleasant but tolerable” intensities of nausea, vomiting, 
diarrhea, headache, chills, fever, cramps, and dizziness. While the success rate and 
risk of complications are said to increase with the age of the pregnancy, family 
planning experts say miso can be an effective abortifacient throughout the first 
trimester and even early in the second trimester with the right dosage, and that it has 
no direct effect on women’s physical abilities to bear future pregnancies. By 
empiricizing miso’s techno-scientific capabilities, family planning scholarship on 
miso replicates pharmocratic notions of techno-scientific revolution that, as 
discussed in previous chapters, reinforce existing neoliberal paradigms.  
 
8 A. B. Goldberg, M. B. Greenberg, and P. D. Darney, “Misoprostol and Pregnancy,” 
The New England Journal of Medicine 344, no. 1 (January 4, 2001): 41. 
9 Marge Berer, “Medical Abortion: A Fact Sheet,” Reproductive Health Matters, The 
Abortion Pill, 13, no. 26 (November 2005): 20–24. 
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Nonetheless, these studies have led a big swathe of family planning experts 
to praise miso as groundbreaking for safe motherhood worldwide, motivating further 
investigations of miso’s obstetric uses in the poorest regions of Latin America and 
Africa. Most of these studies aim to measure access to miso. Several studies found 
that the majority of physicians, obstetric gynecologists, midwives, healers, and 
pharmacists they consulted about the drug all knew about misoprostol’s off-label 
obstetric uses, and that pharmacists were most likely to provide it to women upon 
request despite restrictive abortion laws.10 According to a study on one clinic 
operating in an anonymized Mexican state with abortion laws characterized as 
highly restrictive, health professionals openly offered misoprostol as an early 
abortion option and found that, of the 78 women who evaluated their experience 
using misoprostol, the vast majority said they would use misoprostol again and 
“would recommend it to their friends.”11 Another study estimated that if 40 percent 
of the abortions in Latin America were miso-induced, maternal mortality would be 
reduced by 26 percent, concluding, “The more widespread misoprostol abortion is, 
the greater the gains.”12 
 
10 Billings et al., “Pharmacy Worker Practices Related to Use of Misoprostol for 
Abortion in One Mexican State”; Cohen et al., “Reaching Women with Instructions 
on Misoprostol Use in a Latin American Country”; Lara et al., “How Often and 
Under Which Circumstances Do Mexican Pharmacy Vendors Recommend 
Misoprostol To Induce an Abortion?”; Pick et al., “Pharmacists and Market Herb 
Vendors: Abortifacient Providers in Mexico City”; Sherris et al., “Misoprostol Use in 
Developing Countries.” 
11 Billings, “Misoprostol Alone for Early Medical Abortion in a Latin American 
Clinic Setting.” 
12 Harper et al., “Reducing Maternal Mortality due to Elective Abortion,” 68. 
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While most agree that miso ought to be on hand to treat postpartum 
hemorrhage, not all family planning experts are thrilled about its abortifacient 
capabilities, concerns weighed by their legal and safety risks. Primarily, health 
professionals fear that more restrictive legal contexts mean women do not have 
reliable instructions or guidance from trained medical professionals, leading to 
dangerous health complications if miso is taken incorrectly.13 Because misoprostol’s 
effects mirror a heavy period, family planning experts say, users might think the 
drug is working as expected and hemorrhage without realizing they were ever in 
danger.14 Researchers explain that, especially in rural areas, many women try other 
options first, such as teas, coffee, herbal, and lemon mixtures, further delaying the 
abortion process and increasing the likelihood of incomplete abortion. There are also 
a slew of treatments practitioners recommend on a case-by-case basis prior to taking 
misoprostol to reduce the risk of infection, such as treatment of existing sexually 
transmitted infections.15 Family planning experts point to studies that anonymously 
interviewed women in low-resource contexts about their knowledge and/or use of 
miso-induced abortion; the study results reflect that although most women know of a 
pill that could induce abortion, they do not feel well-informed enough about how to 
get it, when and how to use it, and how to confirm whether or not it actually 
 
13 Berer, “Medical Abortion: A Fact Sheet”; Cohen et al., “Reaching Women with 
Instructions on Misoprostol Use in a Latin American Country.” 
14 Sherris et al., “Misoprostol Use in Developing Countries.” 
15 Berer, “Medical Abortion: A Fact Sheet.” 
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worked.16 To top it off, there is some disagreement about how often miso-alone 
abortions17 result in hospitalization since they are generally done clandestinely, 
unless performed as part of a study (according to one of the most frequently cited 
studies, about 1 in 1000 women bleed so heavily after taking miso that they require a 
blood transfusion).18 
From a reproductive politics perspective, there are a few big problems with 
these discourses. First, throughout this literature, family planning experts tend to 
conflate legality with safety, some arguing that abortion law is in fact the most 
powerful hindrance to safe abortion of any kind. They support this rationale by 
connecting two sets of broad-based data: one set that correlates rates of maternal 
mortality and morbidity with rates of hospital admissions believed to be associated 
with complications from miso-induced abortions, and a second dataset correlating 
rates of hospital admissions with comparisons between countries with more 
restrictive abortion laws and those with less restrictive abortion laws.19 Whether a 
country is characterized as having “more” or “less” restrictive abortion laws is 
typically measured by the circumstances under which abortion is considered legal or 
 
16 Cohen et al., “Reaching Women with Instructions on Misoprostol Use in a Latin 
American Country”; Sherris et al., “Misoprostol Use in Developing Countries.” 
17 A “miso-alone” abortion is one performed without mifepristone. In clinics where 
medication abortion is regularly practiced, miso is typically taken after a dose of 
mifepristone, a drug that blocks progesterone, prompting the gestational sac (or 
embryo or fetus, depending on the stage of the pregnancy) to detach from the uterine 
lining.  
18 Berer, “Medical Abortion: A Fact Sheet.” 
19 David A. Grimes et al., “Unsafe Abortion: The Preventable Pandemic,” The 
Lancet, Sexual and Reproductive Health Series, October 2006; Harper et al., 
“Reducing Maternal Mortality due to Elective Abortion.” 
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illegal (for instance, whether abortion for any reason is allowed, or only in the case 
of rape or incest; whether the gestational limits are 12 weeks or 20 weeks; etc.). 
While these concerns about clandestine abortion more broadly (not just miso-alone 
abortions) are consistent with the priorities of mainstream reproductive rights 
advocates, which have historically privileged juridical approaches to securing 
women’s bodily autonomy, the conflation of legality and safety underpinning these 
assessments of underground miso necessarily assumes that licensed physicians 
operating within legally approved guidelines create “safe” conditions by default, 
despite prolific scholarship from the public health sector, social sciences, and 
humanities that thoroughly tracks how licensed physicians have forced women to 
make reproductive “decisions” under appallingly coercive conditions.20 
Second, these intertwined axioms of legality, safety, and statisticized risk 
tend to masquerade as systemic factors of maternal mortality and morbidity when, in 
practice, these axioms actually further alienate immediate suffering from root causes. 
For instance, family planning’s analyses of law are typically limited to the borders of 
the nation-state, when in fact one of the reasons underground miso is such a 
pervasive clandestine drug is because of its ability to cross nation-state borders. This 
reality changes the definitions and stakes of “safety,” and not just because of the 
 
20 Briggs, Reproducing Empire; Gurr, Reproductive Justice; Gutiérrez, Fertile 
Matters; Tamil Kendall and Claire Albert, “Experiences of Coercion to Sterilize and 
Forced Sterilization among Women Living with HIV in Latin America,” Journal of 
the International AIDS Society 18, no. 1 (March 24, 2015), 
https://doi.org/10.7448/IAS.18.1.19462; Roberts, Killing the Black Body; Silliman et 
al., Undivided Rights; Stern, Eugenic Nation. 
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possibility for third-party distributors to sell counterfeit or expired drugs, as family 
planning scholars who are against community-based distribution fear, but also 
because of the systemic inequities underground markets themselves reflect, whether 
one is a buyer, seller, or analyst of the market, for that matter. 
Ironically, these discourses consequently ignore the fundamental problem 
motivating their inquiry into obstetric uses of miso in the first place: the statistical 
reality that miso-alone abortion is simply not as effective as the FDA-approved 
mifepristone-misoprostol combination drug. For instance, in the study that asks 
women “if they would recommend miso to a friend” or “use it again,” there is no 
consideration of the decision context within which women report this. Of course if 
miso is the only option, they would recommend it to a friend or use it again; this 
does not necessarily indicate that they would use miso over the significantly more 
effective miso and mifepristone combination. “Safety” here becomes a calculation of 
costs and benefits of second-rate treatments, as opposed to an analysis that begins by 
asking what produces the need for second-rate treatment in the first place. 
From this perspective, the data produced and cited in family planning 
discourses are structured such that they actually produce the ethical quandary they 
set out to solve. “Safer” than so-called traditional methods or the spectacularized 
back alley, but “less safe” than the FDA-approved mifepristone-misoprostol 
combination, family planning discourses on obstetric uses of misoprostol in the 
Third World is premised on the maintenance of dysfunctional systems that 
necessitate these compromises. 
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Labors of Evidence Production 
Perhaps most interesting about the miso debacle is how much energy family 
planning researchers have put into reflecting on the dynamics of the debacle itself; 
yet it is in these reflexive moments that the pharmocratic ethics of rationality get 
even further entrenched. One article published in Developing World Bioethics 
specifically analyzes the narrative patterns of the miso debate, describing the feud as 
a problem of “entrenched disagreement.”21 Using the traditional disciplinary 
methods of qualitative and data analysis (“Morse’s outline of the cognitive basis of 
qualitative research, and Charmaz’s outline of data analysis in grounded theory”), 
the authors observe that the two sides of the miso debate reflect conflicting 
philosophies about public health interventions more broadly.22 They argue that the 
miso debate reflects “a strong correlation between epistemic and moral values,” 
which they represent in a graph (Figure 177): 
 
21 Narcyz Ghinea et al., “Overcoming Entrenched Disagreements: The Case of 
Misoprostol for Post-Partum Hemorrhage,” Developing World Bioethics 15, no. 1 
(April 2015): 48–54. 
22 Ghinea et al., 50. 
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Figure 17: Ghinea et al. describe the above graph as a map of 
“prudential commitments observed in the misoprostol debate in terms 
of the correlation between moral priorities and epistemic standards” 
(ibid.). 
Above, the x-axis measures the strength of evidence on a scale from “strong 
evidence” to “weak evidence.” The y-axis—although misleadingly labeled “moral 
priority,” suggesting a scale from the least moral or immoral to infinitely more 
moral—is a scale of “beneficence” (actions taken for the benefit of others) to “non-
maleficence” (actions taken in order to avoid harm). Working from Aristotelian 
moral philosophy summarized as “the application of intuitive reason to scientific 
knowledge,” the graph represents two moral sensibilities: “precautionary prudence” 
and “active prudence.” Moral priorities correlate with quality of evidence: those who 
argue against community-based distribution of miso are said to exhibit precautionary 
prudence—meaning that they are more aligned with a do-no-harm approach to 
maternal mortality and morbidity—and require stronger evidence. Those who argue 
in favor of community-based distribution of miso are said to exhibit “active 
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prudence”—meaning that they are more inclined to take preventative action against 
maternal mortality and morbidity—and require weaker evidence. The authors 
ultimately conclude that the precautionary prudence group is more “uncomfortable 
with scientific uncertainty,” while the active prudence group is more “accepting of 
scientific uncertainty.” 
The immediate implication here is that opponents of community-based 
distribution of miso are, essentially, better scientists than the supporters; opponents 
of community-based distribution of miso are found to provide so-called stronger 
evidence for their position. But the implications here go far beyond the miso debate, 
raising profound questions about what forms of knowledge production—
quantitative, anecdotal, experiential—the field of family planning privileges. After 
all, what constitutes “weak” and “strong” evidence? Or scientific “certainty” and 
“uncertainty,” for that matter? The ethics of rationality performed in this study not 
only renders very subjective, experiential thinking into empirical data, but also uses 
this performed empiricism as justification for privileging existing data-based 
methodologies and devaluing experiential knowledge—knowledge that resists being 
empiricized and disciplined into dichotomous conceptual pairings (e.g. 
morality/immorality, certainty/uncertainty, benevolence/maleficence).  
This failure to value experiential knowledge gives a lot of credence to 
reproductive politics scholars who frame their central intervention into family 
planning as an epistemological one, since it appears that the very methodologies 
family planning experts use to reflect on more foundational epistemological issues in 
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their field only reinforces the same blindspots. At the same time, this reading 
assumes that studies like this are published in a vacuum, expected to solve the 
problems the study raises rather than act as a springboard for further inquiry. From 
this perspective, while I enthusiastically agree with Morsy and other reproductive 
politics scholars that defining maternal mortality as only having to do with 
pregnancy limits the scope of what circumstances can be understood to factor into 
maternal mortality and health more broadly, I also worry that we miss a whole 
movement of family planning scholars for whom each study, while initially focused 
on a specific medical condition, is part of a much larger project of knowledge 
production that does situate maternal mortality as one among many effects of 
systemic injustice, including epistemic violence. 
In fact, Gynuity Health Projects’ mission statement is explicitly responsive to 
these fundamental disciplinary questions, particularly regarding what constitutes 
evidence. Their mission is “to develop scientific, clinical and programmatic evidence 
in reproductive and maternal health and to advocate for its use assuring that each 
individual benefits from the fruits of medical science and technology,” a goal that 
presumably motivated their initiative to add misoprostol to the EML.23 While the 
WHO has no legal authority to regulate which drugs pharmacies and clinics are 
required to stock, public health professionals generally recognize the EML as the 
gold standard for policy and clinical practice worldwide. In line with their general 
 
23 “Homepage,” Gynuity Health Projects, accessed May 23, 2019, 
https://gynuity.org/. 
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strategy “to use research to fill evidence gaps for new models of care, influence 
change, and advocate for improvements in policy and practice,”24 Gynuity’s goal 
was to produce scientifically and clinically legible evidence to prove miso’s 
essential-ness. Their vision was to make miso among the most basic pharmaceuticals 
to stock worldwide—as routinely accepted as amoxicillin, ibuprofen, or emergency 
treatments for anaphylaxis (e.g. EpiPens), all of which have long been on the EML 
with virtually no controversy. 
This is an epistemic project that requires family planning scholarship to not 
only privilege data that critiques systemic issues, but also to essentially redefine 
scientific evidence itself, in part because these critiques tend to emerge in the so-
called “qualitative data,” i.e. narratives from the study subjects. For instance, in a 
recent 2018 study on the role of traditional birth attendants (TBAs) in the 
distribution of miso for postpartum hemorrhage in Mozambique, Hobday et al. 
center women’s challenges and concerns about the work they do in their 
communities by quoting TBAs directly: 
Unfortunately I am not lucky enough to earn money for the work I do, I have 
already brought many people into the world by my hands. If it were a case of 
working for a boss, I think I would be in retirement now and earning money 
for the time spent in this activity. 
 
Well, they tell me that my job is to get pregnant women to the hospital, but if 
it happened before I was there, I should get some plastic [from a 1kg sugar 
bag], and put it on my hands, that’s how I do it, they did not give me gloves, 
they said they wear the gloves in the hospital.  
 
 
24 “Homepage.” 
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For example, when a child is born they do not let it be covered with this 
capulana25 that I used, in the hospital they say it must be a new capulana … 
where will I get money for a new capulana if my only capulana is this one? 
So we do not know… this price we are paying for our misfortune is very 
high. The nurses only know to say that we should produce vegetables to be 
able to sell to get money … but here who will buy what we produce if we are 
all farmers and poor people?26 
 
All of the above statements speak to the labor conditions within which TBAs 
operate, demanding a restructuring of capital and labor that not only provides TBAs 
with pay and baseline materials to do their jobs (soap, gloves, fresh capulanas), but 
that also recognizes the underlying inequities that create the context for high 
maternal mortality in the first place. At the same time, they push readers to 
reimagine the underlying structures of capital one earns through work. While the 
first quote frames earning a living wage as a privilege one can only fantasize about, 
in the third quote, the TBA’s rhetorical questions resist simplistic (neoliberal 
capitalist) solutions to systemic issues, asking: where will I get money for a new 
capulana? Who do they expect will buy my vegetables? There is a circularity to her 
questions—a persistent “then what?”—that, question by question, reveals not only 
the almost pathological absurdity of proposing such band-aid solutions to a 
fundamentally dysfunctional system, but also the urgent need for so far illegible 
solutions that resist the ruling logics of reproductive neoliberalism. 
 
25 A capulana is a kind of sarong popular in southeastern Africa that is often worn as 
clothing (e.g. skirt, dress) or used as a baby carrier. 
26 Karen Hobday et al., “‘My Job Is to Get Pregnant Women to the Hospital’: A 
Qualitative Study of the Role of Traditional Birth Attendants in the Distribution of 
Misoprostol to Prevent Post-Partum Hemorrhage in Two Provinces in Mozambique,” 
Reproductive Health 15, no. 1 (October 16, 2018): 8–9. 
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What is more concerning to me in these narratives is not whether they situate 
obstetric issues within broader institutional and systemic critiques (in fact, they do), 
but that their critiques are inextricable from a kind of self-sacrificial plea for basic 
resources. On one hand, their statements reflect the success of pharmocratic rhetoric 
in disciplining Global South subjects into states of need; on the other hand, all of 
these desires are stated in terms fundamental to the pharmocratic machinery—pay, 
retirement, supply and demand. From this perspective, we might read these quotes as 
systemic critiques that family planning researchers interpret and re-encode as 
demands that can be legible to the institutions that have the power to reshape these 
systems. 
The big caveat here is that Hobday et al. are inconsistently responsive to 
these critiques, sometimes making meaningful recommendations that speak to 
systemic issues, other times making disappointingly limited recommendations that 
reproduce a pharmocratic system in which pharmaceutical responsibility falls on the 
most burdened populations. At their best, Hobday et al. productively point to the 
“unintended consequences” of prior interventions: 
This study unveiled several unintended consequences of promoting facility 
deliveries without major investments in transport or communication systems. 
While some communities did have access to a maternal waiting home, often 
women were not able to leave their children at home without care and/or 
husbands did not see it as appropriate for their wife to be away from the 
home. Giving birth “on the way” to the facility, with no protection from the 
elements has also been described in Malawi, where women had to give birth 
on the roadside often due to a delay to seek assistance from a TBA or SBA 
[Skilled Birth Attendant] at the health facility.27 
 
 
27 Hobday et al., 10. 
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Above, Hobday et al. are identifying the pitfalls of overly simplistic solutions—e.g. 
tell women to give birth at the hospital—in the context of major infrastructural 
deficits. It is one thing to encourage women to go to facilities where they and their 
newborns are less likely to die, and another thing to create structures that enable 
women to get there without taking even bigger risks (e.g. walking to the hospital and 
giving birth on the roadside) than they would if they stayed home. In other words, 
the passage above gives us a glimpse into a potentially transformative, big-picture 
critique: in their pursuit of governmentally and medically recommended “safe 
motherhood,” women only entered into newly horrific birthing circumstances. 
Given this powerful critique—that public health professionals have failed to 
see that the physical presence of a health facility does not necessarily make its 
resources accessible, and that “encouragement” does little to make it accessible—the 
article’s ending recommendations are perplexing. Hobday et al. list these 
recommendations in a table at the end of the article (Figure 188). Each 
recommendation places pharmaceutical responsibility on TBAs: they are to pick up 
the medicine, store it, and determine when and how to use it. But perhaps most 
troubling is that these recommendations are framed as though they were direct 
requests from TBAs. Hobday et al. write in their conclusion: “TBAs request 
resources such as birth kits, communication and transport options to heighten their 
efforts to ensure women can access to [sic.] the safest birth possible.”28 While it is 
true that one of the TBAs requested a car to transport women to the health clinic, this 
 
28 Hobday et al., 11. 
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Table 1  Recommendations 
Operational recommendations for the misoprostol program: 
• Allow TBAs to pick up the medication from the health facility where 
necessary and appropriate to ensure a stable supply of misoprostol. 
• Heighten communication of the Strategy for the Prevention of PPH at the 
Community Level to TBAs. TBAs and MNCH nurses should feel confident 
distributing and administering misoprostol to women who will have a home 
birth as part of the National Strategy. 
• Provide clear information to the community via health facility staff, CHWs 
and TBAs about misoprostol and how to use it correctly, alongside 
messages encouraging facility-based birth to dispel fears and myths in the 
community. 
• Consider clean birth kits distributed through ANC, APEs, and/or directly to 
TBAs. This would alleviate concerns TBAs have about infections to 
themselves, women and newborns while reducing neonatal mortality. This 
study found no concerns that this might undermine facility deliveries. 
 
Recommendations to increase coverage of births attended by SBAs: 
• Transportation, while costly, is a necessary investment to ensure women 
have access to health facilities. Women and TBAs both strongly support 
facility deliveries, but requested assistance with transport and 
communication. 
 
Figure 18: A table of recommendations concluding the Hobday et al. study. TBAs 
are Traditional Birth Attendants; PPH refers to postpartum hemorrhage; MNCH 
nurses are Maternal Newborn and Child Health nurses; CHWs are Community 
Health Workers; ANC refers to early antenatal care; APEs are Agentes Polivalentes 
Elementares; and SBAs are Skilled Birth Attendants. Note: This table is a 
reproduction of the original, not an exact copy. (Hobday et al., 10) 
——— 
 
request was made in the context of a much broader systemic problem—that their 
work is considered voluntary, and not worthy of pay: 
Another problem is transportation, I live far from the health unit, I must pick 
up two cars and pay 40 meticais just to come, so, round trip is 80 meticais 
and no one gives me that money, its personal effort. We are told that this is 
voluntary work and that we should do it of our own free will, so I do it 
without gaining anything.  
 
Above, the TBA does articulate a problem transporting women to the hospital, but 
situates her critique in the reality that, although she is not paid for her work, this 
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work is still expected of her. Instead of recognizing this deeply inequitable reality, 
Hobday et al. evacuate the request from its systemic critique and put it into a list of 
items TBAs need in order to continue bearing the responsibility of reducing maternal 
mortality. 
In this way, family planning scholarship on misoprostol use in the Global 
South both reaffirms and complicates Morsy’s central critique. While the studies do 
explore miso as a specifically obstetric treatment, perpetuating the definition of 
maternal mortality as always pregnancy-related, the so-called “qualitative data” 
presented does critique much broader systemic issues at play. Rather than limiting 
the scope of action to only pregnancy-related health issues, family planning’s focus 
on obstetric uses of miso, even when put in the limited context of maternal mortality, 
functions as a threshold concept—one in which the initial object of analysis 
(obstetric uses of miso) acts as a portal through which to form more complex 
analyses and make counterintuitive connections.29 From this perspective, we can 
understand the focus on maternal mortality in family planning literature about miso 
not necessarily as a limiting factor, but rather as a starting point for more expansive 
and possibly transformational scholarly conversations about health more broadly. 
 
29 The term “threshold concept” originated in education, but it has been used in a 
range of fields, such as writing across the curriculum scholarship and 
psychology/therapy contexts. See: Jan Meyer and Ray Land, “Threshold Concepts 
and Troublesome Knowledge: Linkages to Ways of Thinking and Practising within 
the Disciplines,” in Improving Student Learning: Ten Years On, ed. C. Rust (Oxford 
U Press, 2003); Jan H. F. Meyer and Ray Land, “Threshold Concepts and 
Troublesome Knowledge (2): Epistemological Considerations and a Conceptual 
Framework for Teaching and Learning,” Higher Education 49, no. 3 (April 1, 2005): 
373–88. 
 142 
The limiting factors I see in family planning conversations have more to do with the 
ways in which data is translated into recommendations that inconsistently speak to 
the systemic critiques evidenced in their research. This is clearly a missed 
opportunity for marrying the concreteness of the traditional “list of 
recommendations” to systemic critiques that are too often nonspecific, left in the 
abstract of “heightened communication” and calls for health workers to become 
more “confident”—hallmarks of reproductive neoliberalism that need more 
unpacking. 
Miso as a Surveillant Technology: Tracking Responsibilization 
These calls for more confidence expose the capacity for family planning 
literature to act as a method of surveillance that “promote[s] abstraction, fetishism, 
transformation of bodies into commodified information, and perceptions of reduced 
risk.”30 In this case, family planning studies on misoprostol tend to interpret data in 
ways that reconstitute the contradictory pharmocratic values of self-
responsibilization and humanitarian self-sacrifice for the Greater Good. 
Nearly all of the family planning literature about miso engages with and 
produces a variety of surveillant data on pregnant women and health workers in a 
given town or village. As is standard practice in any clinical study, participants are 
generally required to provide detailed contact information and medical history upon 
 
30 Deborah Wilson Lowry, “Understanding Reproductive Technologies as a 
Surveillant Assemblage: Revisions of Power and Technoscience,” Sociological 
Perspectives: SP: Official Publication of the Pacific Sociological Association 47, no. 
4 (2004): 357. 
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intake at the clinic. Gathering data after this initial meeting, however, requires more 
elaborate processes. For instance, in a study in eastern Uganda evaluating village 
health teams’ (VHTs) ability to conduct postpartum follow-up after antenatal 
distribution of misoprostol—part of a project nicknamed “MamaMiso”—researchers 
instructed VHTs to give each pregnant woman a neck purse containing three items: 
either misoprostol or a placebo, instructions for its use, and a phone number to call 
to “report their delivery.”31 This form of data extraction was easily evaded; in fact, 
some women provided fake names or phone numbers, and, in a few cases, 
extensively detailed directions to made-up villages.32 
What is more troubling is the surveillant “reward” system built into many of 
these studies, particularly when community health workers act as the surveilling 
operatives. In the Ugandan study, VHTs were promised 10,000 Ugandan shillings 
(about 4 USD) for each “timely report of a delivery,” including a test of hemoglobin 
levels.33 Timeliness was measured by three categories: “on-time” for reports sent 
within a week of delivery, “late” for reports sent 8 days or more after delivery, or 
“lost” if VHTs did not follow up successfully (see Figure 19). Rewards were either 
prorated or swapped out according to a somewhat arbitrary ratio of timeliness to 
reporter type (i.e. whether the VHT sent the report or the woman who delivered). 
The more days that passed after delivery without a report, the less money VHTs 
 
31 James Ditai et al., “Achieving Community-Based Postpartum Follow up in Eastern 
Uganda: The Field Experience from the MamaMiso Study on Antenatal Distribution 
of Misoprostol,” BMC Research Notes 10, no. 1 (October 26, 2017): 2. 
32 Ditai et al., 4. 
33 Ditai et al., 2. 
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would receive; if VHTs and women both participated in the notification, they would 
split the earnings. If women reported on their own, researchers gave them an entirely 
different prize: a bar of soap. 
These “measurements” raise some alarm bells. First, the study was structured 
such that VHTs’ access to lifesaving drugs like miso and compensation for the care 
they provide pregnant women appear to be contingent on their ability to comply with 
the study team’s implicit definitions of responsibility and accountability; in order to 
be a “good” VHT deserving of a reward, they must participate in their own 
pharmaceutical self-responsibilization. In other words, the information gathered is 
not simply an accumulation of “raw” data (it never is), but rather an evaluation of 
Global South subjects’ ability to perform the medical, pharmaceutical, and 
humanitarian responsibilities the study bestowed on them. 
Second, the stakes here go well beyond the more immediate injustice of 
withholding “rewards” on terms defined by those in charge of distributing resources. 
If VHTs do not participate in the surveillance processes outlined and measured by 
the study team, not only do they not get compensated for their work nor get basic 
hygienic materials like soap (items that are readily available for study teams to 
distribute anyway), but VHTs also get a paper published in BMC Research Notes 
concluding whether or not they can be trusted to do follow-up work. The production 
of Global South knowledges and labors of care, precarity, and survival are at risk of 
being completely dismissed far beyond the parameters of the study, abstracted and 
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Figure 19: “Postpartum hemoglobin values for all women followed up 
irrespective of place of delivery and use of study medication. This figure 
depicts a scatter plot with the follow up time in days on the x-axis and the 
hemoglobin value in g/dL along the y-axis and incorporates a linear best fit 
line.” (Ditai et al., 7) 
——— 
 
represented to a Global North audience as cultural deficiency and even delinquency. 
This is embedded at the most basic levels of language, evidenced in descriptions of 
study subjects as either “complian[t] with the study protocol” or “non-compliant” 
because of “user-choice failure.”34 
That said, the studies do provide some insight into the study subjects’ experiences of 
being surveilled, exposing the blurry line between surveillance that misrepresents lived 
 
34 B. Elul et al., “Can Women in Less-Developed Countries Use a Simplified Medical 
Abortion Regimen?,” The Lancet 357, no. 9266 (May 5, 2001): 1403. 
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experiences and surveillance that lays the groundwork for those experiences to be made legible 
in meaningful ways. For example, the study team asked women who were categorized as having 
followed up “late” why they did not report their deliveries sooner, producing a table of 
“illustrative quotations” organized by theme ( 
Figure 20). Some women’s statements reflect almost comical resistance to 
being surveilled in the critical days of postpartum recovery and life adjustment 
immediately following delivery (“I was very sick and confused so I could not 
remember to report to you people that I had delivered” [emphasis mine]). Even so, 
the “evidence” this particular study produced, however simplistic, was 
overwhelmingly positive for VHTs. Like Gynuity Health Projects aims to do, they 
produced evidence legible to the public health world that VHTs are important, 
knowledgeable, and trusted actors in their community’s systems of care. To some 
degree, their conclusions reflect this: 
In the MamaMiso study, follow up in the immediate postpartum period was 
feasible and a high follow-up rate (93.6%) was achieved… [S]imilar rates of 
follow up were achieved irrespective of birth and the presence of a skilled 
birth attendant. This finding may suggest that even women who are 
disconnected from the health system at the time of delivery by giving birth at 
home and without a skilled birth attendant are still amenable to postpartum 
follow-up.35 
 
This passage is particularly striking because it seems to identify two different objects 
of study: how well VHTs completed their jobs, and how “amenable” women were to 
being surveilled by VHTs. It is tempting to say that measuring how amenable 
 
35 Ditai et al., “Achieving Community-Based Postpartum Follow up in Eastern 
Uganda: The Field Experience from the MamaMiso Study on Antenatal Distribution 
of Misoprostol,” 5–6. 
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women are to  participate in the surveillance process—to provide their data—is 
evidence yet again of the study structure pushing women to have to perform 
responsibility. At the same time, we could also see this language as an attempt to 
produce evidence that VHTs are knowledgeable, trusted members of their 
communities—a way of solidifying the importance of community trust and 
belonging into family planning knowledges. Their findings support the idea that care 
need not come from hospitals, but rather from their own communities, and that, if 
anything, institutional attended deliveries just complicate the process: 
The MamaMiso study showed that women who delivered at home and 
without a skilled birth attendant were equally likely to be followed up on 
time as those with institutional attended deliveries. Women who enrolled 
during antenatal care at an urban hospital were especially difficult to follow 
up on time. In their own words, women explain that phone difficulties, 
misperceptions, postpartum travel, and condition of the mother or neonate 
also interfere with postpartum visits.36 
 
This passage suggests a pretty radical idea: that proximity to hospitals is also 
proximity to institutional violence that further estranges women from the resources 
they may or may not want to use. The problem here is not one of “access,” but rather 
the way the hospitals conduct (or do not conduct) care. In other words, this is 
specifically an epistemic problem; to attend to the “systemic” does not translate into 
proximity to institutions, but rather to fundamentally change the cultural 
assumptions upon which these institutions operate. 
 
 
 
 
36 Ditai et al., 6. 
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Table 3  Illustrative Quotations 
THEME: 
phone 
difficulties 
 
 
“My phone was faulty, the battery was spoiled so I was off air” (Quotation from woman) 
“I delivered at home and did not report because I did not have the phone because my husband 
had gone for a safari and had not come back…” (Quotation from woman) 
“I left the book which had your telephone number in the hospital. I did not remember about the 
telephone number on the participant information sheet.” (Quotation from woman) 
THEME: 
inaccurate 
baseline 
information 
“I followed up the participant at the given address but failed to get her because the villages 
given don’t exist.” (Quotation from study staff) 
“The [name of contact person provided] had died some time back, [the neighbors] told me that 
they had never come across the name of the participant in their village.” (Quotation from study 
staff) 
THEME: 
misperceptions 
“I thought [reporting my delivery] was not important since I was fine after delivery.” 
(Quotation from woman) 
“I delivered and forgot to call until a nurse called me and asked if I had delivered.” (Quotation 
from woman) 
“Participant followed up late because she feared calling us due to the fact that she swallowed 
only two tablets and missed one… She thought we would blame her for not swallowing the 
third tablet.” (Quotation from study staff) 
“[The husband] answered the phone … He wondered whether it was necessary to follow [the 
wife] up… He said he will need us to follow her up in his presence… He also asked me why a 
man called to find out whether she had delivered.” (Quotation from study staff) 
THEME: 
travel/events 
“On my third day after delivery I lost someone and travelled… for a burial. That’s why the 
MamaMiso staff were not able to find me.” (Quotation from woman) 
“When my baby died, I lost my marriage, that’s why you were not able to get me at my home. I 
had come here to stay with my mother.” (Quotation from woman) 
“When I reached the home, I did not get the participant because she had lost her one twin and 
they had taken the twin to another village for burial.” (Quotation from study staff) 
“I was told by the neighbor that she left for their village… after delivery. She went with her 
mother because they had a misunderstanding with her husband.” (Quotation from study staff) 
THEME: 
condition of 
mother/neonate 
“I was very sick and confused so I could not remember to report to you people that I had 
delivered.” (Quotation from woman) 
“After the death of the baby I was disturbed in the mind so I could not even remember to notify 
you that I had delivered.” (Quotation from woman) 
“I called the participant today… she said she was operated on and the baby passed on… she 
went to a relatives place for more support.” (Quotation from study staff) 
 
Figure 20: Quotations from study subjects in the MamaMiso study. The authors note 
the following: “Participant numbers and locations have been redacted from 
quotations. Quotations from women were typically provided in one of the three local 
languages (Ateso, Lugisu, Lugwere) and translated by study staff into English for 
recording. The English grammar of some quotations has been amended to facilitate 
comprehension” (Ditai et al., 5). Note: This table is a reproduction of the original, 
not an exact copy.  
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Conclusion: Rereading Possibilities 
This analysis pulls me in a few different directions. On one hand, family 
planning literature on obstetric uses of miso reproduces pharmocratic forces that 
discipline Global South subjects into performing self-responsibilization. It does this 
by encoding data as evaluations of whether Global South women are “compliant” 
with miso-use, characterizing women’s non-use of the drug as “user-choice failure.” 
Being non-compliant with drug use is thus read as a failure to choose the 
pharmaceutical solution—an act of cultural deficiency, of defective knowledge, 
evidence of women’s poor decision-making—rather than due to any of the infinite 
reasons, willful or not, that women may not use miso, whether non-use indicates 
some kind of desire, resistance, fear, stoicism, perhaps relationships to the body that 
the family planning literature is simply not set up to see. 
This reality tempts me to conclude that, even when the studies present Global 
South knowledges positively—as in, “compliant” with miso-use—the dualistic 
framework of compliance/non-compliance only reinforces pharmocratic narratives of 
responsibilization and (neo)liberalization, delegating reproductive risk-taking to 
individuals rather than the pharmaceutical corporations, public health organizations, 
and policymakers (for example) that have historically created conditions of risk-
taking in the first place. Regardless of whether women are evaluated as compliant or 
non-compliant, the dichotomy itself reproduces the neoliberal, neocolonial rationale 
for their continued institutional management—management that is clearly 
dysfunctional. From this perspective, family planning sciences are fundamentally 
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built to align with reproductive neoliberalism, the very same ideologies from which 
family planning took off in the 1950s. 
At the same time, I want to at least partly resist this reading because, while 
this argument is in some ways the logical corollary to the analysis I do in this 
chapter, it creates what (I believe to be) an illusion of epistemological entrapment. 
As Deborah Lowry puts it: 
… the general rejection of all or certain contemporary reproductive 
technologies that is promoted by some critical scholars will fail to change the 
embedded power relations and interests permeating the surveillant 
assemblage of reproductive technologies. Cutting off information networks, 
banning sonograms and reproductive testing, and attempting to end 
surveillance of pregnant women are not viable solutions to the question of 
how power, autonomy, and the status of pregnant women and others might be 
altered.37 
 
By the same token, it would be reductive to say that all family planning studies on 
misoprostol should be ended or ignored because they are doomed to be violent tools. 
In other words, rejecting an entire field of study on the premise that it is inevitably 
bound to reproduce epistemic violence is itself a kind of epistemic violence—it 
erases the complexity of family planning scholars’ varying positionalities and 
motivations, a kind of epistemological essentialism. For example, there is clearly an 
opportunity for family planning experts to center existing reproductive care networks 
and local knowledges, an opportunity that many family planning professionals 
already actively pursue. At the risk of naivety, I want to leave open the possibility 
that while performing responsibilization conscripts women into neocolonial systems, 
 
37 Lowry, “Understanding Reproductive Technologies as a Surveillant Assemblage: 
Revisions of Power and Technoscience,” 366. 
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it may also position unexpected actors to rupture the gendered and racialized 
epistemologies undergirding modern forms of reproductive neoliberalism. Holding 
family planning scholarship accountable is not mutually exclusive with reading for 
its possibilities; I think we can do both. 
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EPILOGUE 
 
Elephants in the Room 
 
 
This dissertation project has attempted to trace the biopolitical footprints of 
misoprostol, linking key sites in miso’s material-discursive circulation. Contrary to 
pharmocratic narratives that endow misoprostol with previously unseen techno-
scientific potential, discourses about miso represent the concentration of 
reproductive neoliberalism, a force that joins the rhetorics of pharmaceutical 
revolution, humanitarianism, and reproductive vigilantism. The universalist language 
of empiricism and unity via techno-science masks the individualistic and 
nationalistic ideologies from which misoprostol emerged. 
While underground markets for misoprostol open up the possibility that 
reproductive autonomy may emerge not from state legitimation, but rather, through 
possibly disorganized networks operating both with and outside of juridical and 
health frameworks, the discourses surrounding the drug also idealize these 
possibilities, ignoring the pharmaceutical production and distribution processes that 
precede its circulation. Discourses about underground miso also reproduce colonial-
era notions of race, exoticizing miso users, sellers, and the Global South spaces from 
which miso is (incorrectly) said to originate. These discourses thus tend to reveal 
less about the ways miso-users claim (and miso-sellers enable) reproductive 
autonomy, and more about how liberal-progressive desire for universal reproductive 
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freedom persistently privileges individual action over systemic change, silencing the 
reproductive justice mission. 
Resisting the desire to romanticize or otherwise flatten the complexities of 
underground misoprostol markets as we might other forms of resistance, what draws 
me to study them is that they are not necessarily cohesive or organized, even while 
they produce traceable patterns of exchange and capital. Unlike more traditional 
stories of resistance or subversion, these networks do not necessarily work in direct 
opposition to the state, nor do they ascribe to a specific, uniting ideology as we 
might imagine a social justice movement would. Rather, my research has shown me 
that these underground networks could be so complex and heterogeneous that not all 
participants participate knowingly or intentionally. 
This reality raises more questions for me: How do we reconcile agential, 
subversive readings of resistance with the systemic analyses reproductive politics 
scholars rightfully urge? What does it look like to attend to the agential while also 
reading for the whole? 
While a more complex theory of agency and resistance that does not re-
enable existing paradigms would be helpful here, I call this Epilogue “Elephants in 
the Room” because I think the complexity I am craving may only come from 
ethnographic work (this is one of my elephants). When I presented my dissertation 
prospectus in January 2017, my project included plans for an ethnography at the 
midwifery practice at Bellevue Hospital, a free clinic whose clients are mostly low-
income women of color who have immigrated or are in the process of immigrating to 
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the United States. I believed that Bellevue would be the ideal site to begin to explore 
the ways the Global North/Global South dichotomy haunts reproductive health 
discourses, in part because of its unique partnership with the Doula Project, a New 
York City-based reproductive health and justice organization that trains volunteer 
doulas to support low-income women across the spectrum of pregnancy, including 
birth, abortion, miscarriage, stillbirth, and fetal anomaly. The Doula Project’s 
extensive advocacy in and outside the hospital, grounded in a reproductive justice 
praxis, not only directly impacts Bellevue’s patient demography by drawing under-
resourced clients who otherwise would give birth in the emergency room or not 
receive reproductive care at all, but also generatively complicates what social 
scientists call “the clinical encounter.”1 Unlike a more traditional hospital setting—
one that does not employ midwives, does not make volunteer doulas available on-
site, and requires payment regardless of whether the patient has health insurance—
the clinical and pharmaceutical culture at Bellevue prompts questions about how 
linguistic, racial, ethnic, and bodily borders structure reproductive experiences and 
grammars of health. Anecdotally, it also just so happened that the midwives at 
Bellevue were in the midst of their own passionate debates with Bellevue about 
misoprostol vs. oxytocin (another drug that treats postpartum hemorrhage and tends 
to be more effective, but is more expensive). 
 
1 Judith Farquhar, Knowing Practice: The Clinical Encounter of Chinese Medicine, 
Studies in the Ethnographic Imagination (Boulder: Westview Press, 1994); Earl E. 
Shelp, The Clinical Encounter: The Moral Fabric of the Patient-Physician 
Relationship (Dordrecht: Springer Netherlands, 1983). 
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While I did volunteer as a doula for several months at Bellevue, my 
volunteership was cut short when Bellevue cut funding to the midwifery practice, 
putting a freeze on all new hires in the practice. Morale was at an all-time low, and 
midwives began leaving, many for higher-paying jobs at private clinics. It is only in 
retrospect that I see this funding cut and its consequences as yet another public-
private embrace of reproductive neoliberalism. Reproductive neoliberalism is more 
than an ideology; it is a material force that siloes full-spectrum reproductive care 
meant to center the needs and desires of the most marginalized. 
Part of my desire to do ethnographic work was to be in closer proximity to 
this materialization of reproductive neoliberalism (though I did not call it that at the 
time)—to see if the clinical culture of Bellevue would help me rupture the discourses 
about misoprostol that I was reading. As João Biehl succinctly puts it, “Ethnography 
complicates. It is a way of grounding and dissecting such abstractions, illuminating 
the contingency, multiple interests, and unevenness of the political game that is 
under way.”2 When I look at the striking photographs and poignant stories he pairs 
together in his work, I am reminded of my project’s incompleteness—how 
ethnographic work would complicate and enrich my analysis of underground 
markets for miso. 
While my archival research has given me valuable ways of reading the 
hegemonic forces driving the circulation of discourses about misoprostol, it has also 
provided glimpses into the kind of complication and enrichment ethnography could 
 
2 Biehl, Will to Live, 11. 
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enable—specifically, how reproductive neoliberalism manifests in the everyday 
lived experiences of people whose lives have intersected with misoprostol in one 
way or another. In the next phases of this project, I would like to pry open those 
glimpses. 
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